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S u m m a ry
For cells to proliferate, a certain size needs to be reached, which is mainly determined 
by the rate of translation. Thus, the constituents of the translational apparatus 
play an essential role in cell growth and proliferation. Because some of the products 
transcribed by pol III transcription are constituents of the translational apparatus, 
the rate of pol III transcription will affect cell growth rate. Mitogenic stimulation 
induces pol III activity [1], while differentiation represses pol HI transcription [2].
The retinoblastoma protein (RB) has been implicated in repression of pol III 
transcription by inhibiting TFIIIB activity through binding of its hypophosphory- 
lated form [3,4]. The oncoproteins ErbB2/neu, c-Myc and Id2 have been shown to 
block RB function by inducing its phosphorylation (ErbB2 and c-Myc) [5,6], or by 
binding and sequestrating it (Id2) [7,8]. These oncoproteins have been shown to 
be involved in the upregulation of cell proliferation, growth and the repression of 
differentiation, processes in which pol III transcription displays similar regulation. 
For this reason, their involvement in the regulation of pol III output was investi­
gated. The data presented here demonstrate tha t all three oncoproteins upregulate 
pol Ill-transcribed genes. Although these oncoproteins can inhibit RB function, 
only ErbB2/neu seems to induce pol III activity disrupting TFIIIB-RB complexes. 
In addition, consitutive activation of ErbB2/neu also produces several other changes 
tha t can affect pol III transcription, including protein modifications of the TFIIIB 
subunits TBP and Brf, as well as induction of TBP, the pol III subunit BN51 and 
the transcription factor c-Myc. Furthermore, it was demonstrated tha t by inhibit­
ing expression of c-Myc, the stimulation of pol III activity by ErbB2/neu could be 
overriden. Together these results suggest tha t constitutive activation of ErbB2/neu 
increases pol III transcription through several mechanisms, though induction of c- 
Myc appears to play an essential role in this upregulation.
On the other hand, the activation of pol III transcription by c-Myc and Id2 is 
through an RB-independent mechanism, since their overexpression in the absence
IV
of the entire RB family, still produced pol III upregulation. Instead, they activate 
directly pol III transcription. Chromatin immunoprécipitation revealed tha t both 
endogenous c-Myc and Id2 are present at class III genes in cultured mammalian 
cells. c-Myc and Id2 induction of pol III activity appears to be through direct 
mechanisms by interaction of these proteins with TFIIIB. In the case of c-Myc, 
coimmunoprecipitations demonstrated tha t it interacts with TFIIIB at physiological 
ratios. Furthermore, both endogenous c-Myc as well as endogenous Id2 were found to 
cofractionate with samples containing TFIIIB activity prepared on several columns, 
such as MonoQ gradients. From these results it can be concluded that endogenous 
c-Myc binds stably and specifically to TFIIIB. Further analysis has to be performed 
for to confirm the interaction between Id2 with TFIIIB.
In summary, this work has identified three oncogene products tha t can increase 
pol III transcriptional output. These findings have im portant implications for tu ­
mour development in a range of tissue types.
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1 In t ro d u c t io n
For a cell to express its genome, it needs to transcribe the message encoded in its 
DNA to molecules th a t will perform the functions required for life. To achieve this, 
the genes are converted (or transcribed) into RNA, in a process called transcription, 
which is then converted (or translated) into protein or employed as ribosomal or 
transfer RNA. The work described in this thesis concerns the transcriptional activity 
of eukaryotic cells, particularly tha t performed by RNA polymerase III.
Transcription is the process where one strand of DNA is copied by complementary 
base pairing into one strand of RNA. The RNA sequence is complementary to the 
template strand, which provides the template for its synthesis, and identical to the 
coding strand. RNA polymerase (pol) catalyzes the synthesis of RNA. Transcription 
starts when the enzyme is brought to a region in the DNA called the promoter, 
and is positioned at the start of the gene. From this point, called the startsite 
(or + 1), RNA polymerase binds the double helix of DNA, separating the strands. 
The template strand is now available for base pairing with ribonucleotides and the 
enzyme synthesizes nucleotide bonds in RNA. The DNA helix is unwound as the 
enzyme moves along the gene, covalently adding nucleotides to the 3’ end of the 
growing RNA chain, forming an RNA-DNA hybrid in the unwound region. This 
process continues until a terminator sequence is reached. At this sequence, no further 
bases are added to the RNA chain, the RNA-DNA hybrid is disrupted and both the 
enzyme and the RNA are released [9]. This is the general mechanism by which 
transcription is performed.
The work done in this thesis concerns transcription by RNA polymerase III 
(pol III). Its characteristics are going to be discussed in detail in the following sec­
tions. Pol III products are essential components of the protein synthetic machinery 
and therefore are essential for viability [10]. Its activity is controlled by a number 
of proteins involved in cell cycle regulation, like the tumour suppressors p53 and 
retinoblastoma (RB), by signal transduction pathways like the Ras signalling path­
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way and by viral proteins [11]. These proteins are common targets for deregulation 
in carcinogenesis, which might suggest a tight link between pol III transcription and 
cancer. Indeed, this appears to be the case since transformed and tumour cells show 
increased pol III transcriptional activity [12].
In particular, the work presented in this thesis studies the regulation of pol III 
transcription by three different oncoproteins, ErbB2/Iier-2, c-Myc and Id2. These 
proteins were chosen due to their relevance to cell transformation and oncogenesis, 
and the cellular changes they induce, like cell growth, where pol III transcriptional 
activation plays an im portant role.
The tyrosine kinase receptor ErbB2 is overexpressed in different types of carci­
nomas (e.g. breast, ovary, stomach, colon and kidney) and is associated with poor 
prognosis [13]. Its activation causes induction of several signalling cascades tha t af­
fect gene expression and induce cell proliferation [13], The third and fourth chapters 
address ErbB2 regulation of pol III transcription.
c-Myc is another oncoprotein with particular importance in cancer, as its dereg­
ulation is considered to contribute to one seventh of U. S. cancer deaths [14]. In 
normal cells, it is involved in cell cycle and cell growth control [15]. It has been shown 
to affect RB phosphorylation status and thus it might affect pol III transcription 
activity. Chapters five and six address c-Myc’s regulation of pol III transcription.
And finally, pol III transcriptional regulation by Id2 is addressed in chapter 
seven. This protein is also deregulated in some cancers. It can bind to and inactivate 
RB [16], which leaves an open window for pol III activation.
In this first chapter, pol III transcription, the proteins involved in it and its 
regulation by different factors are going to be described. The following chapters will 
contain a brief introduction to each oncoprotein and the results obtained concerning 
their participation in the regulation of pol III transcription.
1.1 Transcription in Eukaryotes
Prokaryotes (organisms tha t lack nuclei and membranous subcellular organelles) 
contain one RNA polymerase (pol); eukaryotes (organisms tha t contain a membrane- 
enclosed nucleus encapsulating their DNA, as well as membranous subcellular or­
ganelles) require three pols to transcribe their nuclear genes: pol I, pol II and pol 
III [9]. There is a fourth pol in the mitochondria, required for the transcription of 
mitochondrial genes. However, only nuclear pols are going to be discussed.
Pol I transcribes class I genes, encoding 5.8S, 188 and 288 ribosomal RNAs 
(rRNAs), from a single type of promoter. rRNA is synthesized at the nucleoli.
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where tandem arrays of genes specifying rRNA condenses. In these sites, rRNA 
is synthesized as well as processed and assembled into immature ribosomes. Then 
they are exported to the cytosol where the assembly is completed [17]. rRNA genes 
are contained in repeated clusters with mutliple copies of the genes specifying the 
188, 5.88 and 288 rRNAs invariably arranged in this order; and are separated by 
intergenic spacers, where the promoter lies. The core promoter lies <-^ 50 base pairs 
(bp) upstream^ of the startpoint; however its efficiency is quite low. This efficiency 
is very much increased by the presence of the upstream promoter element, 150-200 
bp upstream of +1. Pol I, as well as pols II and III, lacks specificity for particular 
DNA sequences, so to initiate transcription accurately and specifically, it requires 
the assistance of other proteins called transcription factors. U BFl binds to a GC 
-rich element in the core promoter and upstream promoter element; then the factor 
SLl is recruited by U BFl and extends the region of DNA that is covered. Finally, 
these factors recruit pol I to the core promoter and transcription is initiated [18].
Pol II transcribes class II genes encoding messenger RNA (mRNA), which is 
translated into protein, and almost all small nuclear RNAs (snRNAs) [19]. Tran­
scription by pol II occurs in the nucleoplasm. Usually, there is a single copy of any 
particular class II genes in an organism’s haploid genome [17]. In general, their 
promoters contain an initiator element, composed of the first base of mRNA be­
ing A surrounded by pyrimidines at position -3 and +5, and a TATA box located 
^25  bp upstream of -fl, composed of an 8 bp A /T  rich consensus [9]. As for pol 
I, pol II requires transcription factors to start transcription. There are around six 
basal transcription factors involved in initiation of pol II transcription. The order 
of association at pol II promoters of the transcription factors is as follows: TFIID, 
TFIIA, TFIIB, TFIIF, which is bound to pol II bringing it to the promoter, TFIIE, 
and TFIIH [19]. All these proteins constitute the basal apparatus required for pol 
II transcription.
1.2 RNA Polym erase III Transcription
Pol III transcribes class III genes which encode transfer RNA (tRNA), 58 rRNA, 
78L, 78K and a variety of other small cellular RNAs like U6 snRNA and viral VA 
RNA [10]. Pol III transcripts account for 5-10% of all nuclear transcription [20]. The 
transcripts have the common feature of being short (<300 bases) and not translated.
^By convention, if a sequence precedes the startpoint, it is referred to as upstream of it; when it 
is after the startpoint (in the transcribed region), it is referred to as downstream of it. When 
bases positions are numbered, the startpoint has the value of +1 assigned; positive numbers 
increase downstream while negative numbers increase upstream.
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Recently, by confocal and electron microscopy of HeLa cells’ nuclei, it has been 
discovered tha t pol III transcription occurs at discrete locations (^2000 sites) in the 
nucleoplasm  ^ [20]. These sites are specific for pol III, and each site has a diameter 
of ^40  nm with approximately five active polymerases [20]. To comprehend the 
results obtained in this thesis, the characteristics of pol III transcription have to 
be explained in greater detail. Pol III transcription is going to be divided into the 
following subsections: class III genes, promoters, transcription factors, pol III and 
transcription. The third and fourth sections will describe how it is regulated by 
different factors.
1.2.1 Class III Genes
Several pol III products are involved in RNA processing which is paramount for a 
cell to perform its functions. 5S rRNA is an essential component of the ribosomal 
large subunit [9j. It is 120 nucleotides long and like other rRNA genes, there are 
multiple copies of 5S rRNA arranged in clusters. These clusters consist of a 5S 
rRNA gene followed by an untranscribed pseudogene and a spacer, respectively [17]. 
In the human genome, 200-300 5S genes are found in tandem arrays, the largest of 
which has been mapped to chromosome one [22].
Another group of pol III products are transfer RNAs (tRNAs). They serve 
as translators between the triplet nucleic acid code of mRNA and the amino acid 
sequence of protein, by recognizing the sequence in mRNA and bringing with it the 
correspondent amino acid for the synthesis of the peptide chain [9]. There is at least 
one tRNA per amino acid. tRNAs are small molecules of 74-95 bases long, and have 
secondary structure as a cloverleaf [9]. In the human genome, there are ^^497 tRNA 
genes which are dispersed throughout the genome. However, more than 25% of these 
genes cluster at chromosome 6; smaller clusters appear on chromosome 7 and 1, and 
other chromosomes contain fewer than 10 tRNA genes each (except chromosomes 
22 and Y which don’t contain any) [23].
7SL RNA is also transcribed by pol III. It is an essential component of the 
signal recognition particle, involved in protein translocation across the endoplasmic 
reticulum [24]. It is 305 bases long [25] and provides the structural backbone of 
the signal recognition particle; without 7SL, the other constituents of the signal 
recognition particle (proteins) cannot assemble [26].
A fourth pol III product, 7SK, until recently, had no known function. Bensaude 
and Zhou’s groups found tha t it can modulate pol II activity by binding to and
^Pol II “factories” have also been detected in the nucleoplasm; in HeLa cells there are ~8000 of 
them [21].
1 Introduction
inhibiting the activity of P-TEFb, which is responsible for the phosphorylation of pol 
II’s carboxyl-terminal domain tha t is required for activation of transcription [27,28], 
7SK is transcribed from a single gene mapped to chromosome 6 [23].
Contrasting with other spliceosomal RNAs, which are transcribed by pol II, U6 
small nuclear RNA (snRNA) is also a pol III product [19]. It is involved in splicing 
introns of pre-mRNA [9]. There are multiple copies of U6 snRNA in the human 
genome (44) dispersed in chromosome 6 [23].
Another group of class III genes are the short interspersed elements or SINEs. 
The SINEs are repetititive sequences tha t occur throughout the DNA in segments of 
100 to several thousand bp, interspersed with larger blocks of unique DNA [17]. 13% 
of the draft human genome are SINEs, composed of three families: the active Alu 
(comprising 10% of the 13% mentioned above) and the inactive MIR and MIR3 [23]. 
Alus are approximately 300 bp in length [29]. In rodents’ genome, the active SINE 
B1 is analogous to human Alu [17,19]. Rodents also have an abundant SINE called 
B2 tha t is rare in humans. Their promoter regions are derived from tRNAs sequences 
(B2, MIR and MIR3) or 7SL sequences (Alu and B l) [23]. SINEs are often described 
as junk DNA; however, this conception has to be reconsidered. A recent report by 
Ferrigno et. al. has shown that B2 also contains an active pol II promoter outside 
the tRNA-derived region. W ith this promoter it regulates transcription of mouse 
Lama3, a class II gene, thus providing mobile pol II promoters [30]. Furthermore, 
repetitive elements also provide information on genome evolution [23].
Like pol II products, pol III products undergo processing. tRNAs require three 
processing steps for their maturation: 5’ end processing by the ribonuclease P 
(RNase P), 5’ and 3’ end processing by the human phosphoprotein La, and in- 
tron excision by endonuclease- and ligase-mediated splicing [31]. The RNA subunit 
of RNase P is transcribed by pol III from the R PR l gene. This RNA comprises the 
catalytic activity of RNase P, while protein subunits account for its structure [32].
Pol III also trancribes different viral genes like adenovirus VAl, or Epstein-Barr 
virus (EBV) encoded RNAs (EBERs) [10]. However, the bulk of pol III products 
are represented by the genes mentioned in the paragraphs above.
1.2.2 Promoters
Most class HI genes’ promoters have the characteristic of being localized downstream 
of the start site, within the transcribed region [10]. The promoters are composed 
of discontinuous internal elements or blocks within the gene [18]. Internal elements 
show a considerable degree of sequence conservation. There are three general types
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of class III promoters, depending on the blocks present in them. Type I and II lie 
downstream of +1, while type III contains upstream sequences [10]:
Type I promoters contain three internal regions; an A-block followed by an 
intermediate element and a C-block (Fig. 1.1). The space between the blocks is quite 
constant, transcription being affected if it is changed [33]. The transcription factor 
(TF) III A recognizes the blocks and initiates recruitment of the pol III transcription 
apparatus [34,35]. These promoters are found only in 5S rRNA genes.
Type II promoters contain two internal regions: the same A-block as in type 
I and a B-block (Fig. 11.1) [36]. In this case, the A-block is much closer to +1 
[37]. TFIIIC is required for direct promoter recognition, which nucleates complex 
assembly [10,38]. This is the most common promoter used by pol III, found in 
tRNA genes, the adenovirus VA genes and the SINEs. Some tRNA genes contain 
short introns within their coding regions [39,40], so the location of the B-block can 
be extremely variable [41].
In contrast to type I and II promoters, type III promoters are external. They are 
composed of three external elements: a distal sequence element (DSE), recognized 
by Oct-1 and Staf; a proximal sequence element (FSE) recognized by SN A Pc/PTF 
(PSE-associated TF); and a TATA-box bound by TFIIIB which confers pol III 
specificity  ^ (Fig. 1.1) [42,43]. Human and mouse U6 and 7SK genes contain this 
promoter (although some active U6 genes contain type II promoters) [42). Sac- 
charomyces cerevisiae U6 genes lack the DSE and PSE, but contain the A and B- 
blocks, the latter being in a unique location 100 bp downstream of the transcribed 
region [44].
Some class III genes with type I and II promoters also contain sequences upstream 
of - h i  tha t are required for efficient transcription. These sequences are not conserved 
between organisms nor between different pol Ill-transcribed genes [45]. For example. 
Drosophila’s tRNA genes [46] and Schizosaccharomyces pomhe class III genes [45] 
require a TATA-box like element between -25 and -30 bp. Moreover, tRNA genes in 
Gaenorhabditis elegans [47], Neurospora crassa [48], the silkworm tRNA^^“ [49] and 
human 7SL [50] need upstream sequences for their transcription.
^The U class spliceosomal RNA genes share the same promoter organization and can be tran­
scribed by pol II or pol III. The discrimination between pol Il/po l III is given by the TATA-box. 
If a TATA-box is present, pol III transcribes it; if there is none, transcription is performed by 
pol II [42].
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Figure 1.1; Structure of the three general types of promoters used by pol III. Rep­
resenting type I is the Xenopus somatic 5S rRNA genes, type II is from 
Saccharomyces SUP4 tRNA gene and type III is the human U6 snRNA 
gene. IE stands for intermediate element, PSE is proximal sequence el­
ement and DSE is distal sequence element. The site of termination is 
indicated by Tn. Adapted from ref. [10].
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1.2.3 Transcription Factors
Pol III lacks specificity for any particular sequence of DNA, like other pols. To 
initiate transcription accurately and specifically, pol III needs the assistance of other 
proteins to position it on the appropriate start site of class III genes. Each type of 
promoter has its own requirement for different transcription factors. TFIIIB and 
TFIIIC  are required for type I and II promoters; the former also needs TFIIIA  [10]. 
Type III promoters utilise SN A Pc/PTF, Oct-1, T F IIIC l but not TFIIIC2, and a 
TFIIIB th a t is separable chromatographically from the form used by types I and 
II [42].
TFIIIA
Xenopus laevis TFIIIA  was the first eukaryotic TF to be purified to homogeneity [51] 
and cloned [52,53]. The nine zinc fingers present in TFIIIA  recognise and bind to 
>50 bp of 58 rDNA. Three fingers (fingers 1-3) in the N-terminal domain recognise 
the C-block and wrap around the major groove (this interaction contributes -^95% 
of the total binding energy of full-length TFIIIA) [18]. The A-block is recognised 
by fingers 7-9 and the middle three fingers (4-6) bind to the interblock region of 
DNA [10]. TFIIIA is quite divergent between species, sharing similarity only at the 
zinc finger domains [18]. It is the first protein tha t recognizes and binds to 58 rDNA 
and then recruits TFIIIC  to the promoter [54].
TFIIIC
Type II promoters are recognized by TFIIIC. In S. cerevisiae, TFIIIC  or r  is com­
posed of six subunits, T F C l/r9 5 , T F C 3/rl38 , T F C 4/rl31 , TFC6/r90, TFC 7/r55 
and TFC8/r60, with an aggregate mass of 520 kDa. The subunits arrange in two 
globular domains: which is composed of T FC l, TFC4 and TFC7 and recognizes
the A-block, and r g ,  which is composed of TFC3, TFC6 and TFC8 and recognizes 
the B-block [38,55,56]. TFC8 serves as a linker between the two domains. Electron 
microscopy suggests th a t TFC8 stretches so tha t TFIIIC can contact both blocks. 
However, when the interblock DNA is too long, TFIIIC can loop out the DNA in 
between to be able to bind both blocks [55].
Human TFIIIC can be separated by ion exchange or sequence-specific DNA affin­
ity chromatography into two components, T FIIIC l and T FIIIC 2 [57,58]. T F IIIC l 
is generally required for transcription of all class III genes whereas TFH IC2 is only 
required for class III genes containing type I and type II promoters [59]. A third 
component, TFIIICO, has been purified from a phosphocellulose C fraction (fraction 
with TFIIIC activity purified from HeLa nuclear extracts) [59]. Footprint analyses
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showed that TFIIICO binds to the termination region of several class III genes and is 
partially able to substitute for T F IIIC l on type II promoters in vitro [59]. T F IIIC l 
enhances the binding of TFIIIC2, TFIIIA  and PTF, and is required for transcrip­
tional activity [59]. It binds after TFIIIC2 is already bound to the promoter [60].
As mentioned before, the initial recognition of type II promoters is performed by 
TFIIIC 2, through the B-block. When bound, it recruits T F IIIC l and TFIIIB [60]. 
TFIIIC2 is composed of five subunits, TFIIIC220/TFIIIC a, T F IIIC llO /T FIIIC ^, 
TFIIICIO2/T F IIIC 7 , TFIIIC90/TFIIIC5, and TFIIICOS/TFIIICe (the number cor­
responds to molecular weight in kDa) [61-64]. TFIIIC2 can be present in two forms: 
T FIIIC 2a, which is transcriptionally active and TFIIIC 2b, which lacks the TFIIIC/? 
subunit, and is transcriptionally inactive [65]. Moreover, all the subunits are ab­
solutely required for pol III transcription of class III genes containing type I and 
II promoters [10]. There is no homology of TFIIICa, and TFIIIC5 with any of 
the yeast TFIIIC  subunits, which seems quite striking since the sequences in A- 
and B-blocks are well conserved between species [63,66,67]. Three subunits, TFT 
IIC220, T FIIIC l 10 and TFIIIC90, display histone acetyltransferase activity (HAT), 
relieving chromatin-mediated repression of pol III transcription [68].
Crosslinking experiments have shown that TFIIIC220 is responsible for the bind­
ing to the B-block [66]. Its N-terminal domain associates with TFIIIC llO  while the 
C-terminal domain associates with T FIIIC 102 and TFHIC63 (Fig. 1.2) [69]. The 
TFIIIC220 gene is located at chromosome 16.
Sinn et al, using a cDNA library from a human immature myeloid cell line, 
isolated the second largest TFIIIC  subunit TFIIICllO  [67]. PSI-BLAST revealed 
tha t S. cerevisiae TFC6 exhibits sequence homology to human TFIIIC llO  [70]. 
Its gene maps to chromosome 2. TFHIC2b, although transcriptionally inactive, 
can still bind to DNA, demonstrating tha t TFIIICllO  is not required for DNA 
recognition [65].
TFIIIC102 has the highest homology of all the human TFIIIC  subunits with 
its yeast counterpart TFC4 subunit (31% identical) [62]. Its gene is localized at 
chromosome 9. Its amino terminal domain contains acidic regions, 11 copies of a 
tetratricopeptide repeat (TPR) and a helix-loop-helix motif [62]. Through its TPRs 
it interacts with TFIHC63 and TFIIIC90 [62]. The TPRs also recruit TFIIIB to the 
promoter by interacting principally with Brf, but also with B dpl (Fig. 1.2) [71-73]. 
In yeast TFC4, the region responsible for the interaction with Brf maps to the first 
168 residues [74]. In addition, two-hybrid screens have demonstrated an interaction 
between TPRs and the pol III subunits C53 and ABClOa [75,76].
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Figure 1.2: Representation of a network of interactions between the different sub­
units of human TFIIIC (green) and TFIIIB (blue). The different sub­
units of pol III (in yellow) have been ommitted for simplification, however 
the text mentions which subunits interact with TFIIIC.
Human TFIIIC90 was cloned by screening human cDNA cell libraries using de­
generate PCR primers [63j. It specifically acetylates K14 on histone H3 f68j. Direct 
interactions with TFIIIC90 in vitro have been seen with pol III subunit C39 (yC34), 
TFIIIB subunit Brf and TFIIIC subunits 220, 110 and 63 [63]. It can be seen as 
the linker between the subunits 220-110 that lie on the B-block and 63-102 that lie 
on A-block and upstream sequences and the homologue to S. cerevisiae Tfc8 (Fig. 
1.2). The TFIIIC90 gene maps at chromosome 9.
The smallest TFIIIC subunit, TFIIIC63, is homologous to S. cerevisiae TFCl 
(22% identical) [62]. Its yeast counterpart is responsible for the recognition of the 
A-Block [77]. The human TFIIIC63 gene is also localized at chromosome 9. As 
mentioned before, TFIIIC63 interacts with TFIIIC102, TFIIIC90 and with pol III 
subunit C62 ]62]. The protein contains a central helix-turn-helix motif and a C- 
terminal acidic region [62].
There is not much information concerning the regulation of TFIIIC genes. How­
ever, it is known that several conditions, e.g. viral infection or transformation, can 
induce protein levels and TFIIIC activity. This regulation is going to be addressed 
in further sections.
TFIIIB
Once TFIIIC has assembled on the promoter, it recruits TFIIIB. In S. cerevisiae^ 
TFIIIB is composed of three subunits, the TATA-binding protein (TBP) and two 
TBP-associated factors, Brf and B”. TBP and Brf form a very stable complex called 
B’, while B” is less tightly associated and can be separated chromatographically [78]. 
Human TFIIIB also contains TBP, Brf and B”, and might contain other unidentified
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components as well [18].
TBP is a general factor of 38kDa (human) required for transcription by all three 
nuclear pols [79-82]. Its C-terminal domain is very highly conserved between species 
(80% identical between yeast and human), while the N-terminal regions are more 
species specific [56]. The TBP residues involved in the interaction with Brf are 
located in the N-proximal TFIIA-binding lobe [83]. TBP-Brf complexes are found 
even if they are not bound to DNA. A general feature of TBP is that it sharply 
bends DNA; the TBP-Brf complex also bends DNA. Brf must pass accross the 
concave underside of the TBP-DNA complex in order to connect with sites of TBP 
lying on opposite sides of bent DNA [54]. In type III promoters, TBP binds to 
the TATA-box independently of Brf or B” [42]. Brf increases the affinity of binding 
between TBP-DNA complexes [84].
In promoters tha t lack a TATA sequence (type I and II), TFIIIB is recruited to 
the DNA through protein-protein interactions with TFIIIC [60]. The yeast subunit 
TFC4 (human TFIIIC102) is responsible for this recruitment, by interacting mainly 
with Brf, but also with B” [62,71-74]. Brf (or TFIIB-related factor) received this 
name because of its substantial homology to TFIIB, a basal factor that is essential 
in transcription by pol II. It is 23% identical and 44% similar to TFIIB in its N- 
terminal 320 residues [85-87]. Yeast Brf (yBrf) is also referred to as TFIIÏB70 since 
it has a molecular weight of 70 kDa [85]. Human Brf (hBrf) is a 90 kDa protein, of 
which its N-terminal domain is 24% and 41% identical to human and S. cerevisiae 
TFIIB, respectively [88]. Its C-terminal domain is moderately conserved [88]. TFIIB 
interacts with TBP; since a TFIIB-Iike region involved in this interaction is present 
in Brf, it was expected tha t this region was responsible for binding between Brf and 
TBP. Although a weak interaction is observed at this region [89-91], the principal 
Brf region tha t regulates binding to TBP is at the less conserved C-terminal domain 
[83, 90-92]. Brf thus contains two separate TBP-binding domains, allowing the 
interaction with opposite sites of the TBP-DNA complex [83,90,91]. The C-terminal 
domain also interacts with pol III and B” [93]. Brf recruits pol III by interacting 
with pol IIPs subunit yeastC34/humanC39 [91,93,94]. However, effective pol HI 
recruitment to double-stranded DNA requires the entire TFHIB-DNA complex [95]. 
The conserved N-terminal domain of Brf, like tha t of TFIIB, is comprised of a zinc- 
binding region followed by a conserved block of ~15 residues [96]. This zinc-binding 
region is not required for pol HI recruitment, but its disruption causes a defect in 
open complex formation [96]. The B’-TFHIC-DNA complex generates a DNase I 
footprint that covers the start site of transcription and extends further upstream and
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stabilizes binding of TFIIIC to the A-Block [74,97]. So, Brf can be seen as the glue 
between TBP and B” holding TFIIIB together, as the key for TFIIIB recruitment 
to TATA-less promoters by interacting with TFIIIC, and as the recruiter of pol III 
to class III genes.
Once the B’-DNA complex is formed, the last component of TFIIIB, B” binds 
to it. The entry of B” changes the physical properties of the TFIIIB-TFIIIC-DNA 
complex [98]. Yeast B” (or TFIIIB90) is a 90 kDa protein with a SANT domain 
(motif associated with protein-protein and protein-nucleic acid interactions) [99]. 
The SANT domain is quite conserved among putative homologues (S. cerevisiae, 
S. pombe, Drosophila melanogaster, and G. elegans) and helped to find the human 
homologue by homology-based PCR [100]. This domain is associated with protein- 
protein interaction, as well as protein-DNA interactions. Human B” is 160 kDa and is 
absolutely required for pol HI transcription [100]. It also receives the name of Bdpl. 
Three separate segments are required for viability in yeast: region I (aminoacids or 
aa 372 to 487 including the SANT domain), II (aa 312 to 269) and III (aa 263 to 
158) [101]. In yeast, when B” is incorporated into a TFHIB-DNA complex, region I 
and II undergo an extensive burial of surface, while region III is unfolded [98]. The 
first two regions are required for function and are where the interaction with the 
TFIIIB components and the TFIIIC  subunit TFC4 occur; the third region is not 
essential for transcription in vitro [98]. As mentioned before, Brf interacts with yC34 
of pol HI. However the B’-TFIIIC-DNA complex is unable to stably incorporate pol 
III. B” entry to the complex causes the following changes [98]:
• Nuclease protection upstream of the start site is more complete and extended 
'-^10 bp;
• The transcriptional start site becomes available to DNase I cleavage by the 
shifting of TFIIIC and presumably leaving this region clear for pol III binding;
• Photochemical cross-linking of DNA to TFC4 and TBP upstream of the tran­
scriptional start site is diminished;
•  B ’-DNA complex becomes more resistant to high salt and polyanions, making 
the TFHIB-DNA complex more tightly bound, and;
•  Pol HI can stably assemble over the start site of transcription.
All these changes allow pol III transcription to be achieved. A recent article appoints 
B” to be also involved in tRNA processing. As mentioned before, RNase P trims 5’
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ends of pre-tRNA to generate mature tRNA [32], but how this complex is brought 
into contact with its substrate is not known. Ishiguro et. al. demonstrated th a t B” 
interacts directly with RNase P, suggesting the participation of B” in the recognition 
process [101].
In mammalian cells, TATA-containing promoters (type III) appear to use a vari­
ant of the TFIIIB complex. This TFIIIB is composed of TBP, B” and a Brf-related 
factor of 50 kDa referred to as BrfU [100]. Therefore, to distinguish the two dif­
ferent complexes, the complex composed of TBP, B” and BrfU has been termed 
T FIIIB a, and the complex composed of TBP, B” and Brf (Brfl) has been termed 
TFIIIB/5 (for simplicity, TFIIIB/? will be referred here as TFIIIB) [100]. The N- 
terminal domain of BRFU is related to both hBrf and TFIIB, the C-terminal domain 
is divergent [100]. TBP, through its C-terminal core domain, recruits BrfU to the 
TATA-box of the snRNA U6 gene, by interacting with the repeat 2 of the BrfU 
core [102]. Depletion of BrfU debilitates transcription of U6 genes, but addition of 
recombinant BrfU cannot reconstitute transcription. This might suggest the exis­
tence of BrfU-associated polypeptides tha t are essential for transcription [100]. A 
different factor called Brf2 has been reported to be required for U6 transcription. 
Brf2 originates from an alternatively spliced Brf pre-mRNA. This protein lacks the 
Zn ribbon domain and the first repeat present in Brf and TFIIB [103]. W hether 
both BrfU and/or Brf2 are required for U6 transcription remains to be determined.
S N A P c /P T F  and Oct-1
U6 and 7SK genes, tha t contain type III promoters, have different TF requirements 
than those from type I and II promoters. As mentioned before, they utilize TFIIIB a, 
and T F IIIC l but not TFIIIC2. In addition to these TFs, the TFs SNAPc/PTF 
and Oct-1 are necessary for initiation of transcription [42], and a role for the TF 
Staf has also been described [104]. SN A Pc/PTF recognizes and binds to the PSE 
[100,105]. It is a complex of five subunits with approximate molecular masses of 
190, 50, 45, 43, and 19 kDa. SNAP43 and 19 interact with the N-proximal one- 
third of SNAP190, while SNAP45 binds to the C-proximal region of SNAP190; 
SNAP50 is bound to SNAP43 [106]. Oct-1 binds to the octamer sequence of the 
DSE [107]. It contains activation domains as well as a POU domain. The POU 
domain is a bipartite DNA binding domain composed of two flexibly joined helix- 
turn-helix structures, the N-proximal POU-specific (POUg) and the C-proximal 
POU homeodomain (PO U y) segments [108]. The SNAPc-DNA and Oct-l-DNA 
complexes are bound relatively weakly. Each complex is stabilized by interacting 
cooperatively with one another, and this interaction is mediated by the C-proximal
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half of SNAP190 (which occludes the DNA-binding N-proximal domain) and the 
POUg domain of Oct-1 [106,109,110]. TBP binding to DNA is also regulated by 
SNAPc. The N-proximal leader domain of hTBP blocks binding to its TATA site. 
The SNAPc-190]\j-43-50 sub complex interacts with this TBP region, relieving the 
autoinhibition and allowing TBP binding to the TATA-box. TBP then recruits 
BRFU and B” [111].
1.2.4 RNA Polymerase III
In yeast, pol III is composed of 17 subunits; 14 homologuons subunits have been 
found in human [56]. Some subunits are shared by pol I (referred to as A), pol II 
(referred to as B) and pol III (referred to as C); others have homology to subunits 
present in other pols and some are specific to each enzyme. Of the 17 subunits 
of pol III in S. cerevisiae, ABClOa, ABC 10^ 0, ABC14.5, ABC23 and ABC27 are 
shared by all three pols, AC19 and AC40 are shared with pol I, C160, C128, C25 
and C ll  are homologous to either pol I or II, and C82, C53, C37, C34, C31 and 
C17 are unique to pol III [19,56]. The core is composed of five subunits: C160, 
C128, AC40, AC19 and ABC23 (shown in dark yellow in Fig. 1.3). Most of the 
unique subunits (except C37), in addition to ABClOa, appear to function in the 
recognition of the TFIIIC-TFIIIB-DNA initiation complex and pol III recruitment 
to its promoters (Fig. 1.3) [45]. Specifically, two hybrid experiments have shown 
tha t the subunits C34 and C17 interact with the TFIIIB subunit Brf, while ABClOa 
and C53 (human ortholog BN51) interact with the TFC4 (TFIIIC102 in humans) 
subunit of TFIIIC that lies over the transcriptional start site (Fig. 1.3) [75,76]. C34 
forms a sub-complex with C31 and C82 (represented in orange in Fig. 1.3). The 
whole sub-complex is im portant for initiation, since a pol III m utant lacking it is 
unable to initiate transcription specifically [112].
A human holopol III has been prepared by immunoselection from extracts of 
HeLa cells with a FLAG-tagged gene for the C53 subunit. It contains T FIIIC 2, 
T F IIIC l (as judged by DNA footprint), and Brf, TBP and La protein [113-115]. 
In addition, nuclear factor 1, PC4 and topoisomerase I have been reported to be 
associated with TFIIIC2, although its relevance still remains to be determined.
1.2.5 Transcription 
Initiation
Several steps are involved in the initiation of transcription by pol HI. As mentioned 
before, the enzyme has to be recruited through protein-protein interactions to the
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Figure 1.3: Network of interactions in S. cerevisiae pol III, TFIIIB and TFIIIC sub­
unit Tfc4. Orange subunits represent a pol III sub-complex required for 
initiation; the core subunits are in dark yellow. Red dots mark interac­
tions deduced by two-hybrid analysis and black arrows mark interaction 
inferred from multicopy suppression of temperature-sensitive mutations 
(the arrowhead pointing to the suppressed mutation (Adapted and edited 
from [45])
start site. In type III promoters, Oct-1 and SNAPc bind separately to its respective 
sequence, while TBP binds to the TATA-box. Then, TBP recruits the B” and BrfU 
and the latter recruits pol III to the start site. It is not known how TFIIIBa recniits 
pol III [42].
Pol III recruitment to TATA-less promoters is better characterized for the yeast 
tRNA and 5S rRNA genes. The steps involved are:
1. T F IIIC  recognition and binding to  the p ro m o ter. TFIIIC binds to the 
A- and B-Block (or in the case of 58 rRNA genes is brought by protein-protein 
interactions with TFIIIA which binds to the A and C-block) (Fig. 1.4, first 
panel). The location of the different TFIIIC subunits on the SUP4 tRNA gene 
has been found through photocrosslinking to chemical probes [38]. TFC3 and 
TFC6 interact around the B-Block ensuring primary binding to tDNA [II6|. 
TFCl and TFC7 bind in the vicinity of the A-Block on opposite sides of the 
DNA helix [38]. TFC8 does not appear to be bound to DNA and finally, 
TFC4 is cross-linked upstream of -fl, in a region occupied by TFIIIB, and 
downstream between the A- and B-Block [38].
2. T F IIIC  recru itm en t o f  TF IIIB . Once TFIIIC2 is bound to tDNA, it can 
recruit TFIIIB. First, Brf is brought to the DNA by interaction with TFC4 [71, 
74,97, ]. TBP is already bound to Brf, so it is brought by Brf, although TFC8
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also participates in this recruitment [117]. This entry causes stabilization of 
the TFIIIC-DNA complex, increasing the cross-linking of TFC4 to upstream 
DNA [97]. Finally, once the B ’-TFIIIC-DNA complex has formed, B” enters 
the complex. B” is recruited by TFC4 and Brf [73,101]. As mentioned before, 
it increases stability of the complex and shifts TFIIIC leaving the DNA at the 
start site free for pol III binding [98]. The location tha t TFIIIB occupies in 
the tDNA is determined mainly by TFIIIC; however, TBP can also scan the 
region around -30 to choose an optimal site [118]. It occupies a region of ~40 
bp immediately upstream of the transcription start site [54, 90,119]. In the 
SUP4 tRNA gene, TBP cross-links in the minor groove at bp -30 to -20 in the 
coding strand and from -28 to -24 in the template strand [119]. B” and Brf are 
positioned on opposite sides of the TBP-DNA core (Fig. 1.4, panel 2) [119]. Brf 
binds the TBP-DNA complex through the C-terminal region, requiring 15 bp 
downstream of the TATA-like sequence and just 1 bp upstream of it [93]. The 
N-proximal segment of B” cross-links to the upstream end of the TFIIIB-DNA 
complex (approximately 8 bp of the TATA-like sequence), and the C-terminal 
domain is located downstream of the TATA-like sequence [120].
3. T F II IB  rec ru itm en t o f  P o l I I I .  When the TFIIIC-TFIIIB-tDNA complex 
has formed, pol III is recruited to the start site (Fig. 1.4, panel 3). TFI­
IIB alone is responsible for pol III recruitment to the start site. This was 
demonstrated due to the extreme stability of the TFIIIB-DNA complex in 
yeast, since stringent conditions like high salt concentrations (1 M KCl) or 
poly anions (heparin) cannot dissociate the complex, while TFIIIC and T FI­
IIA are readily removed [121]. After exposure to these treatments, pol III 
can still be recruited to class III genes by TFIIIB'^ [121]. Pol III is recruited 
mainly through Brf-C34 (human ortholog C39) interaction, although B rf-C l7 
and TBP-C34 interactions have also been observed [112,125,126]. C53 (hu­
man ortholog BN51) might also be involved in pol III recruitment, through its 
interaction with TFC4, although this remains to be determined [76]. At the 
tDNA, C34 cross-links at the furthest upstream end (bp -17 and -3/-2) from 
the major groove [127], C31 and C82 lie just upstream (bp -3/-2) of the start 
site in vicinity of the non-transcribed strand [128], and C53 contacts it near 
the downstream end of the transcription complex [129].
4. D N A  m eltin g . Upon binding of pol III, the double-stranded DNA is melted
^In the human, the dissociation pathway is the reverse from that of the yeast. TFIIIB is lost 
first, whilst TFIIIC-DNA complexes are more stable [122-124].
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Figure 1.4: Assembly pathway used by genes containing type II promoters for ini­
tiation of transcription in Saccharomyces cerevisiae. TFIIIC recognises 
directly the sequences in the promoter and binds to it. Once bound, it 
recruits TFIIIB by protein-protein interaction, which is positioned up­
stream of +1. Finally, TFIIIB mediates pol III recruitment to the start 
site (+1). Adapted from ref. [10].
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and a bubble forms which extends from -11 and propagates downstream of 
the start site. This separation occurs spontaneously, without ATP hydrolysis, 
unlike pol IPs melting, which requires ^7  bond hydrolysis [130]. Brf and 
B” play a role in this process since certain mutations in these prevent the 
formation of a strand-separated open promoter [92]. B” is involved in unpairing 
of the upstream segment, while Brf unpairs DNA around the transcriptional 
start site [131]. The mechanism of action still remains to be determined.
Elongation, Termination and Reinitiation
Once the DNA is melted, pol III dissociates from the TFIIIB-DNA complex without 
significant pausing or arrest after several ribonucleotides have been incorporated 
[130,132]. As it moves along the gene, the bubble of melted DNA moves with 
it [130]. TFIIIC and TFIIIA  occupy regions tha t are going to be transcribed by 
the enzyme, but these potential obstacles do not seem to affect elongation of pol 
III transcripts. The presence of TFIIIC  delays polymerase by just 0.2 s at a single 
site upstream of the B-BIock making no difference in overall transcription rates (if 
pol III transcribes in the antisense direction, TFIIIC causes a pause of 9 s, while 
TFIIIB  of >1 h) [133]. tRNA elongation in yeast at 20° C occurs at an average of 
~20 nt/s; however, it does not proceed evenly, pausing at internal sites [134]. This 
pausing is associated with the subunits C ll  and 0128 [135,136]. C l l  affects repair 
of nucleotide misincorporation and the efficiency of termination. C l28 is involved in 
catalyzing RNA cleavage, as well as C160 [135-137].
Pol III transcription generally terminates at a run of four or more thymidine 
(T) residues; the efficiency of termination is influenced by flanking sequence and 
increases with the length of the T-run [138-140]. Although pol III is sufficient for 
termination [140], additional factors have also been implicated in human cells. The 
phosphoprotein La may be required for release of RNA chains at the terminator and 
for execution of additional rounds of transcription [141,142]. Moreover, the protein 
N Fl in conjunction with TFIIIC, is claimed to promote accurate termination and 
also reinitiation of transcription [143].
Since class III genes are small units, pol III never leaves the vicinity of the 
promoter, allowing multiple rounds of transcription to occur. The bending of DNA 
feature of pol III TFs facilitates pol III re-attachment to the same transcriptional 
unit. Subsequent cycles of transcription occur more rapidly (~35 s) than the first 
one (~5 min) [144].
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1.3 Activities Regulating RNA Polym erase III 
Transcription
Since the genes transcribed by pol III, like tRNA and 5S rRNA, are an essential 
component of cellular metabolism and the translation machinery, the physiological 
relevance of regulating its transcription is readily appreciated. A substantial part 
of metabolic energy consumed by growing cells goes to the biogenesis of ribosomes; 
the activity of pol I, responsible for the transcription of large ribosomal RNA, is 
closely correlated with cell growth and proliferation. Since pol III products are also 
core components of ribosomes, it would be a waste of energy to regulate only pol 
I transcription and leave pol III activity unfettered. In fact, increasing amounts of 
data show that pol III transcription is strongly regulated by a variety of conditions, 
like cell growth, differentiation and proliferation, viruses, transformation and cancer 
[11,145-147]. In no case of regulation has the polymerase itself been found to be 
controlled; instead the activities of TFIIIB and TFIIIC have been implicated. Due 
to its significance for the work produced for this thesis, the regulation of pol III 
transcription during cell growth and proliferation are going to be addressed in detail 
in another section.
Differentiation
In early mouse embryogenesis, pol III transcript levels are drastically reduced in the 
parietal endoderm [148]. Using F9 embryonal carcinoma cells, this reduction has 
been attributed to down-regulation of TFIIIB, through a decline in abundance of 
TBP and more dramatically of Brf as well as T F IIIC l [2,149,150]. It is interesting to 
note tha t c-Myc’s mRNA and protein levels decline and are virtually undetectable in 
differentiated F9 cells [151]. In addition, Id2 levels are also reduced by differentiation 
[152]. These data might suggest a link between these oncoproteins and pol III 
transcription.
Viruses
There is a lot of evidence showing tha t several viruses can stimulate pol III transcrip­
tion [11]. Viruses often require an increased cellular biosynthetic capacity, which is 
in part achieved by stimulating pol III transcription. Moreover, some of them also 
contain genes transcribed by pol III [153]. These viruses, and/or their products, are 
able to transform cells and participate in the process of carcinogenesis [145]. Studies 
using cell lines transformed with viral oncoproteins have shown abnormally elevated 
levels of pol III transcripts [154,155].
19
1 Introduction
Some tumour viruses, like adenovirus and Simian Virus 40 (SV40), have similar 
mechanisms of increasing pol III transcription in HeLa cells or rodent fibroblasts, 
respectively. When human cells are infected by them, pol III transcripts like Alu 
elements [156,157], as well as tRNA, 5S rRNA and U6 snRNA are increased dram ati­
cally [158-160]. Adenovirus contains two class III genes, VAI and VAII [153]. These 
are synthesized at high levels during late stages of infection, and are required in 
subverting the host cell translational apparatus into synthesis of viral proteins [161]. 
Adenovirus protein E lA  and the large T antigen of SV40 activate pol III tran­
scription by increasing the availability of TFIIIC2a, through the overexpression of 
TFIIIC llO  [67,159,160,162,163]. Moreover, SV40-transformed fibroblasts overpro­
duce other subunits of TFIIIC2 [162]. Herpes simplex virus type 1 also activates 
pol III transcription by increasing the activity of TFIIIC [156,164].
Another mechanism of pol I l l ’s activation is by inactivating the retinoblastoma 
protein (RB). Adenovirus E lA  and SV40 large T antigen bind to RB, relieving 
TFIIIB  from RB’s repression (explained further in the next section) [3,162,165]. 
Moreover, the viral protein E7 from human papillomavirus can also activate pol 
III transcription by binding and inactivating RB [162]. Furthermore, SV40 large T 
antigen can also interact with other components of the pol HI preinitiation complex. 
Damania et al. have shown by coimmunoprecipitation and cofractionation tha t SV40 
large T antigen binds to the TFIIIB subunit TBP [158]. In addition, the human T- 
cell leukaemia virus type 1 tax protein stimulates pol HI transcription by increasing 
the effective concentration of active TFIIIB molecules [166].
Hepatitis B virus (HBV) utilises a different mechanism for inducing pol HI tran­
scription. Its oncoprotein X is essential for viral replication and is also implicated in 
the development of HBV-mediated carcinogenesis, since it can induce liver tumours 
in some transgenic mice [167]. It activates protein kinase C (PKC) and Ras-Raf- 
Mek-mitogen activated protein (MAP) kinase signal cascades [168]. All three classes 
of pol HI promoters are transactivated by X. The mechanism involved appears to 
be through an increase in the cellular levels of TBP and therefore TFIIIB activ­
ity [169,170].Wang et. al. demonstrated tha t the increase in TBP and enhancement 
of pol III transcription are dependent on the ability of X to activate the Ras/Raf-1 
signal transduction pathway [168]. In this study, they showed tha t if Ras activ­
ity is blocked by transient expression of a dominant-negative m utant Ras gene in 
a Drosophila stable cell line or by incubation with a Ras farnesylation inhibitor, 
both X-dependent activation of pol HI transcribed genes and the increase in cellular 
TBP are blocked. The ErbB2 receptor can induce activation of the Ras-MAPK
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pathway [13]. It will be interesting to study if ErbB2 uses a similar mechanism as 
HBV protein X to activate pol HI transcription.
Transformation and cancer
The mechanisms by which viruses contribute to the formation of tumours may in­
volve the deregulation of pol HI transcription. Some viral proteins have the feature 
of transforming cells when transfected. As described above, transformed cell lines 
with viral oncoproteins express abnormally elevated levels of pol HI transcripts. In­
deed, transformed clones tha t are more malignant in nude mice display the highest 
abundance of pol HI products [160]. As well, cell lines transformed with chemical 
carcinogens (e.g. the tumour-promoting phorbol ester 12-0 -tetradecanoylphorbol- 
13-acetate) express high levels of pol HI products [10]. Moreover, different types of 
cancers, like breast carcinoma, colon adenocarcinoma and skin fibrosarcoma, display 
an increase of pol HI transcripts compared to the surrounding tissue [171,172]. A 
link between pol III activation and transformation is also suggested by experiments 
using two fibroblast lines transformed with temperature-sensitive mutants of the 
SV40 large T  antigen. At the non-permissive temperature, pol III gets downregu- 
lated and the cells revert to normal morphology and phenotype [154].
At the moment, there is little information on how pol III transcription gets 
deregulated in vivo. Using ovarian tumors. Winter et. al. found tha t the activation 
of pol HI transcription is due to an increase of TFIIIC activity [12]. These data 
provide the first direct evidence of a pol HI TF being deregulated in malignant 
human cells. In addition, the group of Grzeschik determined the physical local­
ization in the human genome of the TFs involved in pol III transcription. They 
discovered, by chromosomal in situ hybridization, radiation hybrids and somatic 
cell hybrid analysis, tha t the genes for SNAPcl, SNAPc2 and a TFHIB-associated 
protein (GTF3BAP2), are localized within chromosomal regions where recurrent, 
cytogenetically detectable mutations are seen in specific neoplasias, such as carci­
noma of the salivary glands and hemangiopericytoma, or where mutations causing 
inherited genetic diseases map, such as Peutz-Jeghers syndrome, making them in­
teresting candidates for involvement in these pathologies [173].
Finally, products transcribed by pol III have been shown to be oncogenic. EBV is 
a human herpesvirus tha t is associated with >90% of B urkitt’s lymphoma (BL) [174], 
As mentioned before, pol HI synthesizes EBER RNAs, and these products have been 
shown to have a role in tumor development and oncogenicity when transfected into 
human cell lines [174], The present data exposes a role for pol III transcription 
in carcinogenesis, so it will be very interesting to study what other factors and/or
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oncoproteins can regulate its activity.
1.4  Proliferation I
For a cell to proliferate (increase in cell number), it requires both to double its mass :
(cell growth) as well as its DNA content. For this to be accomplished, all eukaryotic ■
cells must follow a correct program, called the cell cycle. The cell cycle is defined as 
the period between two mitotic divisions. While cell growth is a continuous process, 
replication of the DNA occurs only during a specific period.
1.4.1 The Cell Cycle
The cell cycle can be divided into four phases: M phase, or mitosis, where a cell 
is divided into two daughter cells; G1 phase, which follows M phase and is when 
RNAs and proteins are synthesized; S phase, where the DNA is replicated, marking 
the transition from G l; and G2 phase, where the cell continues to grow until the 
next mitosis starts. The different phases of the cell cycle are intimately regulated 
through proteins tha t are periodically expressed within an appropriate window of 
the cycle, and this regulation is at the transcriptional level [9]. Only the cell cycle 
regulation of pol III transcription is going to be described.
1.4.2 Cell Cycle Control of  RNA Polymerase III 
Transcription
During mitosis, all transcription appears to be globally repressed [175]. In the case 
of pol III transcription, this is due to the phosphorylation and inactivation of TFI­
IIB (Fig. 1.5) [146,176,177]. Specifically, using Xenopus eggs, it was shown that 
the mitotic kinase cdc2/cyclin B phosphorylates TBP and a 92 kDa TAF (possi­
ble Xenopus homologue of Brf) [177]. Since Xenopus eggs only display S and M 
phases, somatic cells (with G l, S, G2 and M phases) were used to study if these 
mitotic changes also happen in cells with normal cycles. For this. W hite et. al. 
utilised HeLa cells synchronized at mitosis. In these cells, it seems tha t TBP is also 
hyperphosphorylated, however this phosphorylation is not through cdc2/cyclin B 
kinase and is not limiting for transcription of TATA-less templates. The decrease 
in TFIIIB  activity appears to be through reduced activity of one or more TFIIIB 
TAFs, but the details still remain to be determined [146].
After exiting mitosis, pol HI transcription remains low but increases through G l, 
being at its maximal expression during S and G2 phases [147]. Again, the limiting 
factor responsible for this low activity is TFIIIB. Although it loses its phosphoryla-
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Figure 1.5: Regulation of pol III transcription by the cell cycle in mammalian sys­
tems. At mitosis and G l, transcriptional activity is low compared to 
S and 02 . At mitosis, transcription is repressed by phosphorylation- 
mediated inactivation of TFIIIB. In early G l, although TFIIIB phospho­
rylation is relieved, transcription still remains low due to RB repression 
of TFIIIB. After the G l/S  transition, transcription increases 2- to 3-fold 
and remains elevated until the end of G2. Active TFIIIB is represented 
in green while inactive TFIIIB in red.
tion after mitosis, its activity remains low in early G l phase and increases as cells 
move into S phase (147). At S and G2 phases pol III transcription reaches its max­
imum (Fig. 1.5). During these phases, the availability of TFIIIB has increased so 
that is not the limiting factor anymore. At this stage, TFIIIC becomes the limiting 
factor for pol III transcription (147). In G l, pol III transcriptional activity is mainly 
regulated by the retinoblastoma tumour suppressor protein (Fig. 1.5).
The Retinoblastoma Protein
The retinoblastoma protein (RB) is a 105 kDa nuclear phosphoprotein that is ubiq­
uitously expressed in normal mammalian cells [3j. It regulates cell cycle progression 
by restraining the passage of G l to S phase if growth factors are limiting [178]. 
In early Gl or when growth factors are limiting, RB is in a hypophosphorylated 
form which is able to bind and repress transcription factors like E2F. However, if 
growth factors are plentiful, at mid to late Gl RB becomes hyperphosphorylated 
at multiple sites by cyclin D- and E-dependent kinases (cyclin D/cdk4/6 and cyclin 
E/cdk2) [178]. This hyperphosphorylated form of RB cannot bind to E2F; there­
fore E2F becomes active and promotes transcription of a variety of class II genes 
involved in cell cycle progression, allowing transition to S phase (178). RB remains 
hyperphosphorylated during S, G2 and M phases, being only active in early G l and
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Figure 1.6: Mechanims of pol III inactivation by RB. Hypophosphorylated form of 
RB binds and sequesters TFIIIB from the initiation complex, disrupt­
ing interactions between TFIIIB and TFIIIC, and TFIIIB and pol III. 
Adapted from ref. [182].
GO.
The fact that TFIIIB’s activity is low during the early part of G l despite having 
been released from mitotic repression from, raises the possibility that another factor 
(or factors) are involved in its regulation at this stage. As mentioned above, TFIIIB 
activity increases at late G l which coincides with RB inactivation, targeting RB as a 
good candidate for pol III repression in G l. There is a substantial weight of evidence 
showing this to be the case. RB can repress pol III transcription in vivo, when it is 
overexpressed in cells [3], and in vitro using purified pol III factors [179]. Primary 
fibroblasts from RB-knockout mice display four to fivefold increased pol III activity 
compared to wild-type cells [3|. In addition, pull-down and coimmunoprecipitation 
experiments demonstrate that RB interacts with TFIIIB, and SNAPc [179-181]. An 
interaction between TFIIIC2 and RB has also been reported, although confirmation 
has not been achieved [181]. Although RB interacts with several pol III TFs, TFIIIB 
is the principal target of RB-mediated repression ]179,180]. As with E2F, only 
the hypophosphorylated form of RB can bind to these proteins [4]. TBP is also 
involved in RB regulation, since its addition can restore efficient U6 transcription 
from RB-treated extracts [181]. One mechanism that RB uses to inhibit pol III 
transcription is by sequestering TFIIIB and disrupting the interactions between 
TFIIIB and TFIIIC2, and TFIIIB and pol III (Fig. 1.6) [182]. In conclusion, 
RB can be seen as a general regulator of pol III transcription, since it can repress 
transcription from every pol III template tested (tRNA, 5S rRNA, U6 snRNA, and 
Alu) ]3,162,180].
RB contains a motif known as the pocket. There are two other RB-related 
proteins, pl07 and pl30, which also contain the pocket region and are referred to as
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pocket proteins [178]. The pocket consists of two domains, A and B, separated by 
a nonconserved spacer. This region is essential for the interaction of RB, pl07 and 
pl30 with cellular proteins like E2F or with several viral oncoproteins [183]. pl07 
and pl30 play an im portant role in cell cycle regulation, like RB [183]. Since they 
share a number of functions with RB, they might also regulate pol III transcription. 
Sutcliffe et. al. demonstrated in vivo and in vitro that indeed this is the case [184]. 
Overexpression of pl07 and pl30 in transfected cells results in a decrease of pol 
III transcription [184]. Furthermore, they associate stably with TFIIIB [184]. The 
RB family has also been shown to regulate pol III transcription in growth-arrested 
fibroblasts. In low serum conditions, fibroblasts undergo growth-arrest (GO), exiting 
the cell cycle . The levels of pol III transcription in these cells decrease significantly 
as they switch to GO [4,185]. This downregulation is due to specific reduction of 
TFIIIB activity, being inactivated by pl30 during GO and early G l phase and RB 
during G l [4].
Since RB controls cells progress into S phase, lost of RB’s function results in 
uncontrolled proliferation. In many human cancers, if not all, RB’s function appears 
to be compromised. This is achieved by mutations that inactivate the RB gene, e.g. 
in retinoblastoma, small-cell lung carcinomas and other sarcomas and carcinomas; 
or by the disruption of the regulatory pathway of RB [19]. A common control 
point tha t is disrupted in a number of cancers is the cyclin D-dependent kinases, 
specifically showing an increase in cyclin D1 levels [19]. Therefore, the mechanisms 
by which RB controls the cell cycle are very im portant to understand. All the 
oncoproteins studied in this doctoral thesis are able to deregulate RB activity. It 
will be interesting to study if RB inactivation is involved in their regulation of pol 
III transcription.
p53
Another tumour suppressor involved in the regulation of the cell cycle is p53. p53 
inactivation is considered to be an im portant step in carcinogenesis, since more than 
half of all human tumours have lost p53 protein or have mutations in the gene [9,19]. 
Normal cells express low levels of p53. When a cell suffers DNA damage there is 
an increase in the amount of p53. Two types of events can be triggered by the 
activation of p53: growth arrest and apoptosis, depending on various conditions. If 
it is in early G l, p53 can block further progression through the cell cycle, allowing 
DNA damage to be repaired. However, if it is committed to division, p53 may trigger 
apoptosis. Moreover, the decision between arrest and apoptosis is also determined 
by the cell type and the nature of stress, not only on the cell cycle’s phase [9], p53
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has been shown to regulate pol III transcription. Overexpression of p53 in vitro 
or in transfected cells represses pol III activity [186]. Furthermore, using knockout 
technology it has been demonstrated th a t pol III transcription is increased 4-6-fold 
in p53 knockout fibroblasts from mice ]187]. In addition, tumour-derived mutants 
of p53 lose their ability to repress pol III transcription. Primary fibloblasts from 
individuals with Li-Fraumeni syndrome, who inherit m utant forms of p53, show 
highly elevated pol III transcriptional activity [188]. When p53 is neutralized by 
oncoproteins like human papillomavirus E6 or cellular hdm2, pol III transcription 
gets elevated [188]. p53’s repression of transcription has been shown to be through 
the inhibition of TFIIIB [186,187]. Recombinant p53 interacts with TBP and Brf 
subunits of TFIIIB [186], and coimmunoprecipitates with TFIIIB at physiological 
ratios [187]. TFIIIB stability can also be affected by p53 in a human fibroblast cell 
line [189].
At the moment, cell cycle regulation of pol III transcription has been shown to be 
through regulation by the tumour suppressors p53 and RB family. There are other 
cell cycle regulators tha t have not been investigated yet, leaving an open window for 
their study. c-Myc is an im portant cell cycle regulator, making it a very interesting 
candidate.
1.4.3 Cell Growth and RNA Polymerase III
For a cell to double its DNA and divide, a critical growth rate has to be attained 
in order to conserve cellular resources for daughter cell survival. If DNA is man­
ufactured faster than proper growth is achieved, the cell becomes unstable and 
dies [15]. Therefore, a tight equilibrium between cell growth and cell cycle must be 
accomplished for successful proliferation. A cell grows by increasing its proteins and 
macromolecules. Since proteins constitute the bulk of a cell’s dry mass, the growth 
rate is directly proportional to the rate of accumulation of protein [11]. In fact, 
if protein synthesis is reduced by 50%, cells withdraw from cycle and quiesce [II]. 
Thus, an increase in the protein synthetic machinery will be required for successful 
growth. Ribosomes and tRNAs, as well as translation initiation factors, are con­
stituents of the translational machinery. Thus, their availability is going to be an 
im portant determinant of the rate of translation. Since 58 rRNA and tRNAs are 
pol III products, a high level of pol III transcription is essential for cell growth.
Mitogenic stimulation triggers a coordinate induction of rRNA, tRNA, ribosomal 
proteins and translation factors, causing an increase in the rate of translation [1]. It 
would be interesting to study how this coordination of transcription from different
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genes is accomplished. c-Myc has been shown to regulate transcription of ribosomal 
genes as well as tha t of translation initiation factors, however it is not known if it 
can regulate 5S rRNA or tRNA expression [15]. Since it would be a waste of energy 
to regulate only one set of genes and not the others, it is quite plausible tha t c-Myc 
also regulates transcription of these pol III products.
1.5 O bjectives
As presented in this introduction, pol III transcription can be regulated by several 
proteins and conditions. Conditions like cell cycle progresion, growth, differentiation 
and transformation are regulated by a wide variety of proteins, from plasma mem­
brane receptors to transcription factors. In particular, three proteins have received 
a lot of attention due to their oncogenic potential; the plasma membrane receptor 
ErbB2/neu, and the transcription factors c-Myc and Id2.
The plasma membrane receptor ErbB2/neu induces cell proliferation by activat­
ing several signalling cascades which will alter the expression of genes and ultimately 
induce this process. Some of the signalling cascades it activates include the Ras and 
PI3K signalling cascades. This receptor can also block the inhibitory function of RB 
by affecting its phosphorylation status. Since pol III transcription can be activated 
by the signalling pathways tha t ErbB2/neu activates, the first aim of this thesis was 
to investigate whether the activation of ErbB2/neu can induce pol III activity, and 
if so, what mechanism or mechanisms are involved in this process.
In addition to the effects already mentioned, ErbB2/neu can also stimulate the 
expression of the transcription factor c-Myc. This protein has been studied thor­
oughly because of its role in tumour formation. Furthermore, it has been shown to be 
a regulator of cell growth. As stated in this introduction, the products synthesized 
by pol III have a direct effect upon cell growth, and their availability is an im portant 
determinant of growth rate. Since c-Myc is a positive regulator of growth, another 
aim of this thesis is to investigate the participation of this transcription factor in 
the possible upregulation of pol III transcription in ErbB2/neu overexpressing cells, 
as well as when it is overexpressed by itself.
A possible mechanism by which c-Myc could regulate pol III transcription is 
through the inactivation of the RB family. In the literature there is a bulk of 
evidence showing tha t c-Myc is responsible for the induction of proteins th a t will 
ultimately phosphorylate RB, thus preventing its repressive influence. Since pol III 
transcription is tightly regulated by the RB family, it will be interesting to study if 
this is the mechanim by which c-Myc could be inducing pol III transcription.
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Finally, the regulation of pol III transcription by a third oncoprotein, Id2, will 
also be studied. Id2 can bind and inactivate RB, and has been shown to prevent cells 
from differentiating. Furthermore, recent reports have shown tha t the induction of 
this transcription factor responds to N-Myc. This suggests tha t the ability of Id2 
to overcome the inhibitory function of RB may provide an additional route tha t 
enables the Myc family to ensure high levels of pol III activity. Because pol III 
transcription reacts to RB activity, as well as being inhibited by differentiation, Id2 
strikes as another possible regulator of its activity. Therefore, the last aim of this 
thesis will be to investigate whether Id2 can exert any effect on pol III transcription.
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2 M a te r ia ls  and M e th o d s
2.1 Cell culture
The ROSE cell lines were obtained from Bruce A. J. Ponder [190], which were pro­
duced by stably transfecting ecotropic retroviruses expressing the ^-galactosidase 
gene or a mutated rat neu/c-erhB2 oncogene. The ROSE cell lines, Balb/c 3T3 
(Â31), and mouse embryo fibroblasts (RB wild type and knockout) and primary 
fibroblasts from wild-type or RB, pl07 and 130 triple knockout cells (TKO) were 
routinely cultured in DMEM (Dulbecco’s Modified Eagle Medium) containing 10% 
fetal calf serum (PCS, Sigma), 2mM L-glutamine, lOOU/mi penicillin and 100 jug/ml 
streptomycin and in a humidified atmosphere containing 5% 0 0 2  at 37°0. The 
medium of the ROSE cell lines also contained 0.6 mg/ml G418. In the case of the 
RB mouse embryo fibroblasts (MEFs), the medium required addition of an insulin- 
transferrin-selenium supplement (5 ml in 500 ml of medium, Life Technologies). 
The primary and TKO cells medium was supplemented with 1 mM non-essential 
aminoacids, 1 mM sodium pyruvate and 0.1 mM ^-mercaptoetlianol. The Chi­
nese hamster ovarian (OHO) cells expressing haemagglutinin (HA)-tagged Brfl were 
grown in Glasgow’s MEM containing 10% ECS, 2 mM L-glutamine, 100 U /m l peni­
cillin and 100 Mg/ml streptomycin supplemented with 0.5 m g/m l G418. These cells 
were grown under the same criteria as the ones already mentioned.
Cell culture was performed in a class II hood, using aseptic technique and sterile 
equipment and reagents. Cells were passaged when subconfiuent; approximately 
every 2 to 3 days. After media was aspirated from the flask, 2ml of buffered trypsin- 
EDTA (0.05% trypsin, 0.02% EDTA) was added to the cells, then aspirated imme­
diately. A further 2ml was added and left for approximately 5 minutes at 37° C. 
Following addition of trypsin, fresh media was immediately added to the dissociated 
cells which were centrifuged at 1200g for 5 minutes. The media was removed and 
the pelleted cells were then resuspended in fresh 10% FCS DMEM solution at a 
ratio of 1:10, or as appropriate.
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Cryo-freezing was used for storage of all cell lines. Cells were trypsinised as 
described and, following pelleting by centrifugation, were resuspended in a solu­
tion of DMEM, 20% FCS and 10% dimethylsulphoxide (DMSO). 1 ml aliquots of 
resuspended cells were placed into 1.5 ml cryo-tubes and frozen in stages by ini­
tially being placed at -80°C overnight and subsequently being transferred to liquid 
nitrogen storage. Thawing of cells was performed rapidly by placing cyro-tubes in 
a waterbath at 37°C until just thawed. Cells were then mixed with fresh media, 
centrifuged and the supernatant aspirated off to ensure removal of DMSO prior to 
resuspension in 10% FCS DMEM.
The samples from Chapters 5 and 6 came from Robert Eisenmann group in 
Seattle, prepared by Carla Grandori. Briefly, the MyC^/+ and Myc“ /“ rat fibroblasts 
had been previously described ( [191]), and correspond to the cell line TG R-1, an 
fiprrsubclone of the immortalized embryonic rat fibroblast cell line Rat-1 and c- 
myc knockouts produced by gene targeting of this cell line. The cells were grown 
in DMEM supplemented with 10% CS at 37°C in an atmosphere of 5% COg. The 
WI38 cells (ATCCcat H 75-ccl) are human primary fibroblasts and were prepared as 
previously described [192]: cells were thawed and split once before infection. On day 
1, subconfluent WI38 cells were infected with 5 ml of viral supernatant (pBabe-puro 
vectors expressing either c-M yc-E R ^^ and A-Myc-ER^^^) in a 10 cm plate in the 
presence of 4 /rg/ml polybrene. On day 2, infection was repeated again. On day 3 
cells were split 1:4 or 1:6 in phenol-red free medium containing 10% fetal calf serum 
and selected in the presence of puromycin at 2.5 irg/ml. Selection was monitored 
by control cultures not exposed to the virus, tha t generally died in 2 or 3 days 
upon puromycin adition, while little or no cell death was detected in the infected 
cultures. Cells were grown to confluence, usually 1 week, without further media 
changes. Density-arrested cultures were induced with 200 nM 4-OHT or serum 
starve (0.1% FCS) for 36-48 h and then induced. Where specified, Of-amanitin at 20 
/ig/m l was added prior to addition of 4-OHT.
2.2  Primers and Cycling Parameters
The primers and cycling parameters are shown in table 2.2 on the following page.
2.3  Plasmids
For the in vitro transcription assays, the plasmid templates used were as follows: 
pVAl is a 221bp Sall-Ball fragment of adenovirus 2 DNA containing the VAl gene 
subcloned into pUC18; PHu5S3.1 is a 638-bp RamHI-SacI fragment of human ge-
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Transcript Prim ers P roduct No Cycles
Program  (D énatura­
tion; Cycling; F inal 
Extension)
A R PP PO 5’-G CA C TG G A A G TC C A A C TA C TTC -3’5’-T G A G G T C C TC C T T G G T G A A C A C -3’ 266 bp 18-22
95° C for 2 min;
95°C for 1 min, 58°C 
for 30 s, 72° C for 1 
min;
72° C for 3 min
B2 5 ’-G G G G C TG G A G A G A TG G C T-3’5’-C C A T G T G G TT G C T G G G A T -3’ 120 bp 15-18
95°C for 3 min;
95°C for 30 s, 58° C for 
30 s, 72° C for 30 s;
72° C for 5 min
BN51 5’-C C TA C A C A G TC TG TA C C C TG G -3’5’-G G C A T A T TT C G A G TG TC G TT C C -3’ 150 bp 18-22
95° C for 150 s;
95° C for 30 s, 68° C for 
30 s, 72° C for 30 s;
72° C for 5 min
Cyclin D2 5’-CTGCCCCCA CCTA GATCATA-3’5’-TCCCTTA TG C TG TA C TTC A A A TA G G -3’ 112 bp 20
94° C for 90 s;
94° C for 15 s, 62° C for 
23 s, 72°C for 30 s;
72° C for 5 min
GA PDH 5’-T C C A C C A C C C TG TT G G T G T A -3’5’-ACCA CAGTCCATGCG ATCAC-3’ 452 bp 18-22
95°C for 3 min;
95° C for 30 s, 58° C for 
30 8, 72° C for 30 s;
72° C for 5 min
M2
5’-T C C TG G C A G G C T TC T G A A -3’
5’~C C A TTC A A C TTG TC C TC C -3’ 115 bp 18-22
94° C for 3 m in;
95° C for 30 s, 66° C for 
40 s, 72°C for 1 min; 
72° C for 5 min
p21
5’-G C C T C C T T T C T G T G C C T G A -3’
5’-C C A G C C C TT G G A T G G T T T-3’ 254 bp 30-36
95° C for3 min;
95°C for 1 m in, 52°C 
for 1 m in, 72°C for 1 
min;
72° C for 5 min
snRNA U6 5’-GCTCGCTTCGGCA GCACA TA TA C-3’5 ’-TATCGAACGCTTCACGAATTTGCG~3 96 bp 18-20
95°C for 3 min;
95° C for 1 m in, 60° C 
for 30 s, 72° C for 1 
min;
72° C for 5 m in
T B P 5’-GCTCGCTTCGGCA GCACA TA TA C-3’5’-TA TC G A A C G C TTC A C G A A TTTG C G -3’ 660 bp 25
95° C for 2 min;
94°C for 1 min, 56°C 
for 1 min, 72°C for 3 
min;
72° C for 10 m in
T FIIIC  220 5’-TC C A G C G A G A C C TTC A C A C C -3’5’-G G A T T G A G T G T T G C T G G G C T -3’ 144 bp 20-25
95°C for 3 min;
94°C for 20 s, 62° C for 
30 s, 72° C for 30 s;
72° C for 10 m in
T FIIIC  110 5’-C C A G A A G G G G TC TC A A A A G TG C -3’5’-C TTTC TTC A G A G A T-G TC A A A G G -3’ 303 bp 20-25
94°C for 3 min; 6 cy­
cles (95°C x lm , 66°C 
x40,72°C x40s 
94° C for 20 s, 62° C for 
30 s, 72° C for 30s;
72° C for 10 min
tR N A ^eu 5 ’-GA GGACAACGGGGACAGTAA-3’5 ’-TCCACCAG AAA AACTCCAG C-3’ 88 bp 25-30
95° C for 3 min;
95° C for 30 s, 68°C for 
30 s, 72° C for 30 s;
72° C for 5 min
tR N A ^yi' 5’-A G G A C T T G G C T T C C TC C A TT -3’5’-GA CCTA AGG ATGTCCGCAA A-3’ 84 bp 25-30
95°C for 3 min;
95°C for 1 m in, 65°C 
for 30 s, 72° C for 15 s; 
72°C for 5 min
58 rRNA 5’-GG CCATACCACCC TGA ACG C-3’5’-CAG CACCCGG TA TTCCCAG G-3’ 107 bp 15-18
94° C for 3 min;
95°C for 30 s, 58° C for 
30 s, 72° C for 1 min; 
72° C for 10 min
Table 2.2: Primers and Cycling Parameters.
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Protein Antibody Type Company
TFH IC220 4286 Serum In house
TFHB C18 Polyclonal Santa Cruz Biotechnology
pp44/42 MAPK 9102 Polyclonal Cell Signalling Teen.
phospho-p70^^'^ 92055 Polyclonal Cell Signalling Tech.
Cyclin D1 72-130 Monoclonal Santa Cruz Biotechnology
Cyclin E C19 Polyclonal Santa Cruz Biotechnology
RB 03-245 Monoclonal Pharmingen
phospho-RB 9300 Polyclonal Cell Signalling Tech.
RB C15 Polyclonal Santa Cruz Biotechnology
TAFy48 M19 Polyclonal Santa Cruz Biotechnology
Brf 128 Serum In house
TBP SL-1 Polyclonal Santa Cruz Biotechnology
TBP m TBP-6 Monoclonal In house
c-Myc 9E10 Monoclonal Santa Cruz Biotechnology
Cyclin A BF683 Monoclonal Santa Cruz Biotechnology
BN51 113 Serum Gift from M. Ittm ann
Max H-2 Monoclonal Santa Cruz Biotechnology
Id2 C-20 Polyclonal Santa Cruz Biotechnology
E7 TVG7 lOY Monoclonal Santa Cruz Biotechnology
E47 N-469 Polyclonal Santa Cruz Biotechnology
TBP 58C9 Monoclonal Santa Cruz Biotechnology
Cyclin D1 R124 Monoclonal Santa Cruz Biotechnology
Table 2.3: List of antibodies.
nomic DNA containing a 5S rRNA gene, subcloned into pBR322 pBluescript SK+; 
tRNA^®^ is a 240 bp EcoRLHind III fragment carrying a tRNA^®^ gene subcloned 
into pAT153; tRNA^^S is a 500 bp Hind HI fragment carrying a tRNA'^^S gene 
subcloned into pA TI53.
For the transfections, the plasmid templates used were as follows: pCAT (Promega) 
contains the chloramphenicol acetyltransferase (CAT) gene driven by the simian 
virus 40 promoter and enhancer; pRc-CMV-Myc is a 2.7 Kb (1.8 Kb c-myc cDNA 
+  ~0.9 Kb HBV term inator and T3 excised from psp271-Myc) H indlll/X bal frag­
ment containing full length c~myc gene subcloned into pRc-CMV; pRc-CMV is a 
Stratagene vector; pcDNA3-Id2 contains the Id2 gene subcloned into pcDNA3.
2 .4  A ntibodies
The list of antibodies is shown in table 2.3.
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2.5 RNA Extraction
For the extraction of total cellular RNA, cells were grown to 80% confluence and then 
TRI reagent (Sigma) was utilised in accordance with the m anufacturer’s instructions. 
TRI reagent is a solution of guanidine thiocyanate and phenol. When cells were 80% 
confluent, media was aspirated off, and each dish was harvested by scraping in 1ml 
of TRI reagent per dish and transferred to a sterile eppendorf tube where they 
were left to stand for 5 min at room temperature allowing complete dissociation of 
nucleoprotein complexes. After this period of time, 0.2ml of chloroform was added 
to each tube and the samples vortexed for 15 seconds and left to stand for another 
15 min at room temperature. Then the samples were centrifuged at ISOOO^ r for 15 
minutes at 4°C, separating the contents of the samples into three phases: a lower red 
organic phase containing protein, a middle white interphase containing precipitated 
DNA and an upper colourless aqueous phase containing the RNA. 400 ir\ of the 
upper phase was carefully removed, avoiding contamination from the remaining 
phases, and transferred to fresh eppendorf tubes. The aqueous RNA phase was 
then mixed with isopropanol (500 /il) and thoroughly mixed by repeated inverting. 
This was left for 5 - 1 0  min at room temperature for the maximal precipitation to 
occur and then the samples were centrifuged again at 13000// for 10 min at 4°C. 
The supernatant was discarded and the remaining RNA pellet was washed with 1ml 
of 75% ethanol made up with diethypyrocarbonate (DEPC)-treated dHgO (0.1% 
DEPC), thoroughly mixed into solution, left overnight at room temperature and then 
autoclaved to inactivate the remaining DEPC. After vortexing each sample, they 
were spun at 7500^ for 5 min at 4°C. Then supernatant was thoroughly removed and 
appropriate volumes of DEPC-dH20 (from 10 to 50 fA, depending on the size of the 
pellet) were added to the RNA pellets. The samples were heated in a 65°C waterbath 
for 1 0 - 1 5  min, shaking them throughout this period, allowing resuspension of 
the RNA. Once the RNA was resuspended, the samples were stored at -70‘^ C. To 
determine the RNA concentration of each sample, UV spectrophotometry was used 
with the following formula: R N A  concentration (/ig/ml) — x 40 x dilution 
factor. To determine the purity of the RNA, the readings obtained at 260nm and 
at 280nm were divided and if the ratio was in the range of 1.8 - 2, it indicated that 
the RNA samples were relatively free from contamination with DNA or protein.
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2.6  Northern Blot Analysis
10-20 fig of total RNA samples were usually used in analysis, made up to a total 
volume of 10 jrl with DEPC-dHgO. Each RNA sample was mixed with 10 /il of 2 x 
RNA sample buffer composed of 1 x MOPS comprised of solutions made up with 
DEPC-dHgO (20mM MOPS pH 7.0, 8mM sodium acetate, ImM EDTA pH 8.0) plus 
4.4M formaldehyde and 54% formamide and heated for 15 min at 65°C to denature 
the RNA secondary structure. After the incubation, the samples were immediately 
transferred to ice to prevent any renaturation and were briefly microcentrifuged to 
bring down evaporated solution. Then, 2 /il of Im g/m l ethidium bromide and 2 /il 
of 10 X RNA loading buffer (50% glycerol, ImM EDTA, 0.25% bromophenol blue, 
0.25% xylene cyanol EE) were added to the reaction. The samples were then loaded 
in a denaturing gel (1% agarose, 2.2M formaldehyde, 1 x MOPS) in 1 x MOPS, 
which had been previously pre-run at 40V for 20 min, and run for approximately 
5 hours at 40V allowing separation of different sizes of RNA. After electrophoresis, 
the gel was visualised under a UV transilluminator in order to confirm separation 
and photographed. It was then washed for 20 minutes in 20 x SSC buffer (3M NaCl, 
0.3M sodium citrate pH 7.0) prior to capillary transfer as described by Maniatis et 
al.
To transfer the gel, it was placed on a bridge of W hatm ann 3MM chromatography 
paper supported on a glass plate and suspended over a reservoir of 20 x SSC buffer 
into which the tip ends of W hatm ann 3MM paper were soaked. An appropriate 
size of Hybond N nylon membrane optimised for nucleic acid transfer (Amersham) 
was pre-soaked in 20 x SSC and positioned over the gel, followed by a further two 
layers of pre-soaked W hatm ann paper; and taking care of removing all air bubbles. 
This arrangement was surmounted with a stack of paper towels and an appropriate 
weight in order to allow efficient capillary action. During transfer, the migration of 
the RNA from the gel to the nylon membrane is facilitated by the passive movement 
of the transfer solution through the gel. This was left overnight to ensure a high- 
transfer efficiency. Following transfer, the RNA was fixed to the membrane by 
UV-crosslinking at 1200 fiJ and was then washed for 5 minutes in DEPC-dHgO.
Radiolabelled DNA probes complementary in sequence to a particular RNA of 
interest were used to locate it on the membrane. The pol HI B2 gene probe was 
a 240bp EcoRI-PstI fragment from pTB14 and the pol II acidic ribosomal phos- 
phoprotein PO (ARPP PO) probe, a Ikb EcoRI-HindlH fragment from the mouse 
cDNA. The probes were labelled using a Megaprime DNA labelling system (Amer­
sham) according to the random oligonucleotide priming method of Feinberg and
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Vogelstein. Basicallly, 5 jA of random hexamer oligonucleotide sequences and the 
appropriate volume of DEPC-dH20 were added to achieve a final volume of 50 fil 
to 25ng of purified DNA template. This mixture was denatured by heating at 95°C 
for 5 minutes. DNA synthesis is primed by the hexamer oligonucleotides which are 
able to anneal to the DNA during slow cooling to room temperature. After dénat­
uration, 4 jj,\ each of dATP, dGTP, dTTP (in Tris-HCl pH 8.0, 0.5mM EDTA), 50 
/iCi of [cK-^ P^] dGTP (lOmCi/ml, 3000Ci/mmol) and 2U DNA polymerase I Klenow 
fragment (in lOOmM potassium phosphate pH 6.5, lOmM 2-mercaptoethanoi, 50% 
glycerol) were added and labelling was carried out at 37°C for Ihour in 1 x reaction 
buffer (containing Tris-HGl pH 7.5, 2-mercaptoethanol, MgC12, Amersham). The 
reaction was stopped by heating at 80°C for 5 minutes and kept at 4°C until the 
nylon membrane with bound RNA had been pre-hybridised. This involved rotation 
in a hybridisation oven at 45°C for 20 minutes in 20ml of hybridisation buffer (0.2M 
sodium phosphate buffer pH 7.2, ImM EDTA, 1% (w/v) BSA, 7% (w/v) sodium 
dodecyl sulphate (SDS), 45% (w/v) formamide in DEPC-dH20). Following this, the 
radiolabelled probe was added to 20ml of fresh hybridisation buffer, in which the 
membrane was incubated with rotation at 45°C overnight.
The following day the nylon membrane was washed with rotation in wash buffer 
(40mM sodium phosphate buffer pH 7.2, ImM EDTA, 1% (w/v) SDS in DEPC- 
dH20) at room tem perature for 2 minutes and then twice for 15 minutes at 65° C in 
order to remove non-specific radioactivity before being exposed to autoradiography 
film overnight at -80°C. Membranes were stripped by incubating in boiling water 
for 5 minutes and pre-hybridised again prior to being reprobed. Quantification of 
the RNA was achieved by scanning the autoradiograph and then analysed using the 
software NIH-Image.
2.7  Preparation o f  c D N A s
cDNAs were prepared from 3 /ig of RNA. To each sample was added 1 irl of hexanu- 
cleotide diluted 1:10 (Roche) with DEPC-dH20 and was brought to a final volume 
of 12 (A with DEPC-dH2 0 . Primer annealing was carried out at 70°C and allowed 
to proceed for 10 minutes before transferral to ice. After quickly chilling on ice and 
microcentrifuging to bring down the evaporated material, 4/A of 5 x First Strand 
Buffer (Life Technologies), 2 /il of O.IM DTT, 1 /il of lOmM dNTP mix (made up 
in DEPG-dH20) were added and incubated for 2 min at 42°G. Following this in­
cubation, 1 /il (200U) of Superscript II Reverse Transcriptase (Life Technologies) 
was added to initiate reverse transcription, which was performed for 50 min at 47°G
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before the reaction was stopped by heating at 70°C for 15 min. An extra 20 fû of 
DEPC-dH2 0  were added to give a final concentration of 60 fA.
2 .8  Reverse transcriptase - Polym erase chain  
reaction (R T -P C R )
PCRs were carried out using a PTC-100 thermal controller (MJ Research, Cam­
bridge, MA). 2 fA of cDNA was amplified with 20pmol of primers. Amplification 
reactions contained 0.5U of Taq DNA polymerase (Promega) in 20 /il of 1 x Taq 
DNA polymerase buffer (Promega) containing 1.5mM MgC12, 0.2mM of each dNTP 
plus 1 ^Ci of [a^^P] dCTP (lOmCi/ml, 3000Ci/mmol). After PCR, 20 fA of for­
mamide loading buffer (98% formamide, lOmM EDTA pH 8.0, 0.025% bromophenol 
blue, 0.025% xylene cyanol FF) were added to each sample and the reaction prod­
ucts were resolved on 7% polyacrylamide sequencing gels containing 7M urea and 1 
X THE (45mM Tris, 45mM boric acid, 0.625mM EDTA pH 8.0). Gels were pre-run 
for 30 minutes at 40W in 1 x TBE and 2 fA of each sample was loaded after being 
boiled at 95°C for 2 minutes and quenched on ice. Electrophoresis was carried out 
for a 1 hour at 40W and the gel subsequently vacuum-dried at 80°C for 1 hour before 
being exposed to autoradiography film in order to detect the radiolabelled products. 
Quantification of results was achieved by scanning the autorads and analysed using 
the NIH-Image software.
2.9  Preparation o f  W hole  Cell Extracts and 
Protein Fractions
Whole cell extracts were prepared from cells grown to approximately 80% conflu­
ence in 10cm tissue culture plates. Everything was performed on ice as rapidly as 
possible and all solutions and tubes were kept ice-cold to maintain cell activity and 
avoid protein degradation. Cells were washed twice with 5ml of ice-cold-PBS be­
fore being scraped with a plastic spatula into 5ml of fresh ice-cold PBS. They were 
collected in 50ml Falcon tubes and pelleted by slow centrifugation at 1200g for 8 
minutes at 4°C. The supernatant was decanted and the cell pellet was resuspended 
in 1 ml of fresh ice-cold PBS and transferred to eppendorf tubes. These were then 
microcentrifuged briefly at 4°C to re-pellet the cells and the PBS removed. The 
volumes of cell pellets were then measured by comparison with pre-measured vol­
umes of water. Microextraction requires pellets to be between 50 - 150 /il, giving 
approximately 0.5 - 3 x 10  ^ cells; larger pellets were subdivided. An equal volume of
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freshly made pre-cooled microextraction buffer (450mM NaCl, 50mM NaF, 20mM 
Hepes pH 7.8, 25% glycerol, ImM DTT, 0.5mM PMSF, 0.2mM EDTA, 40 /ig/m l 
bestatin, 1 /ig/m l trypsin inhibitor, 0.7 /ig/m l pepstatin, 0.5 /ig/m l aprotinin, 0.5 
/ig/m l leupeptin) was added to the cells and, following resuspension, the cells were 
immediately snap-frozen on dry ice. Cells were then placed in a 30°C waterbath 
until just thawed, before being immediately returned to dry-ice. This freeze-thaw 
procedure was performed a total of 3 times to ensure optimal cell lysis. After the 
last thaw, the cells were microcentrifuged at 7000g for 7 minutes at 4°C. The su­
pernatant was carefully recovered into a fresh tube, leaving behind the cell debris, 
and then promptly aliquotted and snap frozen. These whole cell extracts were then 
stored at -80°C.
Glutathione 8-transferase (GST) fusion proteins GST-Myc-N262 and GST-Myc- 
C92, as well as GST-Max and GST, were kindly provided by Robert N. Eisenman. 
GST-MyC“N262 contains residues 1-262 of the N-terminal region of c-Myc, while 
GST-Myc-C92 contains the last 92 residues of the carboxyl-terminal region. GST- 
Max contains full size Max protein.
HeLa nuclear extracts were purchased from the Computer Cell Culture Center 
(Mons, Belgium). PC-B is the 0.1 to 0.35 M KCl step fraction from phosphocellu- 
lose step chromatography containing both TFHIB and pol HI. QS-PC-B contains 
TFHIB that has been fractionated by gradient chromatography on Q-Sepharose fol­
lowed by step chromatography on phosphocellulose. The TFIIIC  fraction was oligo- 
purihed (Phosphocellulose followed by S-Sepharose and then a B-block DNA-affinity 
column). The TFHIB fractions were prepared by step fractionation on phosphocel­
lulose followed by a MonoQ gradient. The pol HI fraction was prepared by step 
fractionation on phosphocellulose and DEAE-Sephadex. All these fractions were 
kindly provided by Robert J. White.
In vitro translated pCITE-Brf was produced using the STP3 Kit (Novagen), 
according to manufacturer’s procedures. Basically, 8/il of STP3 T7 Transcription 
Mix was mixed with 0.5 /ig of DNA plasmid to a final volume of 10 fA. This reaction 
was stirred and incubated at 30°C for 15 min. After incubation, 30 /il of STP3 
Translation Mix and 4 fA (40 /iCi) ^^S-methionine were added and brought to a final 
volume of 50 fA with nuclease-free water. This reaction was gently stirred with the 
pipette tip and incubated at 30°C for 1 hour. The protein translation was confirmed 
by analysing with SDS/PAGE, followed by drying the gel and autoradiography at 
room temperature.
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2 .1 0  D eterm ination o f  Protein Concentration
The protein concentration of samples was determined using Bradford’s reagent (Bio­
rad). Quantification of the colour reaction produced upon mixing 1ml of diluted 
reagent (1:4 in distilled water) was measured at an absorbance of 595nm in a UV 
spectrophotometer, which gave a reading proportional to increasing amounts of pro­
tein. At a range of 1-12 /ig of protein, under these conditions, the absorbance is 
approximately linear. Absorbance readings obtained were then compared to a set 
of standards of known protein concentration using bovine serum albumin (BSA) 
measured at 595nm. A range of sample dilutions were measured and compared in 
this manner in order to obtain an average, which would provide a more accurate 
measurement of protein concentration. Where sample absorbance readings fell out­
side the linear range of the standard set, appropriate dilutions were made and the 
samples were re-measured.
2 .11  Transformation o f  c o m p e te n t  cells
E.coli XL-1 Blue supercompetent cells (Stratagene) were transformed for plasmid 
storage and propagation. Cells, which were stored at ~80°C and highly tempera­
ture sensitive, were thawed on ice to prevent loss of transformation ability. Once 
thawed, 50 /rl of cells per transformation reaction were exposed to 0.4 jnl of (d- 
mercaptoethanol (at a final concentration of 25mM), which enhances transformation 
efficiency by disrupting disulphide bonds of plasma membrane proteins. Typically 
10-20ng of plasmid DNA was then gently mixed into the chilled cells. The reaction 
was left for a 30 minute incubation on ice, in which the contents were gently tapped 
occasionally. After the 30 minute incubation, the cells were heat shocked at 42°C 
for exactly 45 seconds and then transferred to ice for a further 2 minutes. Cells 
were incubated at 37° C for 1 hour on an orbital shaker (225 - 250rpm) following 
the addition of 450 pi of preheated (42°C) SOC medium (LB broth, 0.04% glucose, 
lOmM MgS04, lOmM MgC12). Typically, 150 pi of the transformation mixture 
was then plated on LB agar (2% LB, 2% agar) plates containing 50 pg/m l ampi- 
cillin (Amp) and the plates were incubated at 37°C overnight to allow growth and 
colony-formation of the transformed cells.
2 .12  Preparation o f  plasmid DNA
For large scale plasmid DNA preparation, a single isolated bacterial colony was 
selected from a freshly-streaked plate and used to inoculate 4 ml of LB medium con­
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taining the selective antibiotic (50 pg/m \  ampicillin). This was allowed to incubate 
with vigorous shaking at 37°C for ^ 6  hours and was then used to inoculate 250 ml 
of the same medium and left to grow overnight with vigorous shaking at 37° C on 
an orbital shaker (~300rpm). The following day, cells were harvested by centrifu­
gation at 6000// for 15 minutes at 4°C and plasmid DNA was retrieved using the 
QIAGEN Plasmid Maxi Kit following the procedure described in it. The bacterial 
pellet was resuspended in 10 ml of Buffer P I (50mM Tris pH 8.0, lOmM EDTA, 100 
pg/m l  RNase A) and then gently but thoroughly mixed with 10 ml of Buffer P2 
(200mM NaOH, 1% SDS) to initiate an alkaline lysis reaction. This reaction was 
allowed to proceed for 5 minutes at room temperature before neutralising the lysate 
by the addition of 10 ml of chilled Buffer P3 (3M potassium acetate, pH 5.5), which 
subsequently resulted in formation of a precipitate of potassium dodecyl sulphate. 
The SDS-denatured proteins and chromosomal DNA were co-precipitated with the 
detergent whilst the plasmid DNA remained in solution due to a lack of close protein 
associations. Precipitation was enhanced by a 20 minute incubation on ice and the 
precipitate pelleted by centrifugation at 20,000^ for 30 minutes at 4°C. The super­
natant containing plasmid DNA was promptly decanted into a QIAGEN-tip 500, 
previously equilibrated with 10 ml of Buffer QBT (750mM NaCl, 50mM MOPS pH
7.0, 15% isopropanol, 0.15% Triton X-100). The QIAGEN-tip 500 contains an anion- 
exchange resin to which the plasmid binds tightly while the the supernatant pass 
through by gravity flow. The resin was then washed twice with 30 ml of Buffer QC 
(IM NaCl, 50mM MOPS pH 7.0, 15% isopropanol) and the purified plasmid DNA 
was subsequently eluted with 15 ml of Buffer QF (1.25M NaCl, 50mM Tris pH 8.5, 
15% isopropanol) and precipitated with 10.5 ml (0.7 volume) of room-temperature 
isopropanol. This was immediately followed with a 15,000p centrifugation at 4°C 
for 30 minutes. The plasmid DNA pellet was then washed with 70% ethanol, dried 
at room-temperature for 5 - 1 0  minutes and resuspended in an appropriate volume 
of sterile water or TE buffer, pH 8.0 (lOmM Tris pH 8.0, ImM EDTA).
2 .13  RNA Pol III /n Vitro Transcription Assay
In vitro transcription of class HI genes was reconstituted using 15 pg of whole cell 
extracts or nuclear extracts to provide the basal pol HI transcription components. 
The samples were kept on ice while the reactions were prepared. Each sample was 
supplemented with 250 ng of plasmid DNA to supply a specific pol HI template 
and reactions were carried out in a 25 pi volume with a final concentration of 12mM 
HEPES pH 7.9, 60mM KCl, 7.2mM MgC12, 0.28mM EDTA, 1.2mM DTT, 10% (v/v)
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glycerol, ImM creatine phosphate, 0.5mM each of rATP, rCTP and rGTP and 10 
pCi I CK^ P^] UTP (400mCi/mmol) (Amersham). The reaction was performed in a 
waterbath at 30°C for 1 hour. In the case of assays incorporating additional reagents, 
a 15 minute pre-incubation at 30° C was carried out prior to adding the nucleotides 
required to initiate transcription. Transcription was terminated by the addition of 
250 pi of IM ammonium acetate/0.1% SDS containing 20 pg of yeast tRNA, which 
acts as a stabiliser for the synthesised RNA. PhenoPcholoroform extraction of the 
samples was performed to remove protein and DNA by adding 250 pi of a 25:24:1 
ratio solution of PhOH/CHC13/IAA. The samples were vortexed, microcentrifuged 
at 13,000c/ for 5 minutes and 200 pi of the upper aqueous layer was then transferred 
to a fresh eppendorf tube containing 750 pi of 96% ethanol and were inverted several 
times to ensure tha t they were thoroughly mixed. In order to precipitate the RNA, 
the samples were left at -20°C overnight before being micro centrifuged at 13,000 c/ for 
20 minutes to pellet the precipitated RNA. The supernatant was carefully removed 
and the pellet was washed in 750 pi of 70% ethanol and spun again. The supernatant 
was carefully removed to avoid dislodging the pellet and the samples were heated 
at 47°C for 5 - 10 minutes to dry. Once dried, 4 pi of formamide loading buffer 
(98% formamide, lOmM EDTA pH 8.0, 0.025% bromophenol blue, 0.025% xylene 
cyanol FF) was added to each sample, which was then vortexed for 20 minutes to 
ensure the RNA was fully redissolved. 1.5 pi of each sample was loaded on a pre-run 
7% polyacrylamide sequencing gel containing 7M urea and 1 x TBE (45mM Tris, 
45mM boric acid, 0.625mM EDTA pH 8.0) after being boiled at 95°C for 2 minutes 
and quenched on ice. Electrophoresis was performed at 40 W for 1 hour in 1 x 
TBE, before being dried and exposed to autoradiography film in order to detect the 
radiolabelled transcripts.
2 .14  Immunoprecipition and Im m unodepletion
Antibodies for immunoprécipitation experiments were coupled to either protein-A 
Sepharose (polyclonal antibodies) or protein-G Sepharose beads (monoclonal anti­
bodies). 25 pi of packed beads were used per sample and beads were washed twice 
with 1 X LDB (20 mM Hepes-Cl pH 7.9, 100 mM KCl, 12 mM MgClg, 2 mM DTT, 
0.1 mM EDTA, 17% glycerol) prior to incubation with the appropriate antibody on 
a shaker for 1 hour at 4°C. Equivalent amounts of antibodies were used for these 
experiments, to give a final concentration of 1 /ig in a volume of 20 pi. Protease 
inhibitors were used throughout the experiment to reduce loss of activity. Following 
incubation, the beads were washed twice with LDB to ensure removal of unbound an­
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tibody. For immunodepletion experiments, these beads, carrying equivalent amounts 
of prebound immunoglobulin (IgG) were incubated on ice with approximately 225 
pg of cell extract (made up to a volume of 30 pi with LDBO if they were whole cell 
extracts or with LDB in the case of nuclear extracts) for 2 hours, gently mixed by 
tapping every 5 minutes to avoid loss of activity. For co-immunoprecipitation reac­
tions, the cell extract was incubated with the prepared protein-A Sepharose beads 
at 4°C for 3 hours on an orbital shaker. After the incubation, beads were pelleted 
by gentle pulse microcentrifugation and the supernatant was discarded in the case 
of immunoprécipitation. The supernatant of the immunodepletions was recovered 
(20 pi) and 2 pi (~15 pg) were analysed by in vitro transcription assay. The beads 
were then subjected to extensive washing before the bound material was released 
by the addition of an equal volume of 2 x protein sample buffer and analysed by 
SDS-PAGE and subsequent western blotting for the protein of interest.
2 .15  Protein Analysis by Polyacrylamide  
Electrophoresis (SD S-P A G E ) and W estern Blot
Proteins were resolved on denaturing polyacrylamide gels according to molecular 
weight by electrophoresis. Polyacrylamide resolving minigels (375mM T is  pPI 8.8, 
0.1% SDS) were used with a stacking layer comprised of 4% polyacrylamide gel 
(125mM Tris pH 6.8, 0.1% SDS) based on the discontinuous buffer system described 
by Laemmli. Samples were boiled for 3 minutes in 1 x protein sample buffer (62.5mM 
Tris pH 6.8, 0.5% SDS, 5% /3-mercaptoethanol, 10% glycerol, 0.125% bromophenol 
blue) prior to loading. Electrophoresis was performed in 1 x SDS running buffer 
(0.1% SDS, 76.8mM glycine, lOmM Tris, pH 8.3) at an initial voltage of 70 V while 
the bromophenol blue dye front moved through the stacking gel and a subsequent 
voltage of 140 V after it reached the resolving gel. Electrophoresis was allowed to 
proceed until the dye front had reached the bottom of the gel, approximately 1 -1 .5  
hours. After gel separation, the proteins were transferred to a nitrocellulose mem­
brane by electrophoretic transfer using the BioRad Mini Trans-Blot Electrophoretic 
Transfer Cell system. Transfer was carried out in 1 x transfer buffer (76.8mM glycine, 
lOmM Tris, pH 8.3, 16.5% methanol) at 40 V for 1 hour or overnight. Following 
transfer, the membrane was washed in TBS for 10 min and then blocked in milk 
buffer (32.5 mM Tris, 150 mM NaCl, 0.2% Tween-20, 4% skimmed milk powder 
(Marvel)) for 30 min at room temperature. Membranes were incubated with pri­
mary antibodies (typically a 1:1000 dilution in milk buffer) for one hour at room 
temperature or overnight at 4°C. Excess primary antibody was removed by wash­
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ing the blot 3 times for 2 minutes in fresh milk buffer before incubating for one 
hour at room tem perature with the appropriate horseradish peroxidase-conjugated 
secondary antibody (1:1000 dilution in milk buffer) (DAKO). To ensure removal of 
excess secondary antibody, the blot was sequentially washed in batches of fresh milk 
buffer, 3 times for 2 minutes each, followed by 2 washes for 15 minutes. After one fur­
ther 5 minute wash using 1 x TBS (2.5mM Tris-HCl pH 7.6, 15mM NaCl), the blot 
was developed using the enhanced chemiluminescence method (ECL, Amersham), 
as directed by the manufacturers.
2 .15  Pull-Down and Pull-Down Depletion
GST or GST-fusion proteins were coupled to glutathione-agarose beads (SIGMA) 
previously prepared according to manufacturers’ instructions. GST, GST-Myc- 
N262, GST-Myc-C92 and GST-Max bound-beads, as well as BSA samples at differ­
ent known concentrations were then analysed by SDS-PAGE followed by Coomasie 
staining of the gel to measure the concentration of each GST protein and equal­
ize them to the same final concentration (5 pg/pl). Once they were at the same 
concentration, they were stored at -80°C or used for pull-down experiments. Typi­
cally, 250 pg of whole cell extracts or nuclear extracts were incubated with 25 pi of 
packed glutathione agarose-beads carrying GST alone, GST-Myc-N262, GST-Myc- 
092 or GST-Max for 3 hrs on an orbital shaker at 4°C. After the incubation, beads 
were pelleted and the supernatant of the pull-downs discarded or transferred into 
a new fresh eppendorf tube. Equal amounts of depleted supernatants were used in 
transcription assays. In the case of the pull-downs, the beads were washed thor­
oughly to remove any unbound material, once with 1 ml of TBS (2.5mM Tris-HCl 
pH 7.6, 15mM NaCl), 0.25mM NaCl, 0.5% Triton X-100 and a further 4 washes in 
1 ml of TBS. After extensive washing, the bound material was released by the ad­
dition of an equal volume of 2 x protein sample buffer and analysed by SDS-PAGE 
and subsequent western blotting for the protein of interest. Beads were probed by 
immunoblotting.
2 .16  c-M yc A ntisense  Experiment
ROSE cells were plated in 6 cm dishes out at 1x10^ cells/per well and left for 3 
hours until cells adhered to the surface. Once adhered, the medium was replaced by 
medium containing either c-Myc-Sense oligonucleotide (5’-ATGCCCCTCAACGTG- 
3’) or c-Myc-Antisense oligonucleotide (5’-CACGTTGAGGGGCAT-3’) at a final 
concentration of 20 pM. The cells were left for 48 hrs with medium containing the
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oligos, after which time total RNA was extracted with TRI Reagent and analysed 
by RT-PCR.
2 .17  Transient transfection
Expression vectors were kindly provided by Robert N. Eisenman (pRc-CMV-Myc 
and empty vector) and Antonio lavarone (Id2 and pcDNA3) to transform E.coli XL- 
1 Blue supercompetent cells (Stratagene). Large scale plasmid preparation using 
a QIAGEN Plasmid Maxi kit was performed to have sufficient material for the 
transfections. Again, plasmid preparations were verified and DNA concentrations 
determined by UV spectrophotometry.
2.17.1 Transfection with Su perfect
Balb/c 3T3 (A31) and RB wild-type and RB knockout cells were transfected using 
the Superfect reagent (Qiagen). The transient transfection with Superfect required 
cells to be plated out at 3 x 10  ^ cells/well on 6-well plates 24 hours prior to trans­
fection, resulting in a confiuency of r^70-80% at the time of transfection. Two wells 
were transfected per treatm ent, with a total of 4 /ig of plasmid DNA per well of 
cells; this was comprised of 0.5 pg of VAl, 0.5 pg of SV40 CAT (Promega) and 3 
pg  of "empty” pRc-CMV (for c-Myc) or pcDNA3 (for Id2) expression vector, pRc- 
CMV-Myc or p ld2. Master mixes for each set of wells were made up comprising the 
appropriate plasmid DNA and neat DMEM media to give a volume of 100 pi per 
well. Following addition of 8 pi of Superfect per well, the reactions were vortexed 
and incubated at room tem perature for 5 minutes. After this incubation period, 600 
pi of DMEM (10% fetal calf serum (Sigma), 2mM L-glutamine, lOOU/ml penicillin 
and 100 pg/m l  streptomycin) was used to dilute each Superfect mix. Media was 
removed from the cells prior to addition of the mix and washed once with sterile- 
PBS. The reaction mix was added to the plates and they were swirled to ensure the 
wells were evenly covered. Treatment was carried out for 3 hours at 37°C before 
removing the mix, washing the cells once with warm PBS and applying fresh media. 
Cells were incubated for a further 48 hours to allow expression of transfected DNA; 
with media being renewed again after 24 hours. Cells were harvested and total RNA 
extracted for analysis by primer extension.
2.17.2 Transfection with Lipofectamine
Primary mouse embryo fibroblasts and RB-pl07-pl30 knockout cells were trans­
fected using the Lipofectamine reagent (Gibco). The transient transfection with 
Lipofectamine required cells to be plated out at 3 x 10  ^ cells/well on 6-well plates
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24 hours prior to transfection, resulting in a confiuency of ~70-80% at the time 
of transfection. Two wells were transfected per treatm ent with a total of 4 pg of 
plasmid DNA per well of cells; this was comprised of 0.5 pg of VAl, 0.5 pg of SV40 
CAT (Promega) and 3 pg of "empty" pRc-CMV (for c-Myc) or pcDNA3 (for Id2) 
expression vector, pRc-CMV-Myc or p ld2. Mastermixes for each set of wells were 
made up comprising the appropriate plasmid DNA and 0.5 ml of OptiMEM (Gibco) 
per tube containing plasmid DNA. In a separate tube, 0.5 ml of OptiMEM was 
mixed with 25 p\ of Lipofectamine and then this reaction was transferred into the 
tube containing the plasmid with OptiMEM and they were mixed by pipetting up 
and down. The tubes were incubated for 45 min in the dark at room temperature. 
During the incubation period, each 6-well plate to be transfected was washed with 1 
ml of OptiMEM per well, and then 0,76 ml of OptiMEM were added per well. The 
plates were left to incubate at 37°C for the rest of the incubation time (~30 min). 
After the incubation, 1 ml of the Lipofectamine-DNA-OptiMEM mix was added to 
each well and the plates were left at 37°C for 3 hrs in the incubator. After the 
incubation, the Lipofectamine-DNA mix was removed from each well and replaced 
with 3 ml per well of fresh medium. Cells were incubated for a further 48 hours to 
allow expression of transfected DNA; with media being renewed again after 24 hours. 
Cells were harvested and total RNA extracted for analysis by primer extension.
2 .18  Primer Extension
Expression levels of the transfected pol III template VAl and the CAT gene, which 
was co-transfected as an internal control for transfection efficiency, were analysed 
by primer extension. VAl ( 5 ’-C A C G C G G G C G G T A A C C G C A T G -3 ’) or CAT (5’-CGA- 
t g c g a t t g g g a t a t a t c a - 3 ’) oligonucleotides were end-labelled using T4 polynu­
cleotide kinase (PNK). For each primer extension reaction, 10 pg of total RNA (made 
up to 10 pi with DEPC-dHgO) and incubated at 80°C for 10 minutes with 9 /rl of 5 x 
First Strand Buffer (Life Technologies) and 1 pi (2.5ng) of the relevant probe to act 
as a primer. Samples were immediately transferred to a 50° C hotblock for a further 
2 hours incubation. 30 pi of an elongation mix (23 pi DEPC-dHgO, 0.5 p,l 1 M DTT, 
5 /il 5 mM dNTP mix (5 mM in DEPC-dHsO), 0.5 pi 4 mg/ml actinomycin D, 0.5 pi 
RNasin, 0.5 pi (lOOU) of Superscript II Reverse Transcriptase (Life Technologies)) 
was then added to the samples to initiate reverse transcription and the reaction was 
allowed to proceed for 1 hour at 42°C. Reaction products were precipitated overnight 
at -20°C by the addition of 5 /xl of 3 M sodium acetate and 125 pi of ethanol and 
subsequently pelleted by microcentrifugation at 13,000// for 15 minutes. Pellets were
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washed with 300 pi of 75% ethanol and dried at 47°C for 5 minutes before being 
resuspended by vortexing for 10 minutes in 4 pi of formamide loading buffer (98% 
formamide, lOmM EDTA pH 8.0, 0.025% bromophenol blue, 0.025% xylene cyanol 
FF). Electrophoresis through a 7 M urea 7% polyacrylamide gel was used to resolve 
the samples. The reaction products were detected by overnight exposure to autora­
diography film at -80° C and quantified by scanning the autorad and analysing the 
image with the software NIH-Image.
2 .19  Chromatin Immunoprécipitation
Cells (roughly 2 x 10  ^ per immunoprécipitation) were collected and washed with 
ice-cold PBS and then crossliked for 10 min at 37°C in 10 ml of 0.5% NP-40/PBS 
containing 1% formaldehyde. Crosslinked cells were washed with ice-cold 0.5% NP- 
40/PBS and incubated for 30 min with 40 ml of high salt buffer (0.5% NP-40, PBS,
1 M NaCl). Further washing with 0.5% NP-40/PBS was followed by hypotonic 
disruption for 30 min in 40 ml of low salt buffer (0.1% NP-40, 10 mM TrisHCl, pH
8.0, 1 mM EDTA, 0.1 M NaCl). After centrifugation at 478g for 10 min, nuclei 
were obtained with 10 strokes through a 23-gauge needle and re-centrifuged. Nuclei 
were resuspended in 2.7 ml of low salt buffer and lysed with 300 pi of 20% sarkosyl. 
Samples were transferred to a sucrose cushion and spun for 10 min at 4,000//. After 
resuspending the pellet in 3 ml of TE (10 mM Tris, pH8.0, 1 mM EDTA), the 
process was repeated. After resuspension in 2 ml of TE, genomic DNA was sheared 
by sonication (Branson sonifier 250, 10 x 10 s, duty cycle 30%). Sonicated material 
was adjusted with 1/10 volume of x l l  NET (1.56 M NaCl, 5.5 mM EDTA, 5.5% 
NP-40, 550 mM TrisCl, pH7.4) and immunoprecipitated overnight at 4°C with 20 pi 
(4 pg) of antibody. Protein A or protein G Sepharose beads were added for a further
2 h incubation and then recovered on Polyprep columns (BioRad). After washing 
twice with 10 ml of RIPA buffer (50 mM TrisHCl, pH 8.0, 150 mM NaCl, 0.1% SDS, 
0.5% deoxycholate, 1% NP-40), twice with 10 ml of LiCl buffer (10 mM TrisHCl, 250 
mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 mM EDTA, pH 8.0) and twice with 10 
ml TE, beads were transferred to 1.5-ml tubes and immunoprecipitated material was 
eluted twice with 200 pi of 1% SDS in TE. To isolate precipitated DNA, proteins and 
antibodies were degraded by proteinase K treatm ent overnight at 42°C. DNA was 
extracted twice using phenol/ chloroform/ isoamylalcohol and ethanol-precipitated. 
Immunoprecipitated DNA was quantified by PCR performed on the input and bound 
fractions.
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III T ra n s c r ip t io n  by th e  T y ro s in e  
K inase  R e ce p to r  E r b B 2 /N e u
3.1 Introduction
The human proto-oncogene erhB2 (also referred to as HER2) and its rat homologue 
neu encode a 185 kDa transmembrane glycoprotein tha t is ubiquitously expressed 
in different tissues. The erbB2/neu gene was identified as the oncogene associ­
ated with the development of neuroblastomas in rats exposed to ethylnitrosourea in 
utero [193,194]. It belongs to class I of the super family of receptor tyrosine kinases. 
This class is known as the ErbB family and includes three other members: the epi­
dermal growth factor receptor (EGER), also termed E rbB l/H E R l, ErbB3/HER3 
and ErbB4/HER4 [195]. All members contain an N-terminal extracellular ligand- 
binding domain, a single membrane-spanning region and a C-terminal cytoplasmic 
tyrosine kinase domain [195]. Activation occurs upon ligand binding to the extracel­
lular domain, which leads to the formation of homo- and heterodimers. Dimerization 
activates the tyrosine kinase activity of the intracellular domain in each monomer 
and triggers autophosphorylation of specific tyrosine (Tyr) residues within the cyto­
plasmic regions of each other (Fig. 3.1) [9,195]. Consequently, the phosphorylated 
tyrosine residues serve as docking sites for signaling molecules which will transfer ac­
tivation to intracellular signaling cascades (Fig. 3.1) [13,195]. Ultimately, receptor 
activation will affect gene expression.
In the embryonic rat and human fetus, ErbB2/neu is expressed in a variety of 
tissues of epithelial, mesenchymal and neuronal origin, excluding those of hematopoi­
etic origin . However, in adult animals immunoreactive ErbB2 is localized to épithé­
lia. Cultured cell lines of epithelial or mesenchymal origin express moderate levels
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Constitutive Autophosphoryiation Dimer Formation
Activation of 
Signaiing cascades
Figure 3.1: Activation of the ErbB2/neu receptor. Upon ligand binding to the 
extracellular domain or through overexpression, ErbB2 protein binds to 
ErbB2 molecule or to other members of the Erb family, creating homo- or 
heterodimers respectively. The formation of dimers produces autophos­
phoryiation of Tyr residues which will transduce the activation to sig­
naling cascades.
of ErbB2 (approximately 10^  molecules/cell) [13|. This receptor is fundamental in 
development, since ErbB2 null mice die at midgestation (E10.5) due to trabeculae 
malformation of the heart [196]. It is also required for proliferation and differen­
tiation. In particular, this has been studied in the mammary gland. Most of the 
proliferation and differentiation of this organ happens postnatally. Expression of a 
dominant-negative mutant of ErBb2 in the mammary gland of mice results in de­
fective lobuloalveoli and reduced milk protein secretion, although ductal growth is 
normal [197].
3.1.1 Ligand
Although there are several ligands that can bind and activate the ErbB receptors, 
no direct ligand has been identified for ErbB2 yet. The first candidate ligands to 
be studied were the neuregulin (NRG) peptides (also referred to as heregulins, neu 
differentiation factors, acetylcholine receptor-inducing activity and glial growth fac­
tor) [13]. NRGs contain epidermal growth factor-related domains which were shown 
to activate Tyr phosphorylation and substrate binding of ErBb2. However, this 
effect was dependent upon the presence of ErbB4 or ErbB3, since in lymphoblas- 
toid T cell lines and Sf9 insect cells, as well as fibroblasts that were engineered 
to express ErbB2 solely, NRG couldn’t stimulate dimerization nor Tyr phospho­
rylation [198-200]. Therefore, NRGs activate ErbB2 by binding to other ErbB 
members and stimulating heterodimerization with ErbB2. In fact, ErbB2 is the
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preferred heterodimerization partner of ErbB family members, mediating lateral 
signal transduction from them [201]. Other ErbB2 agonists th a t have been pro­
posed include the neu activating factor (NAF), and the mucin MU0 4 /sialomucin 
complex (SMC). NAF was found in medium from a transformed human T cell line 
ATL-2. It specifically binds to the ErbB2 extracellular domain stimulating dimer­
ization and tyrosine kinase activity [202]. In addition, S amant a et. al. found tha t 
NAF binds to purified ErbB2 expressed in baculovirus and promotes dimerization 
in vitro [203]. However, no further studies have been published on this ligand since 
1994, and the scientific community hasn’t completely accepted this protein to be a 
true ErbB2 ligand. MUC4/SMC (also referred to as ascites sialoglycoprotein-2 or 
ASGP2) is a major cell surface protein in rat ascites 13762 cells [204]. Its transmem­
brane subunit contains two EGF-like domains, one of which binds directly to and 
specifically activates ErbB2 [204,205]. However, MUC4/SMC rather than a ligand, 
is a modulator of ErbB2’s activity, potentiating its phosphorylation in the presence 
of other ligands like NRGl [205].
3.1.2 ErbB2/neu and Cancer
There is a considerable amount of data demonstrating the participation of ErbB2/neu 
in cancer development and progression. Overexpression of ErbB2/neu is implicated 
in the genesis of carcinomas affecting different organs, like breast, ovary, stomach, 
colon, kidney, bladder and salivary gland [13]. In human breast and epithelial ovarian 
cancer, ErbB2 is overexpressed in 20-30% of the cases and is usually associated with 
poor prognosis [206-210]. The overexpression is generally caused through gene am­
plification, and tumours from patients containing multiple copies of the gene respond 
poorly to chemotherapy and have an increased propensity to metastasize [206-210]. 
Furthermore, their tumours have shorter time to relapse and a shorter overall sur­
vival, and the presence of erbB2 gene amplification can be used as a predictor of 
clinical outcome [206-210]. ErbB2 overexpression is also accomplished through tran ­
scriptional upregulation of the erbB2 gene, localized on chromosome 17q21 [206,207]. 
When ErbB2 is overexpressed, constitutive homodimerization and kinase activation 
is achieved in the absence of ligand (Fig. 3.1) [211].
The rodent models of neuroblastomas induced by exposure to N-nitrosoethylurea 
present a different mechanism of ErbB2/neu activation [212,213]. In these cases, 
a single point mutation in the membrane-spanning region, from valine at position 
664 to glutamic acid yields constitutive homodimerization as well as kinase activa­
tion and elevated Tyr phosphorylation of cellular substrates [212]. This activating
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mutation alone is sufficient to induce Schwann cell immortalization and transforma­
tion, without requiring activation of another oncogene [214]. Analysis of a panel of 
neu proteins with second-site mutations has shown th a t not only the Glu664 sub­
stitution is responsible for dimerization and transformation but also the aminoacids 
surrounding it, forming the domain Val 663-Glu-664-Gly665 (VEG) [215]. If this 
domain is localized elsewhere within the transmembrane region, it can still promote 
weak dimerization but its transforming activity is lost, suggesting tha t in some cases 
receptor dimerization is not sufficient for transformation [216]. In fact, the enhanced 
receptor dimerization seen in the neu Glu664 substitution appears not to be a di­
rect effect of Glu contacts, but of changes produced in the relative orientiation of 
the dimerization interface [217]. Moreover, a recent report has demonstrated th a t 
a sequence (VVÏ at position 966-968) in the intracellular domain is responsible for 
homomeric association of ErbB2 in the absence of ligand [218]. When these amino 
acids are mutated to alanines, no self-association is observed with wild type or mu­
tant ErbB2, indicating tha t the Glu664 substitution only causes stabilization of the 
homodimer, but does not initiate ErbB2 self-association [218]. It is interesting to 
note tha t neither the Glu664 substitution nor any other mutation have been identi­
fied in human malignancies. Nevertheless, an ErbB2 gene polymorphism at codon 
655^ (isoleucine to valine) in the coding region corresponding to the transmembrane 
domain has shown an increased risk of breast cancer [219]. The same polymorphism 
was studied for the susceptibility to develop bladder cancer [220]. Although no asso­
ciation with the Ile/Ile genotype was found, an increased risk of disease progression 
was observed in tumours containing this genotype [220].
As mentioned before, ErbB2 is involved in the pathogenesis of different types 
of human cancers. Breast cancer and ovary carcinoma account for one quarter of 
cancer-related female deaths in the United States [206]. In the case of epithelial 
ovarian cancer, it is usually detected when patients are in advanced stages of the 
malignancy, with poor chance of survival. Therefore, it is paramount to under­
stand the changes involved in the neoplastic transformation of the ovarian surface 
epithelium which might also be entailed in other malignancies. Since ErbB2 overex­
pression is one of the changes observed in this malignancy, it is im portant to study 
what other cellular changes this overexpression leads to. Cancer cells proliferate at 
increased rates, requiring to double their DNA and cellular contents faster than nor­
mal cells do. Indeed, elevated growth rates are observed in transformed cells. Since
^This human codon (655) does not correspond to the rat 644 codon which is frequently mutated 
from valine to glutamate inducing constitutive activation. The corresponding human codon is 
659, which also encodes a valine [218].
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pol III transcripts are im portant determinants of growth rate (as they are involved 
in protein synthesis), ErbB2 overexpression might trigger activation of pol III tran­
scription. Winter et. al. have shown that epithelial ovarian tumours present high 
levels of pol III transcripts compared to adjacent healthy tissue, although ErbB2 
expression was not analysed [12]. Furthermore, overexpression of pol III transcripts 
has been observed in breast, lung and tongue carcinomas, the same types of carcino­
mas where ErbB2 overexpression is involved [171,172,206]. Therefore, the regulation 
of pol III transcription by ErbB2/neu was investigated.
To study ErbB2/neu regulation of pol III transcription, a cell line was used in­
stead of tumour samples, since tumour cells have the disadvantage of presenting 
modifications other than ErbB2/neu overexpression. Furthermore, a cell line allows 
one to analyse the mechanisms involved in ErbB2 regulation of pol III transcription. 
The ROSE 199 cell line was chosen for this research because it is a spontaneously 
immortalized rat ovarian surface epithelial cell line tha t is normal and nontumouri- 
genic^ [221]. This cell line was stably transfected by Ponder’s group with ecotropic 
retroviruses containing the m utated rat neu oncogene (with the activating Val to 
Glu664 substitution) or the jd-galactosidase (yd-gal) gene, under the control of the 
^-actin promoter [190]. The untransfected cells express low levels of endogenous 
neu; after neu oncogene is transfected, an eightfold induction in its expression is ob­
served [190]. The increase in neu expression is not due to the process of transfection 
per se, since the cells transfected with /9-gal do not show any change in neu protein 
levels [190]. For this reason, R0SE-/9gal transfected cells were utilised as a control 
for the experiments reported in this and in chapter four.
^It is interesting to note that spontaneous transformation of the ovarian surface epithelium of 
animals is very rare, so animal transformed cell lines from this tissue are quite unusual [190].
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3.2 Results
3.2.1 Pol III Transcription is Increased in Neu 
Overexpressing Cells
The ROSE-neu transfected cells (ROSE-neu) exhibit an increase in proliferation, 
induction of anchorage independence, reduced intercellular and cell/substrate adhe­
sion and increased invasive potential with the creation of tumours relative to the 
parental ROSE 199 or ROSE-^gal transfected cells (ROSE-ydgal) [190]. One of the 
changes induced by neu overexpression is a reduction in the doubling time of al­
most one third, compared to tha t of R0SE~/9gal (ROSE-neu take 12.5 hrs while 
R0SE-/9gal take 17.2 hrs to double), so it can be concluded th a t ROSE-neu cells 
are proliferating faster, thus might present faster growing rates. Since pol III tran ­
scripts are involved in cellular growth, their expression was compared in these two 
cell types. First, expression of the B2 gene was tested. Induction of the B2 transcript 
in malignant cells and in cells infected with viruses like SV40 and papillomavirus is 
well documented [154,222,223]. Furthermore, Crone et. al. have shown that down- 
regulation of the cytoplasmic B2 transcript causes a direct reduction in proliferative 
rate of up to 80% [224]. Therefore, if neu overexpression is accelerating the growth 
rate of ROSE cells, an induction of the B2 gene might be expected. Indeed, primer 
extension analysis revealed th a t the RNA levels of the B2 transcript are induced by 
neu overexpression compared to ROSE-,dgal transfected cells (Fig. 3.2).
The upregulation seen in the B2 transcript could be a specific effect of neu on 
the expression of this gene and not a general activation of pol III transcription. 
To assess if neu upregulation of the B2 transcript reflects a general effect upon pol 
III transcription, the expression of different class III genes was tested. RT-PCR 
was performed to assay the levels of primary transcripts from tRNA^^^^, tRNA^®^, 
and U6 snRNA genes by using as template cDNAs derived from RNA extracted 
from each cell group (R0SE-/9gal or ROSE-neu transfected cells). As shown in Fig. 
3.2, the levels of all the pol III transcripts tested are increased compared to the 
control. This effect upon pol III transcription by neu overexpression is specific, 
since the mRNA levels of the pol II transcribed gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) did not change (Fig. 3.2, Bottom left). The tRNA levels 
reflect pol HI transcriptional activity at the time of extraction of RNA and not the 
build up of these products, because the primers used for the tRNAs were designed 
to the intron sequences of short-lived precursor tRNAs, which are rapidly degraded. 
These results demonstrate tha t neu overexpression activates pol HI transcription
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Figure 3.2: Induction of pol III products by neu overexpression. (A) Primer ex­
tension analysis of total RNA (10/ig) extracted from ROSE-^gal (lanes 
1 and 2) or ROSE-neu transfected cells (lanes 3 and 4). The probe 
used was against the B2 product. (B) RT-PCR from the the same total 
RNA samples used in panel A. cDNA was prepared from 3pg of RNA 
and amplified by PCR using primers specific for tRNA^®^^ (top right)^ 
tR N A ^y^(top  left), U6 snRNA (bottom right) and GAPDH (bottom, left).
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Figure 3.3: Extracts from neu overexpressing cells contain higher pol III transcrip­
tional activity. The class III gene, pVAl, was utilised as template for an 
in vitro transcription assay to assess the activity of pol III transcription. 
lb fig of whole cell extracts prepared from ROSE-^dgal or ROSE neu cells 
were used in each reaction. Lanes 1 and 3 are from two different ex­
tractions of ROSE-^gal cells, while lanes 2 and 4 are from two different 
extractions of ROSE-neu cells.
from different class III genes, and therefore can be regarded as a general activator 
of pol III transcription.
To further address the transcriptional activity of pol III in the neu overexpressing 
cells, an in vitro transcription assay was performed. Whole cell extracts prepared 
from R0SE-/3gal or ROSE-neu cells were incubated with the adenovirus VAl gene 
for 50 min at 30°C. Then the RNA produced was extracted and analysed in a 7% 
polyacrylamide gel. As shown in Fig. 3.3, extracts from ROSE-neu transfected cells 
are significantly more active than those from ROSE-^gal transfected cells. From 
these experiments it can be concluded tha t pol III transcription is increased in neu 
overexpressing cells.
3.2.2 TFIIIC2 Expression Is Not Affected by Neu 
Overexpression
There are several possible mechanisms that could mediate the induction of pol III 
transcription by the overexpression of neu. The first mechanism investigated was the 
induction of TFIIIC2. Increased activity of TFIIIC2 has been observed in ovarian 
tumours, as well as in adenovirus-infected and SV40-transformed cells [12,67,160, 
162,225]. In human ovarian tumours with induced pol III activity, the deregulation
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in TFIIIC2 appears to reflect the overexpression of the TFIIIC2 subunits, at the 
mRNA and protein levels [12]. Therefore, TFIIIC2 overexpression was investigated 
in the ROSE model. Again, RT-PCR was performed with cDNAs produced from 
mRNA of R0SE-/5gal and ROSE-neu cells to assay the levels of different TFÏIIC 2 
subunits. In contrast to expected, the mRNA levels of all TFIIIC  subunits were 
reduced in ROSE-neu cells compared to the control cells (Fig. 3.4A and data not 
shown). Since the mRNA levels of the TFIIIC2 subunits might not reflect the actual 
amount of protein present in the cells, the protein levels of the subunit TFIIICo; 
was examined by immunoblot analysis of whole cell extracts. As shown in Fig. 
3.4B, the levels of this subunit are the same in ROSE-^gal and ROSE-neu cells, 
suggesting an increase in protein stability of the subunits in neu-overexpressing 
cells. Eurthermore, TFIIIC 2 activity is slightly elevated in extracts from ROSE-neu 
cells compared with tha t of R0SE-/5gal cells [226]. The overexpression of the U6 
transcript induced by neu overexpression could not have been explained through an 
induction of TFIIIC2 activity, since this T F is not required for U6 transcription [42]. 
Therefore, these results implicate a different mechanism used by neu for pol III 
transcription upregulation.
3.2.3 Signal Transduction from Neu
Neu’s activation induces its carboxyl-terminal kinase which phosphorylates Tyr 
residues within a 200-300 amino acid stretch at the carboxyl-terminus [227]. The 
phosphorylated Tyr become docking sites for downstream cytoplasmic or plasma 
membrane associated proteins involved in the transduction of signals to the nu­
cleus [228]. Downstream proteins bind stably to these sites through SH2 (Src ho­
mology) domains and trigger different signaling cascades, depending on the protein 
bound [13]. Proteins tha t have been seen to interact specifically with ErbB2/neu 
phosphorylated Tyr residues include phospholipase C7 I (PLC7 I) [229,230], c-Src 
[231], and Grb7 (growth factor bound 7) [232,233] as well as proteins involved in the 
modulation of the Ras/M APK (mitogen-activated protein kinase) pathway by ei­
ther promoting the active Ras-GTP complex formation through Sos GTP exchange 
proteins like She [234,235], Grb2 [232,234,235] and Nek [236] or by accelerating 
the hydrolysis of Ras-GTP to its inactive Ras-GDP state like Ras-GAP (GTPase- 
activating protein) [229,230,236] (Fig. 3.5). The phosphatidylinositol 3 kinase 
(PI3K) pathway, implicated in cell survival, has also been observed to be active 
in ErbB2/neu overexpressing cells, although this activation is likely to be through 
ErbB3 interactions with the PI3K regulatory subunit p85 [237]. The contribution
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Figure 3.4: Expression of the TFIIIC subunit, TFIIIC a, in ROSE-^gal and ROSE- 
neu cells. (A) cDNAs prepared from total RNA (3/ig) extracted from 
ROSE-^gal (lane 1) or ROSE-neu cells (lane 2) were used as template 
for RT-PCR analysis. The primers used were designed against T FIIIC a 
(upper panel) or GAPDH (lower panel). (B) Proteins (100/ig) extracted 
from ROSE-^gal (lanes 1) or ROSE-neu cells (lanes 2) were resolved in 
a 7.8% polyacrylamide gel and then analysed by Western blotting with 
antiserum Ab2 against T F IIIC a (upper panel) or the rabbit antibody 
C-18 against TFIIB (lower panel).
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Figure 3.5: Binding of signaling molecules to specific phosphotyrosine residues from 
the ErbB2/neu receptor. The tyrosine residues tha t have been found to 
be phosphorylated in the ErbB2/neu receptor are indicated [227]. The 
protein She has been found to bind to T yrll96  and Tyr1248 via its PTB 
domain, and to Tyrl221/2 and Tyr1248 via its SH2 domain [234,235]; 
Grb2 binds to T yrll39  through an SH2 domain [228,234]; and Grb7 
interacts with T yrll39  through its SH2 domain [232].
towards tumourigenesis of the signaling pathways activated by ErbB2/neu still re­
mains to be elucidated.
Activation of these pathways induces changes in gene expression which will af­
fect the cell’s proliferation state. The activation of Ras is of particular importance, 
since it plays a pivotal role in a wide variety of cellular processes, as well as being 
frequently deregulated in carcinogenesis. It can activate multiple effector-mediated 
signaling pathways like the Raf-MEK-MAPK or PI3K cascades (Fig. 3.6A) [238]. 
The mammary tissue of transgenic mice overexpressing v-Ha-ras present mammary 
carcinomas [239]. In addition, Ras effector pathways are found activated in many 
breast cancer samples and derived cell lines, suggesting Ras activation in primary 
tumours [228]. The activation observed in transformed cells is probably due to the 
action of receptors like ErbB2/neu on its function, although Ras mutations are ex­
tremely common (^30% of human tumours present m utated Ras). Infection with 
HBV, which is implicated in hepatocarcinogenesis, activates the Ras/M APK path­
way [240). This activation is essential for successfull transformation of hepatocytes 
by the HBV X protein [241]. As mentioned in the introduction, HBV X protein 
induces pol III transcription through activation of the Ras/M APK pathway [170]. 
Therefore, the activity of this pathway was investigated in R0SE~/3gal and ROSE- 
neu transfected cells. To assess this, western blot analysis of whole cell extracts was 
performed. The membrane was probed with an antibody tha t recognises the active 
phosphorylated forms of MAPKs/ extracellular signal-regulated kinase-1/2 (E rk l/2) .
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As shown in Fig. 3.6B, upper panel, ROSE-neu transfected cells present higher lev­
els of E R K l/2  phosphorylation than control cells. This result suggests th a t neu 
overexpression is causing an increased activation of the Ras/M APK pathway which 
might have an effect on pol III transcriptional upregulation.
Since neu overexpressing cells proliferate faster than control cells, it would be in­
teresting to study if other pathways involved in cell growth regulation, in particular 
tha t of ribosome synthesis are being activated. The ubiquitous mitogen-activated 
Ser/T hr kinase, p70 ribosomal protein S6 kinase (p70^®^^) phosphorylates the 40S 
ribosomal protein 86, which drives translation of 5’ TOP (terminal oligopyrimidine 
tract) mRNA [242]. This family of mRNA generally encode ribosomal proteins and 
components of the translation apparatus like elongation factors; thus activa­
tion is a prerequisite for protein synthesis [242]. As neu activation has been shown to 
stimulate the p70^®^  ^pathway [243], kinase activity was tested in the ROSE system. 
Immunoblot analysis of whole cell extracts using an antibody against phosphory­
lated p70^6K showed th a t neu overexpression causes increased phosphorylation of 
the kinase (Pig. 3.6B, middle panel). The antibody used was raised against phos­
phorylated Thr-389, which is essential for kinase activity [244]. The phosphoryla­
tion of Thr-389 is mediated mainly through the mammalian target of rapamycin 
(mTOR) [244], although recently it has been reported tha t the Raf/M APK path­
way can also phosphorylate this residue [245]. As shown in Fig. 3.6A, activation 
of mTOR can be through the PI3K pathway which responds to Ras activation, al­
though it can also be activated by amino acids [246]. TOR has been ascribed as 
a central controller of cell growth, which regulates a diverse set of growth-related 
readouts including pol III transcription [246].
The data presented so far demonstrate tha t the ROSE-neu transfected cells be­
have in a similar fashion to ErbB2/neu overexpressing cells studied before, activating 
the Ras/M APK and mTOR signaling cascades. These pathways have been shown 
to induce pol III transcription, thus it is very probable tha t they are involved in 
neu’s regulation of this process.
3,2.4 Cyclin Levels in ROSE Transfected Cells
ROSE-neu cells present faster rates of growth than control cells. This could be ex­
plained through the activation of the Ras/M APK pathways, since it contributes to 
cell cycle progression from 01 to S phase [247,248]. Overexpression of mutation- 
ally activated Ras leads to shortening of the 01 phase of the cell cycle [249]. The 
Ras/M APK pathway achieves this by stimulating the activity of TFs which will in-
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Figure 3.6; Neu overexpression causes activation of the Ras/MAPK and
pathways. (A) A suggested cascade triggered by neu activation for the in­
duction of transcription and translation. Neu activation produces phos­
phorylation of its carboxy-terminal tyrosine residues which will serve as 
docking sites for Grb2. Grb2 will transduce the activating signal to Ras 
through Sos. Activated Ras will then induce the MARK pathway and the 
mTOR pathway, maybe through PI3K, which will activate transcription 
and translation of genes involved in cell growth and cell proliferation.(B) 
Western blot analysis of proteins (50^g) extracted from ROSE-/?gal (lane 
1) or ROSE-neu cells (lane 2) resolved in a 7.8% polyacrylamide gel. Im- 
munoblotting was performed with antibodies against the phosphorylated 
forms of E R K l/2 (p42/44) {upper panel), phosphorylated p70^®  ^ {mid­
dle panel) or TFIIB {lower panel). TFIIB was used as a loading control.
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Figure 3.7: Neu overexpressing cells contain higher protein levels of cyclin D1 and 
cyclin E, Proteins (50/ug) extracted from ROSE-^gal (lanes 1) or ROSE- 
neu cells (lanes 2) were analysed by Western immunoblotting with an­
tibodies from Santa Cruz Biotechonology against cyclin D1 (antibody 
72-13G, upper panel), cyclin E (antibody 019, middle panel), or TFIIB 
(antibody C-18, lower panel).
duce transcription from cyclin D genes |247,249|. The TFs involved in the induction 
of cyclin D1 expression have not yet been elucidated, but there is evidence to sug­
gest that the API complex of transcription factors (consisting of c-Fos, Fos B, Fra-1, 
Fra-2, c-Jun, JunB and JunD), c-Ets-2, Spl and E2F-1 might be involved [250,251]. 
Activation of mTOR also plays a role in cyclin D1 protein availability. mTOR 
controls cyclin D1 translation by activating the translation initiation factor eIF4E, 
which regulates translation of mRNAs containing a highly structured 5’ untrans­
lated region, like tha t of the cyclin D1 transcript [252]. Since ROSE-neu transfected 
cells present both Ras/M APK and mTOR activation, the cyclin D1 levels are most 
probably induced.
Aberrant expression of cyclin D1 has been observed in breast tumor cell lines and 
the majority of breast cancers and in epithelial ovarian tumours [249,253]. Mammary 
tumours produced by overexpression of wild-type neu contain increased cyclin D1 
protein levels ]250]. Lee et. al. also demonstrated that neu-induced transformation 
of Rat-1 cells requires cyclin D 1 induction, and that this induction involves activation 
of the Ras/M APK pathway, as well as Rac, Rho, c-Jun N-terminal kinase and p38
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[250]. Therefore, protein levels of cyclin D1 were analysed in the ROSE transfected 
cells by western blot. Figure 3.7, upper panel, shows tha t indeed cyclin D1 levels 
are induced in the neu overexpressing cells.
Cyclin E induction is also required for G l/S  transition [254]. Its expression is 
regulated by the TFs E2F and c-Myc [251,255]. Overexpression of cyclin E has been 
observed in breast cancer and in epithelial ovarian tumours and it is significantly 
associated with malignancy in ovarian tumours [256-258]. When cyclin D1 function 
is lost, activated m utant neu can no longer induce oncogenesis of the mammary gland 
[259]. However, 35% of the cyclin D 1 null mice regain mammary tumour potential 
through overexpression of cyclin E [259]. These data suggest tha t neu’s induction of 
both cyclin D1 and cyclin E expression are important events for the modulation of 
neu-induced tumourigenesis. Since ROSE cells transfected with neu are transformed 
cells tha t produce tumours when injected into mice peritoneal cavities, the protein 
levels of cyclin E were investigated. As expected, cyclin E levels are also increased 
by neu overexpression (Fig. 3.7). Both cyclin D1 and E induction is a specific 
event, since TFIIB protein levels remain constant in normal and transformed cells 
(Fig. 3.7, lower panel). Thus, ROSE-neu transfected cells induce cyclin D1 and 
cyclin E, which are required for transformation. As these cyclins have been shown 
to regulate pol III function through inactivation of the RB protein, this mechanism 
was explored.
3.2.5 RB Activity
Induction of cyclin levels are required for Gl / S  progression. Cyclin D/cdk4/cdk6 
complexes partially phosphorylate RB [260,261]. This process is completed by cyclin 
E /cdk2 [260,261], which is activated shortly after cyclin D/cdk4/cdk6 activation, 
producing complete RB phosphorylation and abrogating its growth inhibitory activ­
ity upon TFs like E2F and TFIIIB, which will then induce transcription of different 
genes involved in cell cycle progression and growth (Fig. 3.8) [4,178]. As mentioned 
in the thesis introduction, RB phosphorylation status plays an important role in 
controlling pol III transcriptional activity. When RB is in the hypophosphorylated 
form, it binds to TFIIIB and blocks its activity, inhibiting pol III transcription; 
however when it is phosphorylated, it can no longer bind to TFIIIB and pol III 
transcription increases [3,4,179,182]. Since ROSE-neu cells overexpress cyclin D 
and E proteins, RB might be hyperphosphorylated with the concomitant activa­
tion of pol III transcription. For this reason, the phosphorylation state of RB was 
investigated in the ROSE system.
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Figure 3.8: RB is hyperphosphorylated in ROSE-neu cells compared to control. (A) 
Mechanism of activation of pol III transcription by inactivation of RB 
through cyclinD,E/cdk complexes. An increase in the protein levels of 
cyclin D and cyclin E produce activation of the cyclin D /cdk4/6 and cy­
clin E /cdk2 complexes which are involved in the phosphorylation of RB. 
Hypophosphorylated RB binds to TFIIIB and inhibits pol III transcrip­
tion; however, when it is phosphorylated by the cyclin/cdk complexes, 
it can no longer bind to RB and repression of pol III transcription is 
released |11]. (B) Western blot from whole cell extracts (50/ig) prepared 
from R0SE-/5gal (lane 1) or ROSE-neu cells (lane 2). Upper panel shows 
that RB from ROSE-neu extracts is primarily in the hyperphosphory­
lated form compared to that of ROSE-^gal (upper panel). The antibody 
used was G3-245. Lower panel shows again that RB from the neu overex­
pressing cells is highly phosphorylated. The antibody used was specific 
for phosphorylated serine 780.
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First, western blotting with an antibody tha t reacts with both the hypo- and hy­
perphosphorylated forms of the RB protein was tested in ROSE whole cell extracts. 
The two forms of RB can be distinguished by their electrophoretic mobility, since 
the hyperphosphorylated form has retarded mobility compared to the hypophospho­
rylated protein in SDS-polyacrylamide gels [262,263]. As expected, a bigger fraction 
of the hyperphosphorylated form of RB is present in ROSE-neu cells compared to 
RB present in R0SE-/3gal cells (Fig. 3.8). This demonstrates tha t phosphorylation 
of RB is increased in neu overexpressing cells, eventhough both groups are cycling. 
To test this further, an antibody tha t exclusively recognizes cyclin D/cdks phospho­
rylation of RB at serine 780 was utilised [264,265]. Extract from neu overexpressing 
cells gave a stronger signal compared to tha t of control cells (Fig. 3.8). Taken 
together, these results demonstrate tha t RB is being phosphorylated as a result of 
neu overexpression.
3.2.6 TFIIIB Association with RB
Once it had been demonstrated tha t RB phosphorylation is increased in the neu- 
overexpressing cells, association of RB with TFIIIB in the two RO8E-transfected cell 
types was investigated. Since only the underphosphorylated form of RB can bind 
to TFIIIB [4], it would be expected tha t less TFIIIB from neu overexpressing cells 
is associated with RB than in control cells. Evidence of this can be seen in figure 
3.9A, where coimmunoprecipitation experiments show that the interaction between 
RB and the TFIIIB  subunit Brf in ROSE-neu extracts is diminished compared 
to tha t in ROSE-^gal extracts. For this experiment, an antibody raised against 
RB was used to immunoprecipitate proteins from ROSE-transfected cells and the 
precipitated material was then probed by Western blotting using an antiserum for 
the Brf subunit of TFIIIB. Precipitation with an antibody against TAFj48 was 
used as a negative control (Fig. 3.9). The same samples were also analysed for RB 
concentration in each cell type (data not shown), demonstrating tha t RB is present 
at similar levels in both. From this, it can be concluded tha t TFIIIB from ROSE- 
neu cells is less tightly associated with the inhibitor RB, and this suggests tha t the 
increase in pol III transcription observed in these cells might be through activation 
of TFIIIB.
3.2.7 TFIIIB Regulation by Neu
The reduction observed in the association between RB and Brf might be one mech­
anism by which neu induces pol III transcription. In addition to this effect, neu 
might be inducing pol III transcription by mechanisms independent of RB. Activa-
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Figure 3.9: Decreased association between TFIIIB subunit Brf and RB in ROSE-neu 
extracts. (A) 150/ig of ROSE-^dgal (lanes 1 and 2) or ROSE-neu extracts 
(lanes 3 and 4) were immunoprecipitated with anti-RB antibody 0-15 
(lanes 1 and 3) or anti-TAFj48 antibody (lanes 2 and 4). Precipitated 
material was resolved on a 7.8% SDS-polyacylamide gel and then anal­
ysed by Western immunoblotting with antiserum against Brf.
tion of the Ras/M APK pathway has been shown to stimulate pol 111 transcription 
not only by inducing RB phosphorylation, but also by producing an elevation in the 
protein levels of the TFIIIB subunit TBP [170]. To address this possibility, Western 
blot analysis was carried out to determine the amount of TBP and Brf present in 
whole cell extracts from ROSE-neu cells compared to ROSE-^gal cells. The signals 
of these proteins from ROSE-neu extracts appeared as a doublet for both Brf and 
TBP (Fig. 3.IDA). Nevertheless, it can be observed that the levels of TBP are higher 
in the ROSE-neu cells compared with the ROSE-/9gal (Fig. 3.10A, lower panel).
The retardation in electrophoretic mobility of these proteins suggests tha t a 
modification is occurring. There are several modifications tha t could affect the 
electrophoretic mobility of a protein, including phosphorylation, acétylation, and 
ubiquitination. Recently, it has been demonstrated that casein kinase 2 (CK2) is 
able to phosphorylate TBP and Brf in vivo, stimulating pol 111 transcription in both 
mammals and yeast [266-268]. The data presented in these reports suggested that 
phosphorylation of Brf and TBP might facilitate recruitment of TFIIIB by TFIIIC 
to the promoter [266,268]. Furthermore, activated ERK phosphorylation of Brf has 
been detected in mouse fibroblasts after addition of serum, and this phosphorylation 
is required for pol 111 transcriptional activation [269]. Thus, phosphorylation was 
tested as the possible modification observed in the neu overexpressing cells. Whole 
cell extracts were treated with phosphatase and then analysed by Western blot.
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Although the experiment was performed several times and with different conditions, 
no clear result could be obtained for Brf. In the case of TBP, phosphatase treatm ent 
did not have any effect on the doublet (data not shown). From this result it could be 
concluded tha t the modification observed in TBP is not phosphorylation; however, 
it has to be considered whether the experiment did not work, maybe because it was 
not properly designed or because different reagents had to be used, since no clear 
result could be seen for Brf.
To investigate this further, the induction of TBP mRNA was studied. RT- 
PCR was performed using cDNAs prepared from the mRNA of ROSE-^gal and 
ROSE-neu cells. The primers utilised were designed to recognise TBP mRNA. 
Neu overexpression produces an increase in the mRNA levels of TBP compared to 
control (Fig. 3.10B). This result suggests tha t activation of pol III transcription 
by neu overexpression not only involves RB inactivation, but also an increase in 
TBP mRNA. Overexpression of TBP has been shown to induce transcription of 
tRNA and U6 snRNA genes in Drosophila cells [270]. This is quite interesting since 
the same genes are induced by neu overexpression (Fig. 3.2). Furthermore, it has 
also been observed th a t TBP mRNA is over expressed in human breast carcinomas 
compared to normal tissue [271]. Since neu is overexpressed in 20 to 30% of human 
breast tumours, the induction observed in TBP mRNA might be regulated through 
ErbB2/neu. The result obtained with the ROSE-neu overexpressing cells indicate 
tha t this might be the case.
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Figure 3.10: Expression of the TFIIIB subunits TBP and Brf. (A) Proteins (IOO//g) 
extracted from ROSE-^^gal (lanes I) or ROSE-neu cells (lanes 2) were 
resolved in a 7.8% polyacrylamide gel and then analysed by Western 
blotting with antiserumI28 against Brf (upper panel), or antibody SI- 
I against TBP (lower panel). (B) cDNAs prepared from total RNA 
(3/ig) extracted from R0SE-/9gal (lane I) or ROSE-neu cells (lane 2) 
were used as template for RT-PCR analysis. The primers used were 
designed against TBP (tipper panel) or GAPDH (lower panel).
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Figure 3.11: Possible mechanisms of pol III transcriptional induction by the activa­
tion of the ErbB2/neu receptor. Neu activation triggers induction of 
different signaling cascades, like Ras/MAPK and PI3K which will then 
increase the expression of different genes, including cyclins and tran­
scription factors like TBP. Cyclin induction will inactivate RB, allowing 
pol III transcription to occur. Furthermore, an increase in the TFIIIB 
subunit TBP will also increase the activity of pol III transcription; plus 
phosphorylation of Brf may also promote pol III activity.
3.3 Discussion
Over the past 20 years since the discovery of ErbB2/neu, intense research has been 
performed to study its normal cellular functions and the mechanisms involved in its 
tumourigenicity. Its gene is among the most frequently altered in human cancer, 
which makes it an attractive candidate to study towards the understanding of this 
process. Cancer cells often proliferate at a much faster rate than normal cells; for 
this reason, they require to increase their growth rate to achieve a sufficient size 
before they can divide. As explained in the introduction chapter, high levels of pol 
III transcription are essential to mantain rapid growth. Indeed, pol III transcription 
is deregulated in rapidly growing cells like human cancers and transformed cell lines. 
Thus, activation of pol III transcription might be a necessary event leading to cell 
transformation and tumourigenesis by neu overexpression.
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The results presented in this chapter show that neu overexpressing cells, which 
are transformed cells tha t proliferate at a faster rate than control non-transformed 
cells, have increased pol III transcription. It has been shown in ovarian epithelial 
cancer tha t pol III transcripts and TFIIIC2 are overexpressed [12]. Although pol III 
transcription is increased in the ovarian epithelial neu-transformed cell line, these 
cells do not overexpress the TFIIIC2 subunits (Fig. 1.2). In fact, a reduction in TFI- 
IIC2 mRNA levels was observed in ROSE-neu compared to R0SE-/5gal; however, 
the protein levels were similar in both transfected cell lines and TFIIIC2 activity is 
very slightly higher in ROSE-neu cells compared to control cells (Fig. 1.2 and [226]).
There are other possible mechanisms involved in neu’s regulation of pol III tran­
scription. Pol III transcription can be stimulated by factors tha t have been shown to 
be induced by neu overexpression. These factors include Ras activation, increase in 
cyclin levels and RB inactivation. As demonstrated in this chapter, the ROSE-neu 
transfected cells present all these alterations, so the activation of pol III transcription 
in the ROSE-neu cells might be through these mechanisms. Ras activation induces 
RB inactivation by increasing the levels of cyclin/cdk complexes which will phospho­
rylate this protein (Fig. 3.11). Since inactivated RB can no longer bind and inhibit 
TFIIIB, neu might be using this mechanism to stimulate pol III transcription. The 
coimmunoprecipitation experiments presented here demonstrate tha t TFIIIB sub­
unit Brf from ROSE-neu cells is largely dissociated from this inhibitor. Furthermore, 
the Ras/M APK pathway can also increase the cellular levels of the TFIIIB subunit 
TBP [170]. TBP has been shown to be a limiting factor for pol III transcription and 
its induction can mediate transactivation of class III genes [168,270]. ROSE-neu 
cells also express elevated levels of TBP mRNA. Therefore TFIIIB activity is ex­
pected to be increased in these cells compared to tha t of control, and this activation 
might be responsible for the induction of pol III transcription (Fig. 3.11).
Induction of cyclins and RB phosphorylation by activated Ras has been shown to 
be regulated also through the TF c-Myc. Neu stimulation of Ras produces activation 
of the MAPK and PI3K pathways (Fig. 3.6) [5,13, 228]. These pathways have 
been implicated in the control of c-Myc cellular levels. In addition, the mTOR 
pathway, observed to be induced in the ROSE-neu cells through the phosphorylation 
of also regulates c-Myc expression. This TF is frequently deregulated in
human cancers, and it not only regulates transcription of genes involved in cell 
cycle progression, but also genes involved in cell growth, like ribosomal proteins and 
translation initiation factors [15]. It has been proposed th a t c-Myc is a primary 
effector of ErbB2/neu oncogenicity [5], c-Myc expression is induced upon activation
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of ErbB2/neu through the Ras/M APK and PI3K pathways in breast tumour cells 
and can partially rescue the neu phenotype from cells tha t had lost functional neu [5]. 
Hynes group showed that expression of c-Myc lead to an increase in cyclin D levels 
and phosphorylation of RB [5]. R would be interesting to study if this oncoprotein 
is exerting any role upon neu’s upregulation of pol III transcription. The following 
chapter will address this question.
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4.1 Introduction
Cancer probably occurs due to the accumulation of mutations within growth regula­
tory genes, which will produce the activation and/or suppression of several different 
pathways. The different resulting combinations will affect the characteristics of the 
tumour, like its agressiveness or its response to treatment. In breast and epithelial 
ovarian tumourigenesis, abnormal expression of the erbB2/neu, c-myc and ras genes 
has been implicated, although other genes are also involved [206,207,210,272-275]. 
In addition, combinations of abnormal coexpression between these genes may act 
synergistically, endowing tumour cells with a highly aggressive phenotype. Studies 
from patients with epithelial ovarian cancer have shown tha t tumours containing 
both c-myc amplification and high ErbB2 coexpression have significantly worse sur­
vival than those of patients with normal expression of ErbB2 [273,275]. Moreover, 
simultaneous overexpression of ErbB2 and Ras have been also observed in epithelial 
cancer, and this is associated with shorter disease free and overall survival than 
tumours presenting overexpression in only one oncoprotein [273,275]. Furthermore, 
when these three oncoproteins are overexpressed in the same cancer, the survival of 
patients is significantly worse tha t tha t of patiens with tumours tha t do not over­
express these proteins [273]. In the case of human breast carcinoma, a correlation 
between c-Myc and ErbB2 overexpression has also been observed [274]. As well, a 
role for Ras activation and ErbB2 overexpression in mammary tumourigenesis has 
also been documented, and alterations in both oncoproteins also lead to a more 
aggressive tumour phenotype [235]. In addition to the ovarian and breast cancers.
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simultaneous abnormal expression of these oncoproteins have also been found in 
other types of cancers (e.g. lung carcinomas [276]). Taken together, these findings 
suggest tha t the abnormal expression of the oncoproteins ErbB2, Ras and c-Myc 
are a common feature of different cancers. Therefore their study provides a good 
system to investigate the process of carcinogenesis. i
4.1.1 ErbB2 Regulation of c-Myc Expression
Overexpression of ErbB2, Ras and c-Myc are usually observed in late stage cancers, 
and happen through a succession of genetic alterations; thus, the modification of 
one protein might have an effect upon the regulation of the other two. There is 
increasing data demonstrating tha t the activation of ErbB2 triggers the activation 
of the Ras/M APK pathway; therefore, this receptor might be contributing to the 
increased activity of this oncoprotein found in tumours [5,228,234, Chapter 3]. On 
the other hand, c-Myc expression can be affected by ErbB ligands as well. Li et. al. 
demonstrated tha t neuregulins, which bind and activate ErbB2 in association with 
ErbB3 or ErbB4, can upregulate the expression of c-Myc mRNA and protein [277].
This experiment showed that this transcription factor can be induced by the ErbB 
family; however, it did not address the possible regulation of c-Myc expression upon 
activation of ErbB2 solely. Neve et. ah, using a strategy for efficient down-regulation 
of the ErbB2 receptor through intracellular expression of an ErbB2-specific single 
chain antibody, demonstrated tha t the activation of the ErbB2 receptor does indeed 
stimulate c-Myc expression [5]. This report also showed that the induction of both c- 
Myc’s mRNA and protein levels by ErbB2/ErbB3 dimers is through the activation of 
the signaling cascades Ras/M APK and PI3K [5]. In a different report, it was shown 
that ErbB2 overexpression produces both Ras/M APK activation and upregulation 
of c-Myc expression following epidermal growth factor stimulation (EOF). However, 
in this study the activation of the PI3K was lower in the ErbB2 overexpressing cells 
than in the control. From this study, it can be concluded tha t ErbB2 overexpression 
can induce c-Myc expression through the activation of the Ras/M APK pathway 
solely [278]. Taken together, these findings show that there is a link between c-Myc 
expression and ErbB2 activation, and tha t the induction of c-Myc expression by 
ErbB2 can be achieved through the activation of the Ras/M APK pathway, as well 
as in conjunction with the PI3K signaling pathway. Hence, the signaling pathways 
act as intermediaries transferring the growth-promoting signal from ErbB2 at the 
plasma membrane to c-Myc at the nucleus. c-Myc is a transcription factor whose 
increased expression has been associated with increased cell survival, stimulation
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of cell growth, and cell cycle progression; furthermore, its overexpression can also 
cause apoptosis [279,280]. Its induction will affect the expression of its different 
target genes (discussed in detail in the following chapter).
4.1.2 Regulation of c-Myc Expression by Signalling 
Pathways
The Ras/M APK and the PI3K pathways utilize different strategies to upregulate 
c-Myc expression. These signaling pathways increase c-Myc expression at both the 
transcriptional and translational levels; in addition, the Ras/M APK pathway can 
also enhance c-Myc protein accumulation through post-translational modifications 
[245,281-284]. Evidence for the regulation of c-Myc expression at the transcriptional 
level by these pathways comes from experiments using erythroid cells stimulated by 
the hematopoietic growth factor erythropoietin. In these cells, erythropoietin, when 
interacting with its cognate receptor (EpoR), initiates the activation of a cascade of 
signaling pathways, including the PKC, the MAPK and the PI3K pathways, which 
produce an increase in c-myc gene expression [281]. In this system, if the MAPK is 
blocked after Epo stimulation, a reduction in c-myc elongation at the 3’-end of exon 
1 is observed, whereas inhibition of PI3K blocks transcription initiation at exon 1; 
therefore, PI3K is required for c-myc gene transcriptional initiation, while MAPK 
acts on elongation [281].
Upregulation of c-Myc expression at the translational level by these signaling 
pathways is mediated through their activation of p70^ ®^ '^  (the 70-kDa isoform of 86 
protein of 408 small ribosomal subunit protein kinase) [245,284]. This kinase is 
im portant for G1 cell cycle progression and is responsible for the phosphorylation 
and activation of the 86 protein of the ribosomal translational complex, causing 
accelerated protein synthesis [242]. Following activation, the 86 protein induces 
protein synthesis biased toward mRNA transcripts tha t contain a polypyrimidine- 
rich 5’ untranslated region, like tha t of the mRNA of c-Myc, as well as early growth 
response genes, cyclins and ribosomal elongation factors [242]. Thus, activation 
of p70^®^  ^ diverts the translational machinery to translate c-Myc mRNAs, among 
others, increasing the levels of this protein. It is interesting tha t ErbB2 activation 
has been shown to stimulate the phosphorylation of p70^6K Thr^^^ (Chapter 3). 
The phosphorylation of this residue has been shown to regulate c-Myc levels, since 
when its dephosphorylation is induced, a dramatic down-regulation of c-Myc levels 
is observed [285]. Therefore, ErbB2 induction of Thr^^^phosphorylation of 
might provide another positive control for c-Myc’s upregulation.
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In addition to positive effects exerted by the Ras/M APK pathway upon c-myc 
transcription and translation already mentioned, this signaling cascade is also able 
to enhance the accumulation of the c-Myc protein through post-translational modi­
fications by increasing its stability. c-Myc has a very short half life of approximately 
30 min, being rapidly degraded by the 26S proteasome [283]. However, this rapid 
degradation is slowed dramatically by the activation of the Ras/M APK pathway, re­
sulting in an increase of its half life to approximately 50-65 min [283]. This increase 
is achieved by the phosphorylation of c-Myc Ser 62 through the action of MAPK 
(ERK) [282].
In the previous chapter, it was demonstrated that overexpression of ErbB2 in a 
spontaneously immortalized ra t ovarian surface epithelial cell line (ROSE 199) pro­
duced an increase in pol III transcription compared to control cells. The ErbB2/neu 
overexpressing cells present higher levels of the Ras/M APK and the path­
way activation than the control cells, which might account for the induction of 
pol III transcription. As mentioned in the previous chapter, it is known tha t the 
Ras/M APK pathway can upregulate pol HI activity by affecting TFIIIB activity 
through different mechanisms, like by increasing the protein levels of the TBP sub­
unit as well as by relieving TFIIIB from RB repression [170, Chapter 3]. These 
alterations are indeed present in the ErbB2/neu overexpressing cells; thus, they 
might account for the activation of pol III transcription. However, other factors 
might also be involved. Since these cells show higher activation of the Ras/M APK 
and pYoSsA: pathways than the normal cells, it is quite probable tha t they will ex­
press higher levels of the c-Myc protein as well. Recently, it has been proposed tha t 
c-Myc is a primary effector of ErBb2/neu oncogenicity and its expression can par­
tially rescue the ErbB2 phenotype from cells that had lost functional ErbB2/neu [5]. 
Furthermore, c-Myc is an im portant regulator of cell growth; and since the tran­
scripts produced by pol III are essential in this process, it might be quite probable 
tha t c-Myc is participating in the upregulation of pol III transcription by ErbB2 
overexpression. This chapter will address if the oncoprotein c-Myc is involved in the 
ErbB2/neu activation of pol III transcription. To assess this, the same cell line as 
the one studied in the previous chapter (a spontaneously immortalized rat ovarian 
surface epithelial cell line (ROSE 199) overexpressing ErbB2/neu or /5-galactosidase) 
is going to be used.
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4 .2  Results
4.2.1 c-Myc Expression Is Increased in Neu Overexpressing 
Cells
The first experiment performed was to test whether overexpression of neu could 
affect the levels of the c-Myc protein in the ROSE system. As mentioned in the 
introduction, c-Myc protein levels are known to be controlled by the activation of 
different signaling pathways, including the Ras/M APK cascade and . The
Ras/M APK pathway, through ERK activation, increases the stability of the c-Myc 
protein, enhancing its accumulation. As shown in chapter 3, the ROSE cells that 
overexpress the receptor neu present higher levels of ERK and activity than
that of the cells overexpressing /5~galactosidase (R0SE-/3gal, Fig. 3.6). These find­
ings suggest tha t there might be an induction in the expression of the c-Myc protein 
in the ROSE-neu cells compared to tha t of the control cells. To assess whether this 
is indeed happening, whole cell extracts from both ROSE-^gal and ROSE-neu cells 
were analysed by Western immunoblotting, with antibodies specific for c-Myc or 
TFIIB, the latter used as a loading control. As shown in figure 4.1, c-Myc protein 
levels are increased in ROSE overexpressing neu compared to the expression in con­
trol cells, whereas the TFIIB protein levels remain constant. The increase in the 
levels of c-Myc is highly reproducible and not due to unequal protein loading because 
equal amounts of total protein were loaded into each lane based on protein assays, 
and based on immunoblotting with a TFIIB antibody as a loading control (Fig. 4.1, 
lower panel). From this result it can be concluded tha t constitutive activation of 
neu upregulates c-Myc expression in ROSE cells.
4.2.2 Regulation of Pol III Transcription by c-Myc in ROSE 
cells
Having established th a t the ROSE-neu cells overexpress c-Myc, the participation 
of this protein in the upregulation of pol III transcription was investigated. Since 
pol III transcriptional activity can be assessed by in vitro transcription assays, an 
experiment was designed to test whether the removal of the c-Myc protein from 
whole cell extracts could have any effect on pol III transcription from ROSE-neu 
extracts compared to ROSE-/?gal extracts. Whole cell extracts were immunode­
pleted using an antibody against c-Myc or an antibody against the pol Il-specihc 
factor TFIIB and then were used for in vitro transcription of the class III gene, VAl. 
Mock-depletion or immunodepletion of c-Myc or TFIIB from ROSE-^gal extracts
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Figure 4.1: Neu overexpression induces c-Myc protein levels. Proteins (150/ig) 
extracted from ROSE-/?gal (lane 1) or ROSE-neu cells (lane 2) were 
resolved in a 7.8% polyactylamide gel and then analysed by Western 
blotting with an antibody against c-Myc (upper panel), or an antibody 
against TFIIB (lower panel).
has little effect on pol III transcription (Fig. 4.2, lanes 1-3); however, when ROSE- 
neu extracts are depleted of c-Myc with an anti-Myc antibody, they display reduced 
VAl transcription (Fig. 4.2, lane 6). This effect is specific, since mock-depletion or 
immunodepletion of the pol Il-specific factor TFIIB has no effect (Fig. 4.2, lanes 
4 and 5, respectively). These results demonstrate tha t c-Myc overexpression plays 
a role in the increase of pol III transcriptional activity observed in the ROSE cells 
overexpressing neu, while the low levels of pol III transcription observed in ROSE- 
jdgal cells are not dependent on c-Myc expression. They suggest tha t the high pol 
III activity caused by neu overexpression is via the induction of this transcription 
factor. Thus, neu upregulation of c-Myc might be responsible for the activation of 
pol III transcription.
4.2.3 Inhibition of  c-Myc Expression and Pol III 
Transcription in ROSE Cells
In order to further investigate whether c-Myc induction is required for the activa­
tion of pol III transcription in the neu overexpressing cells, the following exper­
iment was designed to inhibit c-Myc expression at the mRNA level. Previously, 
Heikkila et. al. have shown that c-Myc protein expression can be inhibited by us­
ing a pentadecadeoxyribonucleotide complementary to the initiation codon and four 
downstream codons of human c-m,yc mRNA |286]. Therefore, the same approach 
was utilised to analyse c-Myc participation in pol III transcriptional upregulation 
by neu overexpression in the ROSE system. Cell cultures from ROSE-^dgal and
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Figure 4.2: Immunodepletion of c-Myc reduces pol III activity in ROSE-neu over- 
expressing cells. Transcription of the VAl gene was assayed using whole 
cell extracts prepared from ROSE-^gal or ROSE-neu cells, which were 
mock depleted (lane 1 for ROSE-^dgal and lane 4 for ROSE-neu) or pre­
viously immunodepleted for 2 hours on ice with antibodies raised against 
TFIIB (C-18 Santa Cruz, lane 2 for ROSE-^gal and 5 for ROSE-neu), 
or c-Myc (9E10 Santa Cruz, lane 3 for ROSE-^gal and 6 for ROSE-neu).
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ROSE-neu cells were exposed to antisense oligodeoxyribonucleotides (complemen­
tary to the first five codons of ra t c-myc mRNA) or sense oligodeoxyribonucleotides 
(complementary to the antisense construct) at a final concentration of 20/rM for 48 
hours. Total RNA was extracted from these cells and used for cDNA preparation. 
This cDNA was used as template for RT-PCR reactions to assay levels of tRNA 
precursors and 5S rRNA, as well as GAPDH mRNA. An intron-specihc primer was 
employed to study levels of tRNA precursors, which are processed very rapidly and 
so provide an assay of ongoing transcriptional activity [12]. When ROSE cells over­
expressing the oncoprotein neu were exposed to c-myc antisense oligonucleotides, 
both tRNA and 58 rRNA levels decreased considerably (Fig. 4.3, lane 6), while the 
levels of the pol III products in the control cells did not suffer any change (Fig. 4.3, 
lane 3). This effect is specific since exposure to c-myc sense oligonucleotides did 
not have any effect on pol III transcription in both ROSE-^gal or ROSE-neu cells. 
Furthermore, the expression of GAPDH mRNA did not change in response to ei­
ther sense or antisense c-myc oligonncleotides. Taking together the results obtained 
here with those of the immunodepletion experiment, it can be concluded tha t neu 
overexpression requires the induction of the transcription factor c-Myc in order to 
activate pol III transcription. Furthermore, they are the first results to demonstrate 
tha t this trancription factor is capable of regulating pol HI activity.
4.2 .4  Induction o f  the pol III subunit BN51 by Neu 
Overexpression
Having established tha t expression of the oncoprotein c-Myc does affect pol III ac­
tivity in the neu overexpressing cells, it was investigated whether other proteins 
might also be induced in this system. In the literature, there is evidence showing 
tha t the c-Myc-ER fusion protein in an immortalized R a ti cell line, can upregulate 
expression of the pol Ill-specific subunit BN51 [287]. Since the ROSE-neu cells are 
also a transformed cell line th a t overexpress the oncoprotein c-Myc, through con­
stitutive activation of the receptor neu, the protein expression levels of the BN51 
subunit were analysed in the ROSE system. Equal amounts of whole cell extracts 
prepared from either R0SE-/5gal or ROSE-neu cells were analysed by Western blot­
ting using an antiserum raised against BN51. Elevated levels of the BN51 protein 
were observed in the neu overexpressing cells compared to the cells overexpressing 
/?-gal (Fig. 4.4, upper panel). Induction of BN51 in the ROSE-neu cells is specific, 
since the levels of the pol Il-specific subunit TFIIB remained constant in both cell 
types (Fig. 4.4, lower panel). These data show tha t not only the c-Myc oncoprotein
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Figure 4.3: Depletion of c-Myc by antisense oligonucleotides selectively reduces 5S 
rRNA and tRNA^®^^ gene expression in neu-overexpressing cells. Grow­
ing ROSE-ydgal or ROSE-neu cells were grown in the presence of 20 /^M 
sense (lanes 2 and 5, respectively) or antisense (lanes 3 and 6, respec­
tively) c-Myc oligonucleotides. RNA was harvested 48 hrs after transfec­
tion and analysed by RT-PCR, for the expression of 5S rRNA, tRNA^®^ 
and mRNA encoding GAPDH.
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Figure 4.4: Expression of the pol III subunit, BN51, in ROSE-^bgal and ROSE-neu 
cells. Proteins (100//g) extracted from ROSE-,dgal (lanes 1 and 3) or 
ROSE-neu cells (lanes 2 and 4) were resolved in a 7.8% polyacrylamide 
gel and then analysed by Western blotting with antiserum 113 against 
BN51 [upper panel) or the rabbit antibody C-18 against TFIIB [lower 
panel).
is upregulated when the neu receptor is constitutively activated, but also the pol 
Ill-specific subunit, BN51 is induced. The fact that the transcription factor c-Myc 
has been shown to positively regulate transcription of the BN51 gene suggests that 
the induction observed of this protein in the ROSE-neu cells might be through a 
c-Myc-dependent mechanism; however, this still has to be examined.
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4 .3  Discussion
In the literature, there is compelling evidence showing tha t ErbB2/neu receptor acti­
vation leads to the activation of several signaling cascades th a t will consequently af­
fect gene expression. In the previous chapter, it was demonstrated that constitutive 
expression of neu in an immortalized ovarian epithelial ra t cell line produces activa­
tion of different kinases, shown by the phosphorylation of MAPK (ERK1/ERK2) as 
well as which are downstream kinases of the Ras and PI3K pathways (see
Fig. 3.6). These cascades are well known to be induced by activation of ErbB2/neu 
(see introduction); thus the results obtained were expected. Activation of the signal­
ing cascades will affect gene transcription and, ultimately, the rate of proliferation of 
a cell. ErbB2/neu activation in a breast luminal cell line and in a breast tumour cell 
line has been shown to induce c-Myc oncoprotein expression through activation of 
the MAPK and the PI3K cascades [5,278]. In this chapter, it is shown that overex­
pression of neu also upregulates the expression of c-Myc in an ovarian epithelial cell 
line. This cell line does display activation of the MAPK cascade, as well as p70^®^ ;^ 
however, it was not determined if this is responsible for the observed upregulation of 
c-Myc levels. Nevertheless, it is quite probable that these pathways are involved in 
this process, but it would be interesting to address the mechanisms of this induction.
The c-Myc oncoprotein is known to be a positive regulator of both cell growth 
and proliferation [279,280,288]. In the previous chapter, it was demonstrated tha t 
constitutive activation of neu in the epithelial cells produces an activation of pol 
III transcription (see Chapter 3). As previously mentioned in the introduction of 
this thesis, the genes transcribed by pol III are essential factors of cell growth, since 
they function in mRNA m aturation and protein synthesis required to achieve an 
increase in cell mass. The fact th a t a transcription factor like c-Myc, which induces 
cell growth, is upregulated in the same cells where pol III transcription activity is 
observed to be higher, suggested a possible participation of this transcription factor 
in pol III regulation. As shown in this chapter, this appears to be the case. De­
pletion of c-Myc either in vitro (by immunodepleting whole cell extracts of c-Myc, 
see 4.2) or in vivo (by antisense oligos specific to c-Myc mRNA, see 4.3) in the 
ROSE-neu cells reduced pol III transcription to the levels obtained in the control 
cells (ROSE-jdgal), or even less for some transcripts (see 4.3, for tRNA^®^). These 
findings show tha t indeed pol III transcription is sensitive to the presence of the 
transcription factor c-Myc, and suggest a role for this protein in its regulation. To 
date, this is the first evidence demonstrating tha t pol III transcription responds 
to c-Myc oncoprotein levels. Although the antisense experiments show tha t c-Myc
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downregulation reduces transcription from class III genes to the levels observed in 
the control cells and suggests upregulation of c-Myc to be the mechanism by which 
oncogenic neu impinges on pol III transcription, it has also to be considered tha t 
constitutive expression of neu produces other alterations tha t will positively regulate 
pol III transcription (like RB phosphorylation and TFIIIB derepression, see Chap­
ter 3) and might be involved in the induction of pol III activity in the ROSE-neu 
cells. To address this, different experiments have to be performed to investigate 
the contribution of each alteration. c-Myc is known to affect RB phosphorylation, 
so it might also account for the hyperphosphorylation observed in the ROSE-neu 
cells. Moreover, the pol Ill-subunit BN51 was observed to be upregulated in the 
neu-overexpressing cells, and there is evidence in the literature showing tha t is a 
c-Myc target gene [287]. Nevertheless, the data presented here present a new mech­
anism of inducing pol III transcription, through the oncoprotein c-Myc, and it will 
be interesting to investigate whether c-Myc regulation of pol III transcription is a 
characteristic particular to this type of cell line, or if it is a general effect in multiple 
types of cells.
In summary, it can be concluded tha t constitutive activation of the oncoprotein 
ErbB2/neu positively regulates pol III transcription. It might be doing so through 
alterations at multiple points, including TFIIIB release from RB repression, upreg­
ulation of the TFIIIB subunit TBP and the pol Ill-subunit BN51, and induction 
of the transcription factor c-Myc. Regulation of pol III transcription by RB and 
induction of TBP through Ras has been studied in numerous publications; however, 
c-Myc regulation of pol III activity has not been addressed yet and presents an 
interesting area of research. For this reason, the following chapters will investigate 
c-Myc participation in pol III transcription. To study this, the ROSE cell line will 
no longer be used since it presents so many different changes; instead, primary cells 
will be used to investigate if c-Myc is a general regulator of pol III transcription.
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5.1 Introduction
The oncogene myc was discovered around 20 years ago as the transforming se­
quence of neoplastic avian retroviruses (e.g. the myelocytomatosis virus and the 
avian leukosis virus), referred to as v-myc, (for review see [288]). Soon after, v- 
myc cellular homologues (c-myc) were identified, including those of chicken, mice 
and humans [288-291]. Later on, two different genes were also identified containing 
strong homology to c-myc in human neuroblastomas and small cell lung carcinomas, 
and were dubbed the N-m^c and h-myc genes, respectively [288,292,293]. Other 
cellular sequences with high homology to some portions of c-myc have been found, 
including B-m^c and S-myc [294,295]. The c-myc allele is localized to chromosome 
8 (8q24) [296] and its translocation to different chromosomes has been shown to 
be involved in the generation of cancer [272,280,288,296]. Homozygous deletion of 
c-myc is lethal at embryonic day 9.5-10.5; myc null embryos are smaller, retarded 
in development and show abnormalities of the heart, pericardium, neural tube, and 
a delay or failure in embryonic turning [280,297].
The myc members are considered to be proto-oncogenes, since alterations in 
their expression play an im portant if not essential role in the development of a wide 
variety of human and animal cancers [272,280,288,290,293]. A good example of this 
are the translocations of the c-myc locus, on chromosome 8, to immunoglobulin loci 
of B lymphocytes, on chromosomes 2, 14, or 22, observed in B urkitt’s lymphomas 
in humans and plasmacytomas in mice [272,288,298,299]; as well as amplification 
of the N-myc and L-myc genes in neuroblastomas or small cell lung carcinomas.
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respectively [292,293]. Furthermore, overexpression of the Myc proteins with no 
genetic alterations can be seen in a wide variety of human cancers (like in breast 
and epithelial ovarian cancer) [272,290]. In fact, c-Myc deregulation contributes to 
one seventh of all cancer deaths in the USA [272,280,288]. However, the myc genes 
can only partially transform primary cells in culture [288]. To elicit a tumourigenic 
phenotype, cooperation between Myc plus the activation of another oncogene (like 
ras), or the loss of a tumour suppressor gene, is required [300,301]. This is also 
confirmed by its ability to transform when overexpressed in established cell lines 
tha t already contain deregulation in other genes [288].
Overexpression of c-Myc in transgenic animals has also confirmed and extended 
the results mentioned above. Transgenic mice with c-Myc overexpression under 
the control of the glucocorticoid-responsive murine mammary tumour virus long 
terminal repeat, MMTV LTR, develop tumours in breast, testicles, or B and T 
lymphocytes [302,303], Although c-Myc was widely expressed in different tissues, 
it only produced malignancies in certain organs, which implies the requirement for 
a secondary event for c-myc tumour formation [288,302]. Other strategies have 
been developed to target c-Myc overexpression in specific tissues. When a c-myc 
transgene containing the Ep  immunoglobulin enhancer is expressed in mice, they 
develop B cell malignancies which vary according to the susceptibility of each of the 
inbred mouse strains used [272,288,304]. Taken together, these results establish the 
c-myc gene as an im portant factor in the etiology of cancer.
5.1.1 c-Myc Protein Structure
c-Myc protein is mainly localized in the cell nucleus and contains a transactivation 
domain (TAD) in the N-terminal region and a basic helix-loop-helix leucine zipper 
(bHLH-LZ) domain in the C-terminal region (Fig. 5.1) [305-308]. The TAD com­
prises the first 143 amino acids (aas) and is responsible for gene activation [306]. 
It contains two regions, Myc box I (MBI; from approximately aas 45-63) and Myc 
box II (MBII; from approximately aas 128-143) (Fig. 5.1), which are highly con­
served among the Myc family [306,309]. MBII is absolutely required for c-Myc 
transforming activity, while a deletion in MBI only attenuates its transforming ac­
tivity [310,311]. The C-terminal bHLH-LZ domain is also required for c-Myc tran­
scriptional activities, biological activities and transformation [308,312-314]. Pro­
teins containing bHLH-LZ domains can form homo- and heterodimers, bind specific 
DNA sequences and usually act as transcription factors [19]. However, c-Myc cannot 
form homodimers nor bind DNA by itself. It heterodimerizes with the ubiquitously
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Figure 5.1: Schematic model of the c-Myc and Max proteins. The structural ele­
ments in c-Myc and Max are indicated. In the amino-terminal domain 
of c-Myc: transactivation domain (TAD), including Myc Box 1 (MBI) 
from aas 45 to 65 and Myc Box 2 (MB2) from aas 121 to 144. In the 
carboxy-terminal domain of c-Myc and Max: the nuclear localization 
signal (NLS); the basic region (b) from aas 352 to 357; the helix-loop- 
helix region from aas 357 to 411; and the leucine zipper from aas 411 to 
439. P indicates sites of in vivo phosphorylation.
expressed bHLH-LZ protein Max (myc associated X protein) [280,315,316]. Myc- 
Max heterodimers bind DNA, recognizing specifically the hexameric DNA sequence 
CACGTG (which belongs to the sequences known as E-boxes, with the CANNTG 
consensus that is recognized by most bHLH proteins) and activate transcription of 
genes containing it [308,317]. Usually, the E-boxes recognised by Myc-Max com­
plexes are localized in the first introns of its target genes [308]. Max can homod- 
imerize and bind to DNA, but Max homodimers appear to be transcriptionally in­
ert [260,280]. Activation of transcription by Myc-Max heterodimers of certain genes, 
like cyclin D2, appears to be mediated by the recruitment of histone acetyltrans- 
ferases and chromatin remodelling, though activation by other mechanisms might 
also be involved (discussed further in the next chapter) [318-321].
5.1.2 Funtions of  c-Myc in Cell Proliferation
c-Myc participates in a wide variety of cellular processes including cell cycle progres­
sion, cell growth, differentiation, and apoptosis, which explains its involvement in 
the process of tumourigenesis [15,272,279,280,314,318,322-325]. No expression of 
c-Myc can be detected in quiescent cells; entry to the cell cycle by mitogen or serum 
stimulation, produces a rapid and transient burst in c-Myc rnRNA and protein lev­
els, which peaks 3-4 h after growth factor stimulation, followed by a gradual decline 
to low levels in proliferating cells [326,327]. Because its expression is increased by
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mitogenic stimuli during the GO to G1 transition, it belongs to the immediate early 
response genes, which are involved in the cell’s progression through the cell cycle. 
In cycling cells (in the presence of growth factors), c-Myc expression remains low 
and even throughout the cell cycle [325,327,328]. However, when there is growth 
factor withdrawal, c-Myc levels decline to undetectable values [329]. Differentia­
tion also produces a decline in c-Myc levels, which is mantained in differentiated 
cells [288,314,330]. c-Myc is required for G1 to S phase progression and its over­
expression in fibroblasts decreases the cell requirement for serum growth factors, as 
well as shortening the G1 phase [280,286,325,330,331]. Furthermore, activation of 
a conditional c-Myc is sufficient to drive quiescent cells into the cell cycle [6,332]. 
In neoplastic cells, deregulated c-Myc expression drives cells to uncontrolled prolif­
eration [280,288,325]. However, in primary fibroblasts, c-Myc overexpression alone 
cannot sustain a complete round of cell cycling, allowing progression of the cell cy­
cle followed by arrest in the G2 phase. The tumour suppressor proteins p53 and 
p21 appear to play a role in this G2 checkpoint, since the arrest is compromised 
in the absence of these proteins [330]. Overexpression of c-Myc in primary cells 
induces apoptosis in low serum conditions, through p53-dependent and independent 
mechanisms [324].
5.1.3 c-Myc Target Genes
Induction as well as repression of a number of potential c-Myc target genes have been 
implicated in its regulation of the cell cycle [279,280,323,330]. A list of these genes 
is presented in table 5.1. It is im portant to mention that validation of these putative 
genes as c-Myc target genes has been difficult because c-Myc only produces a slight 
increase (on the order of 2-5 fold) in their induction. Nevertheless, it can be noted 
from table 5.1 tha t c-Myc potential targets are required for RB phosphorylation 
and progression of G l. Since RB affects pol III transcriptional activity, it is quite 
probable tha t c-Myc is inducing pol III transcription.
5.1 .4  c-Myc and Growth Control
c-Myc also influences cell growth. For a cell to divide, it needs to gain a certain size 
before it can separate into two daughter cells. As mentioned in this thesis introduc­
tion, the increase in size depends primarily on protein synthesis. Induction of c-Myc 
produces an increase in protein synthesis tha t precedes DNA synthesis [340]. More 
evidence of c-Myc regulation of cell growth comes from experiments in which myc 
alleles have been deleted in RATI fibroblasts. Loss of a single myc allele produces a 3 
hr delay in S phase entry and a similar increase in doubling time [342]; when both al-
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Table 5.1: c-Myc target genes.
Myc target gene Effect Cellular Function Reference
cdc25A A Cell cycle phosphatase [333]
cdk4 A Cell cycle kinase [334]
Cell cyclin D1 A Cell cycle regulator [335]
Cycle cyclin D2 A Cell cycle regulator [323,336]
Id2 A Inactivation of RB [16]
p21 R Cell cycle inhibitor ]323]
p27 R Cell cycle inhibitor ]335]
ODC A Polyamine biosynthesis [323,337]
cad A Pyrimidine biosynthesis [338]
LDH-A A Metabolic enzyme [339]
GAPDH A Metabolic enzyme [287]
Nucleolin A rRNA processing ]287,323]
Cell Fibrillarin A rRNA processing [323]
Growth BN51 A Pol III subunit [287]
R P S ll A Ribosomal protein [323]
eIF-2ft A Tranlation initiation factor [340]
eIF-4E A Translation initiation factor [340]
lARS A Isoleucine-tRNA synthetase [323]
DDX18 A RNA helicase [341]
cad, carbamoyl-phosphate synthase carbamoyl transferase/dihyroorotase; LDH- 
A, lactate dehydrogenase-A; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
R P S ll, ribosomal protein S ll; DDX18, Dead box helicase. A stands for activated; 
R stands for repressed.
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leles are deleted, a 2.5 fold increase in doubling time with a delay in both G l and G2 
phases is observed [191]. These cells present a reduction of 2.5 fold in net protein syn­
thesis as well as decreased rates of rRNA synthesis, resulting in reduced growth [191]. 
Moreover, its direct role on cell growth was demonstrated in Drosophila, where mu­
tations tha t diminished dmyc expression (Drosophila ortholog of vertebrate c-myc) 
resulted in smaller but developmentally normal flies [343]. When imaginai disc cells 
were analysed, dmyc-mutant cells were smaller, but the cell cycle distribution stayed 
the same as in normal cells. However, if dmyc is over expressed, the cells become 
larger than normal without significant change in cell cycle length (although G 1 be­
came shorter while G2 increased) [343]. These findings demonstrate tha t dmyc is 
affecting only cell size, leaving the cell cycle normal, and suggest tha t it may do 
so by directly regulating the cell growth machinery. In mammals, overexpression of 
c-Myc in B-cells both in vivo and in vitro^ in the absence of growth factors, also pro­
duces larger cells without cell cycle progression or RB hyperphosphorylation [344]. 
Furthermore, in hepatocytes and the adult myocardium in vivo, overexpression of 
c-Myc provokes hypertrophy in the absence of proliferation [167,345]. In the hepato­
cytes, prominent nuclei and nucleoli were observed, associated with an upregulation 
of large- and small-subunit ribosomal protein genes and nucleolar genes [346]. In 
fact, several candidate c-Myc genes are involved in cell growth, including ribosomal 
proteins and translation initiation factors as well as genes involved in cell metabolism 
(Table 5.1). Because pol HI is tightly linked to growth, c-Myc might also regulate 
its activity by a direct mechanism. This chapter will address c-Myc regulation of pol 
III transcription and study the possible mechanisms responsible for this induction.
86
5 Activation o f R N A  Polymerase III Transcription by the Oncoprotein c~Myc
5.2  Results
5.2.1 Pol III Transcription in c-Myc Knockout Cells
Due to the fact tha t the c-myc null RATI fibroblasts present a general reduction in 
cell growth, this system was chosen to study whether pol III transcription could be 
affected in the absence of c-myc. The group of Sedivy generated this cell line by gene 
targeting from a previous ra t fibroblast cell line tha t contained a genetic disruption 
of one copy of the c-myc gene. A second disruption was generated, resulting in 
homozygous deletion of c-myc [191]. The parental cell line used for the targeted 
deletion was TGR-1, an hprt- subclone of the immortalized embryonic rat fibroblast 
cell line Rat-1, and was utilised as control. The c-myc-/- cells do not express c-Myc 
protein. In addition, no detectable expression of N-myc or L-myc is observed either 
in the parental cell line or in the c-myc null cells [191]. Northern blot analysis 
of total RNA extracted from quiesced parental and c-Myc knockout cells, as well 
as at different time points after serum stimulation, was performed. When c-myc 
null cells and matched wild-type fibroblasts are compared, the former show <^ 6 fold 
lower expression of pol III transcripts from the B2 repetitive gene family (Fig. 5.2). 
Transcription of the B2 gene provides a reliable indicator of the rate of pol III 
transcription since its transcripts are rapidly degraded after being transcribed [10], 
reflecting pol III transcriptional activity at the time of extraction of RNA and not 
build up of products. In all the samples, the B2 RNA levels are lower in the c-Myc 
knockout cells than in the parental cell line. The decrease observed is specific, since 
mRNA encoding acidic ribosomal phosphoprotein (ARPP) PC is unaffected (Fig. 
5.2). ARPP PO was chosen as a control due to the fact tha t it is not modulated 
by c-Myc, estradiol, OHT, mitogens or serum growth factors, the RB pathway or 
upon cell cycle entry [287]. The results presented demonstrate tha t pol III activity 
is sensitive to the presence of endogenous c-Myc.
5.2.2 Rescue of Pol III Activity by Myc-ER in c-Myc Null 
Cells
To test whether the decrease in pol III activity in the c-myc null cells is due to the 
lack of c-Myc expression and not because of possible secondary mutations produced 
during the gene targeting process of the c-myc gene deletion, c-myc null cells infected 
with a conditional Myc were used to study if c-Myc can recover pol III activity. 
Retroviral transduction of a modified inducible c-Myc-estrogen receptor (Myc-ER) 
system into c-Myc knockout cells has been shown to rescue the null phenotype, with
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Figure 5.2: c-Myc expression affects pol III activity in vivo. Total RNA extracted 
from Myc-null fibroblasts (M yc"/") or wild type (Myc+/+) was analysed 
by Northern blot using a DNA probe against the pol III transcript B2 
(upper panel) and ARPP PO (middle panel). The lower panel shows 
the quantified values of B2 RNA normalized to the levels of ARPP PO 
mRNA, which were obtained from a scanned image analysed with the 
NIH-Image software.
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Figure 5.3: Schematic representation of c-Myc-ER fusion protein activation. An 
inactivated c-Myc-ER fusion protein, composed of c-Myc and the ligand 
binding domain of the estrogen receptor protein which only binds to 
4-hydroxytamoxifen (OHT; TM in the figure) and not to estrogen, is 
expressed in the cells. The fusion protein remains in the cytoplasm in 
the absence of tamoxifen. Addition of tamoxifen promotes dissociation 
of the inhibitory complex and triggers translocation of the c-Myc-ER 
protein to the nucleus. Once in the nucleus, c-Myc-ER transactivates 
transcription from different target genes [347|.
the cells regaining normal growth [191,192,348|. The Myc-ER system allows the 
expression of an inactive c-Myc-ER fusion protein that is composed of a modified 
estrogen receptor ligand-binding domain that binds to hydroxytamoxifen (OHT), 
fused to the c-Myc protein (Fig. 5.3) [347]. The Myc-ER fusion protein stays 
in the cytoplasm; addition of (OHT) causes translocation of the Myc-ER protein 
into the nucleus, activating c-Myc functions (Fig. 5.3) [347, 348]. Northern blot 
analysis was carried out with total RNA extracted from TGR-1 following serum 
stimulation or from Myc knockout cells infected with Myc-ER or Myc-S-ER following 
OHT addition in the absence of serum. Réintroduction of Myc-ER into the c-Myc 
knockout cells stimulated B2 expression (Fig. 5.4). Some increase occurred in the 
absence of OHT, which reflects leakiness of the conditional protein that has been 
previously reported. However, OHT induced a further increase in pol III transcript 
levels. Again, this response is specific, since the mRNA of ARPP PO was not induced 
(Fig. 5.4).
Previously, it has been reported that the réintroduction of the c-Myc naturally 
occurring variant, MycS can also rescue the slow growth phenotype of c-myc null 
cells, albeit at lower efficiency than wild-type Myc-ER [192,348]. The MycS protein 
arises from translation initiation at two downstream AUG codons of wild-type c- 
Myc, yielding proteins that lack the first ~100 aas from the amino-terminus. Thus,
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Figure 5.4: Expression of c-Myc rescues pol III transcription in c-Myc null cells.
(A) Representation of c-Myc protein and its naturally occurring m utant 
c-MycS, lacking the first 100 aas of the N-terminal domain which in­
cludes MBI. (B) RNA extracted at the indicated times after addition 
of OHT, from c-Myc null fibroblasts transduced with retroviral vectors 
carrying Myc-ER (KO-Myc-ER) or MycS-ER (KO-MycS-ER) |192|, was 
analysed for B2 [upper panel) and ARPP PO [middle panel) expression 
by northern blotting. The lower panel shows the values of B2 RNA 
normalized to the levels of ARPP PO mRNA, which were produced by 
scanning the image and quantitating the values of each sample using the 
NIH-Image software.
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MycS lacks much of the TAD, including MBI, but preserves MBII [295]. In immor­
talized rodent cell lines, MycS promotes cell proliferation and apoptosis; however, 
in primary cells it cannot mimic c-Myc activities [192,348]. It has also been shown 
to act as a weak transactivator of endogenous target genes [192]. Figure 5.4 shows 
th a t the réintroduction of an inducible MycS-ER fusion protein into c-myc null cells 
does not rescue pol III activity; however, it would have been interesting to study 
MycS effect upon pol III transcription at longer time points than those chosen,
5.2.3 Activation of  Myc-ER is Sufficient to Induce Pol III 
Transcription in Quiescent Primary Cells
Having demonstrated tha t pol III transcription responds to c-Myc expression in 
established cell lines th a t are immortal, it was investigated if it could have the 
same effect in mortal cells. Mortal cells offer the opportunity to study c-Myc effects 
exerted on pol III transcription in the absence of possible mutations tha t commonly 
occur during the immortalization process. Early passage human primary fibroblasts 
referred to as WI38 were chosen for these experiments. The extracted RNA from 
cells previously prepared by Carla Grandori from Bob Eisenman’s group were used 
for RT-PCR. Early passage WI38 were infected with a retroviral vector expressing 
the Myc-ER fusion protein or with empty vector, then selected with puromycin 
and grown to confluence with no further passages. Once confluent, the cells were 
quiesced by leaving in the same medium for 7 to 8 days after plating [192]. It has 
been previously reported tha t under these conditions the levels of endogenous c-myc 
RNA are very low [341]. Once quiesced, OHT was added to the cells and total RNA 
was extracted at different time points.
cDNA was prepared from total RNA and used as template for RT-PCR. An 
intron-specific primer was employed to study levels of tRN A precursors, which are 
processed very rapidly and so provide an assay of ongoing transcriptional activity 
[12]. Pol III activity was induced by Myc-ER in these cells (Fig. 5.5, upper panel). 
Precursor tRNA^®^ levels increase '^7-fold in quiescent cells infected with Myc- 
ER relative to vector-infected controls; a further increase occurs within three hours 
of adding OHT, whereas OHT has no effect on cells carrying empty vector (Fig. 
5.5, upper panel). Similar results were obtained with tRNA^7^ (data not shown). 
Activation of tRN A genes reached 12-fold in the presence of Myc-ER and OHT, while 
the established Myc target, cyclin D2, had a response of only ^3.6  fold induction in 
these conditions (Fig. 5.5, middle panel). The effects observed by Myc-ER and OHT 
are specific, since ARPP PO mRNA is unchanged (Fig. 5.6, bottom panel). Further
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evidence of specificity came from the m utant AMyc-ER, which lacks a region within 
the TAD, from aa 106 to 143, tha t includes MBII. AMyc-ER failed to activate both 
tRN A and cyclin D2 transcription upon addition of OHT. Therefore, activation of 
pol III transcription is induced by Myc-ER and this upregulation requires the TAD 
of c-Myc. It can also be observed tha t pol III transcription can be activated in the 
absence of growth factors by the sole presence of c-Myc.
5.2.4 Activation o f  Pol III Transcription by c-Myc and 
Induction of  Pol III Machinery
Several plausible mechanisms might explain the c-Myc responsiveness of pol Ill- 
transcribed genes. The first one considered was if c-Myc might be inducing genes 
tha t encode proteins from the pol III transcriptional machinery. It has been reported 
tha t in R a ti cells c-Myc upregulates the BN51 gene, which encodes a subunit of pol 
III [287]. c-Myc activates transcription from the BN51 gene via E-boxes present 
in its first intron. RT-PCR analysis from cDNAs prepared from total RNA of 
human primary fibroblasts containing Myc-ER before and after addition of OHT 
was performed using primers designed for the BN51 mRNA. As shown in figure 5.6, 
no induction of BN51 by c-Myc was found in the primary human fibroblasts.
Another pol Hl-specific factor th a t has been shown to be overexpressed in trans­
formed cells that present high pol III activity is TFIHC2 [12]. Therefore, the same 
analysis as the one mentioned above was performed to study the expresssion levels 
of different mRNAs encoding the subunits of TFIIIC2. Again, no increase was ob­
served in TFIIIC2 subunits TFIIIC a/220 and TFIIIC^g/llO (Fig. 5.6). Therefore, 
c-Myc activation of pol HI transcription does not require induction of these proteins 
from the pol III apparatus.
5.2.5 RB Family Participation in the Pol III Response to  
c-Myc
Activation of c-Myc can provoke hyperphosphorylation of RB [6]. c-Myc induces a 
number of genes tha t are involved in this process at different levels, to ensure RB 
phosphorylation. It induces the expression of cyclin D1 and cyclin D2 genes, tha t 
form complexes with ckd4 and cdk2 [323,335,336]. These complexes are responsible 
for phosphorylating RB. Cyclin D1 and D2 are also responsible for sequestrating the 
cyclin dependent kinase inhibitors p2J^^^, p 2 7 ^ ‘^P and which bind to cdk4/2
and inhibit their activation (Fig. 5.7) [335,336]. Furthermore, another c-Myc target 
gene encodes the phosphatase cdc25A, which removes inhibitory phosphates from
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Figure 5.5: Pol III transcribed genes respond to c-Myc in vivo in quiesced hu­
man fibroblasts. (A) Representation of c-Myc protein and the mutant 
AMyc-ER, in which residues 106-145 (including MB2) within the TAD 
have been deleted. (B) Gene expression was analysed in WI38 cells 
transduced with empty retroviral vector (Vector) or vector carrying c- 
Myc-ER. Cells were serum-starved for 48 hrs to downregulate endoge­
nous c-Myc expression and then treated with 200 nM tamoxifen (OHT) 
( [192]). RNA was extracted at the indicated times after induction and 
used for cDNA preparation (3^g). RT-PCR analysis of tRNA^^^ (up­
per panel), cyclin D2 (middle panel) and ARPP PO (lower panel) was 
performed.
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Figure 5.6: Activation of pol III transcription by c-Myc does not depend on in­
duction of TFIIIC2 or BN51. WI38 cells were transduced with empty 
retroviral vector (Vector) or vector carrying c-Myc-ER (c-Myc-ER), as 
indicated. Cells were serum starved and then treated with 200 nM OHT. 
RNA was extracted at the indicated times after induction and analysed 
by RT-PCR for expression of TFIHC220, TFHICllO , BN51 and ARPP 
PO.
94
5 Activation o f R N A  Polymerase III Transcription by the Oncoprotein c-Myc
cdk2/4 proteins (Fig. 5.7) [333]. In addition, it has been recently demonstrated 
tha t c-Myc activates transcription from the Id2 gene, whose product binds and 
sequestrates RB, inactivating this tumour suppressor [7,16]. The induction of all 
these proteins ensures tha t RB gets phosphorylated and inactivated. Activation of 
Myc-ER in the quiescent primary human fibroblasts produces hyperphosphorylated 
RB by 8 to 13 hrs after OHT treatm ent, promoting cell-cycle progression [192].
Since RB represses tRN A synthesis in a phosphorylation-dependent manner [3,4], 
it was tested whether the pol Ill-response to c-Myc is RB-dependent. To achieve 
this, immortalized fibroblasts from wild-type or RB knockout mice were transiently 
transfected with a c-Myc expression vector or empty vector, together with the class 
III gene adenovirus VAl and the SV40-CAT vector as reporter. Total RNA was 
extracted and analysed by primer extension. Transfection of c-Myc expression vector 
stimulated pol III transcription of the adenovirus VAl gene in fibroblasts from either 
wild-type or RB knockout cells, whereas the cotransfected SV40-CAT reporter was 
unaffected (Fig. 7.6). Although the RB knockout cells have higher pol III activity, 
the overexpression of c-Myc produced a ^^3 fold increase of VAl in both the wild-type 
and the RB null cells (Fig. 7.6).
The RB-related proteins pl07 and pl30 also repress pol III transcription [184]; 
since c-Myc can bind and neutralise pl07 [301], it was tested whether c-Myc overex­
pression continues to activate VAl in the absence of the entire RB family. The same 
experiment as the one mentioned above was performed in primary fibroblasts from 
wild-type or RB-pl07-pl30 triple knockout mice [349]. A robust and specific VAl 
induction was obtained even in triple knockout fibroblasts lacking all three pocket 
proteins (Fig. 7,8). Taken together, from these findings it can be concluded tha t 
pol III regulation by c-Myc does not require the RB family.
5.2.6 Involvement o f  Pol II Transcription in c-Myc  
Activation of Pol III Transcription
So far, there is a bulk of evidence showing tha t c-Myc can transactivate transcrip­
tion from a vast amount of genes involved in different processes [280,323]. c-Myc 
induction of pol III activity might require the transactivation of class II genes tha t 
have not been investigated yet in our system. Since it would be time-consuming 
to study all the class II genes with a potential role in pol III induction, instead 
the effect of blocking pol II transcription was investigated. From the experiments 
with the human primary fibroblasts it can be observed tha t the tRN A induction 
following activation of Myc-ER parallels tha t of the cyclin D2 gene, which is known
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Figure 5.7: Schematic model of c-Myc inactivation of RB leading to a probable acti­
vation of pol III. c-Myc induces expression of different genes, like cdc25a, 
cyclin D and Id2, which are involved in the process of RB phosphory­
lation. The phosphatase cdc25A removes inhibiting phosphate groups 
from cdk, allowing them to associate with their respective cyclin part­
ners. Induction of cyclin D produces sequestration of cki which block 
cdks from binding to their cyclin partners; as well as increasing cy­
clin D/cdk4,6 complexes. The cyclin/cdk complexes phosphorylate RB, 
which will no longer be able to bind and inactivate TFIIIB, indncing 
pol III transcription. On the other hand, M2 binds and sequestrates 
hypophosphorylated RB, releasing TFIIIB from RB repression.
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Figure 5.8: Activation of pol III transcription by c-Myc does not require neutralisa­
tion of RB. Immortalized fibroblasts from RB null (RB“/~, lanes 3 and 
4) or wild type (RB"^/+, lanes 1 and 2) mice were transiently transfected 
with pVAl (0.5^g), pCAT (0.5/ig) or plasmid (2/ig), encoding wild type 
c-Myc (lanes 2 and 4) or empty vector (lanes 1 and 3). RNA was ex­
tracted after 48 hrs of transfection. VAl {upper panel) and CAT [middle 
panel) RNA levels were assayed by primer extension analysis and quan­
tified using the NIH/Image software. Values shown in the lower panel 
represent the signal for VAl normalized to the levels of CAT expression 
to correct for transfection efficiency.
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Figure 5.9: Activation of pol III transcription by c-Myc does not require neutral­
isation of the pocket proteins. Primary fibroblasts from pl07-pl30-R B  
triple knockout mice (TKO, lanes 3 and 4) or wild type (WT, lanes 1 
and 2) were transiently transfected with pVAl (0.5^g), pCAT (0.5/zg) 
or pMyc (2/ug), encoding wild type c-Myc (lanes 2 and 4) or empty vec­
tor (lanes 1 and 3). RNA was extracted after 48 hrs of transfection. 
VAl {upper panel) and CAT {middle panel) RNA levels were assayed by 
primer extension analysis and quantified using the NlH/Image software. 
Values shown in the lower panel represent the signal for VAl normalized 
to the levels of CAT expression to correct for transfection efficiency.
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Figure 5.10: Activation of pol III transcription by c-Myc does not depend on induc­
tion of pol II transcription. WI38 cells were transduced with retroviral 
vector carrying c-Myc-ER, serum-starved and then treated with 2//g/ml 
A-amanitin, 2.5 hrs before induction with 200 nM OHT. RNA was ex­
tracted at the indicated times after induction (Grandori). The RNA 
was analysed by RT-PCR for tRN A ^yr, tRNA^eu^ R12, cyclin D2 and 
ARPP PO expression.
to be a direct target of c-Myc [323,335,336]. If pol III induction by c-Myc needs the 
action of another c-Myc target, such a quick induction would be unlikely. Indirect 
c-Myc targets generally take more than 9 hr to respond in this system and S phase 
entry takes ~17 hr [323]. Therefore, because of the rapidity of pol III activation, 
it is quite possible tha t c-Myc activates pol III transcription directly. So, if pol III 
transcription is still being induced upon activation of Myc-ER by OHT when pol II 
transcription is inhibited, a direct effect can be inferred.
To inhibit transcription only from pol II, while leaving pol I and HI active, the 
different sensitivities to the drug A-amanitin of the pols were exploited. A-amanitin 
is a bicylic octapeptide derived from the poisonous mushroom Amanita phalloides
99
5 Activation o f R N A Polymerase III  Transcription by the Oncoprotein c~Myc
[9]. Pol II has the highest sensitivity to it, being affected at low concentations; pol 
I, has the lowest, requiring high concentrations to inhibit its function, and pol III 
has intermediate sensitivity [19,56]. A concentration th a t would only inhibit pol
II transcription was chosen to study the requirement for pol II transcription in c- 
Myc activation of pol III. Tamoxifen treatm ent was carried out in the presence of 
2/ig/ml a-am anitin, specifically blocking pol II. Whereas cyclin D2 and Id2 mRNA 
levels decline after a-am anitin treatm ent (Fig. 5.10, lanes 4 and 5), the more stable 
ARPP PO transcript remains steady throughout the experiment (Fig. 5.10). By 
contrast, tRNA^®^ and tRNA^^W were induced robustly even in the presence of 
a-am anitin (Fig. 5.10). This suggests tha t c-Myc regulation of pol III templates 
does not require stimulation of protein-encoding genes and may therefore be direct.
5.2.7 c~Myc Interaction with Pol III Templates
Since no participation of class II c-Myc target genes appears to be required for pol
III activation, the presence of this oncoprotein on pol III templates might be in­
volved in their transactivation. To test if endogenous c-Myc is actually associating 
with class III genes in vivo, chromatin immunoprécipitation was performed on either 
mice fibroblasts (Balb/c 3T3) or rat ovarian epithelial cells (ROSE-neu). Antibodies 
against c-Myc, TBP, Brf, the pol III subunit BN51, TFIIIG220 and heamaglutinin 
(HA) were used to precipitate their respective proteins tha t had been previously 
cross-linked to chromatin. As shown in figure 5.11, the TFIIIB subunits TBP and 
Brf are detected at tRNA^^^ , tRNA^^^^ and 5S rRNA genes in both cycling fi­
broblasts and epithelial cells, but not at the ARPP PO gene or at the p21^^^^ pol II 
promoter. This interaction is specific, since no signal was observed from TAFj48 or 
HA controls. These results demonstrate tha t c-Myc is located at pol HI templates 
in vivo.
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Figure 5.11: c-Myc interacts with pol III templates in vivo. (A) Chromatin im­
munoprécipitation of Balb/c 3T3 cells (2x10^ per immunoprécipitation) 
was performed with 20/d of the respective antibodies (HA, c-Myc 9E10 , 
serum against Brf, serum against TBP, serum against RNA Pol HI sub­
unit BN5I and serum against TFHIC220). Immunoprecipitated DNA 
was quantified by PGR performed on the input (diluted 1:200) and 
bound fractions, using primers against 5S rRNA, tRNA^^^, tRNA^^^\ 
and ARPP PO. (B) The same experiment as the one described above 
was performed on ROSE-neu cells; for these cells, PGR against 5S 
rRNA, tRNA^®^ and p21 were performed.
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5 .3  Discussion
Over the past few years, it has been shown that c-Myc can stimulate cellular growth 
and tha t this effect can be distinguished from its effects on cell proliferation. Several 
lines of evidence support this hypothesis. In mammalian cells, it has been shown 
in quiesced B-cells, and hepatocytes, as well as in cells th a t have lost the ability 
to proliferate like cardiomyocytes, tha t overexpression of c-Myc can produce hy­
pertrophy without inducing cell proliferation [344-346]. Furthermore, a mutation 
in Drosophila melanogaster of c-Myc leads to diminutive flies tha t present a slow 
growth phenotype, while overexpression of c-Myc produces bigger flies without any 
apparent change in cell division [343]. These findings suggest tha t the upregulation 
of c-Myc can increase cell mass in the absence of cell proliferation and might be an 
essential function of this oncoprotein. Since pol III products are required to achieve 
a coordinated increase in cell mass, it was investigated whether c-Myc could induce 
pol III transcription. The results shown in this chapter demonstrate tha t indeed pol 
III transcription is regulated by c-Myc expression.
From the experiments using the c-Myc knockout mice, it can be observed th a t 
in the absence of c-Myc expression pol III transcription is quite diminished com­
pared to the wild-type cells (Fig. 5.2). The diminished pol III activity observed 
in the c-myc null cells can be rescued by the introduction of a c-Myc-ER fusion 
protein upon activation with OHT, which demonstrates tha t the observed reduction 
in pol HI transcription is due to  the loss of c-myc expression. c-Myc-ER has been 
reported to be quite leaky; in fact, c-myc null cells harbouring c-Myc-ER can be 
phenotypically rescued in the absence of hormone, which explains the increased B2 
transcript observed in quiesced cells before addition of OHT (time point 0) (Fig. 
5.4) [322]. In these experiments, introduction of the naturally occurring variant 
c-MycS-ER could not recover pol III transcription. c-MycS is still able to produce 
proliferation and apoptosis of immortalized cells and can still repress some genes 
while giving weak transcriptional activation of certain genes (like ODC) [192,348]. 
It has also been documented tha t it cannot induce S phase progression in quiescent 
primary human fibroblasts or induce transcription of the known c-Myc target gene 
cyclin D2 [192, Grandori pers. communication]. Its expression in c-Myc knock­
out cells can rescue the slow growth phenotype; however, this rescue was observed 
starting from day two, being more clear at day three, while c-Myc-ER rescued the 
slow growth phenotype from day 1, expressing the same growth rate at day two as 
the wild-type cells [192]. The last time point chosen to study the pol HI transcript 
B2 was at 8 hrs after addition of OHT, which is quite early compared to the time
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at which Myc-S-ER starts to rescue the slow growth phenotype. Thus it might be 
interesting to study the effect of this mutant after longer periods of time.
The results presented here also demonstrate that c-Myc induction of pol III activ­
ity is by direct action on pol III transcription rather than by inducing class II genes 
which will then affect pol III transcriptional activity. Several known and unknown 
c-Myc target genes transcribed by pol II could be affecting pol III transcription (like 
BN51 or induction of pocket proteins phosphorylation). However, the fact tha t pol 
III transcription is still responsive to c-Myc expression while pol II transcription 
is inhibited demonstrates tha t c-Myc activates pol HI transcription directly (Figs. 
5.10, 7.6, and 7.8). Furthermore, no induction of BN51 or TFIIIC  subunits expres­
sion could be observed in these experiments (Fig. 5.6). Previously, BN51 has been 
shown to be a c-Myc target gene [287]. In tha t study, they utilised immortalized rat 
cells, while in the experiments presented here, primary human fibroblasts were used. 
In immortalized rat cells, the induction observed for cyclin D2 was ^ 8  fold while 
tha t of BN51 was ^ 2  fold [287]. The primary fibroblasts used here only presented 
an increase of ~3.6 fold in cyclin D2 expression (Fig. 5.5). These findings sug­
gest that primary cells may be less responsive than immortalized cells, which might 
explain the lack of response of the BN5I gene to c-Myc expression. Nevertheless, 
pol HI transcription showed a clear induction upon activation of c-Myc-ER, which 
reflects a direct effect on it. Moreover, it is quite interesting to note tha t c-Myc 
can activate transcription from most class III genes tested; since the expression of 
these genes may be expected to impact strongly on cell growth, the effect exerted 
upon pol HI activity by this oncoprotein might explain the slow growth phenotype 
observed in the c-myc null cells, although other factors like pol I transcription are 
also involved [191]. Furthermore, induction of tRNA levels by Myc-ER exceeds the 
weak transactivation often observed for established c-Myc targets, such as cyclin D2 
(Fig. 5.5). In addition, a direct interaction of endogenous c-Myc could be observed 
at pol III templates in vivo (Fig. 5.11).
In this chapter it has been demonstrated th a t c-Myc induces pol HI activity 
through a direct mechanism, although it has not addressed how this is achieved. 
Thus, it would be interesting to study the mechanism or mechanisms involved in 
this activation. The following chapter will identify the way this regulation is being 
achieved.
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6.1 Introduction
The transcription factor c-Myc is able to activate transcription of different target 
genes, including those transcribed by pol II and III [279, Chapter 5]. It is still not 
well understood how c-Myc exerts its transactivation properties. Two regions of c- 
Myc protein have been shown to be required for the activation of transcription from 
class II target genes, its C-terminal DNA binding/dimerization domain and its N- 
terminal transactivation domain (TAD). The C-terminal DNA binding/dimerization 
bHLH-LZ domain recognizes and binds to E-Box DNA sequences with the core motif 
5’-CACGTG through its basic region, while it heterodimerizes with Max through 
its HLH-LZ region (although the HLH-LZ region has also been shown to make 
contacts with DNA, [308]) [315,316]. c-Myc target genes usually contain E-boxes 
downstream of the promoter regions, in introns, 5’ untranslated, or coding regions. 
However, class III genes, which have been shown to be c-Myc target genes [Chapter 
5], do not contain matches to the E-box DNA sequence; thus c-Myc transactivation 
of these genes must be through protein-protein interactions in the absence of a DNA 
recognition site.
6.1.1 Myc Binding Partners other than Max
Different proteins, in addition to Max, have been identified to interact with c-Myc, 
mainly with the TAD, although there are some that interact with the C-terminal 
domain. The C-terminal domain has been shown to interact with the transcrip­
tion factors YingYang-1 (YYl), AP-2, TFII-I, the breast cancer susceptibility gene 
(BRCAl), and Miz-1 [350]. In the case of Y Y l and TFII-I, c-Myc binding modulates
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their activity by sequestering them or preventing their interaction with other factors 
like TBP [351]. It is interesting to note tha t c-Myc interacts with the factor tha t 
is responsible for transactivating ribosomal protein genes, YYl; however, until now, 
c-Myc’s binding to this transcription factor appears to repress rather than activate 
transcription from these genes, although the biological relevance has to be stud­
ied further. This result strikes as surprising, since there are several studies showing 
th a t c-Myc transactivates ribosomal protein genes rather than inhibiting them [346]; 
therefore, the YYl-c-Myc binding should be analysed in detail to understand what is 
the physiological significance of this association. These findings suggest tha t the C- 
terminal domain might also be involved in the regulation of transcription, although 
the main regulator of this activity in c-Myc is the TAD, If would be interesting to 
study whether the activation of pol III transcription by c-Myc is through an inter­
action between a protein from the pol III machinery and the C-terminal domain of 
c-Myc.
The N-terminal TAD has been shown to interact with different proteins involved 
in various processes, like cell cycle regulation, histone acétylation and apoptosis; it 
is responsible for both activation and repression of transcription. As mentioned pre­
viously, the cell cycle regulator pl07 when it is hypophosphorylated binds to c-Myc 
through the TAD [301]. This interaction inhibits c-Myc transactivation properties. 
It has been shown that it might have this effect by inhibiting cell cycle phosphory­
lation of MBI in vitro. However, pl07 does not appear to be required for c-Myc’s 
regulation of pol HI transcription, since in its absence c-Myc can still induce tran­
scription of class HI genes [Chapter 5].
Another protein tha t has been observed to interact with c-Myc’s TAD is TR- 
RAP (TRansformation/tRanscription-domain-Associated Protein) [352]. TRRAP 
is a protein of >400 kD (3830 aa’s) with homology to the PI3K/ATM  family, lack­
ing the kinase function [352]. It works as a transcriptional cofactor, mediating the 
recruitment of histone acetyltransferase (HAT) complexes like CCN5/PCAF and 
Tip60/NuA4 to sequence-specific activators, like c-Myc [353]. It binds to c-Myc’s 
MBH, which is essential for c-Myc oncogenic transformation. In fact, mutations in 
MBH which disrupt TRRAP interaction render c-Myc unable to transform cells, 
thus c-Myc recruitment of TRRAP might be critical for its oncogenic activity, al­
though the interaction with some other molecules is also MBH-dependent. Histone 
acétylation has been shown to activate gene expression, therefore TRRAP binding to 
c-Myc might mediate HAT recruitment to c-Myc target genes with their consequent 
induction. Recently, it has been demonstrated that indeed activation of cyclin D2
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gene expression by c-Myc is dependent on TRRAP recruitment and histone acéty­
lation at the cyclin D2 promoter [318]. Since c-Myc can bind to class III genes and 
induce their transcription, it would be interesting to study whether the recruitment 
of TRRAP is necessary for this induction. However, this would not show how c-Myc 
is recognizing and binding to class III genes, which it remains to be determined.
An interesting candidate for c-Myc recruitment to class III genes is TBP. TBP 
binds to the c-Myc N-terminal TAD [354]. This interaction appears to require the 
full TAD, since shorter fragments of it cannot bind to TBP [355]. Furthermore, 
complex formation between TBP and c-Myc’s TAD produces a change in protein 
conformation in the TAD, with the induction of a more structured transactivation 
domain conformation. This rearrangement in structure is common for transacti­
vation domains which remain unstructured until they interact with specific target 
factors, and suggests the physiological importance of the c-Myc-TBP interaction. 
Since TBP is a component of TFHIB [82], it is very probable tha t it is involved in 
c-Myc’s recruitment to class HI genes.
This chapter will address which protein or proteins are participating in the re­
cruitment of c-Myc to class III genes. It will also investigate which regions of this 
transcription factor are required for the interaction with the pol HI transcriptional 
machinery.
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Figure 6.1: Immunodepletion of c-Myc reduces pol III activity. Transcription of 
the VAl gene was assayed using HeLa nuclear extracts undepleted (lane 
1), mock depleted (lane 2) or previously immunodepleted for 2 hours on 
ice with antibodies raised against TFIIB (C-18, lane 3), TBP (mTBP-6, 
lane 4), or c-Myc (9E10, lanes 5 and 6).
6 . 2  R e s u l t s
6.2.1 c-Myc Is Required for Pol III Transcription i n  v i t r o
Although a direct interaction between c-Myc and class III genes was demonstrated 
(Chapter 5, 5.11), from this evidence it cannot be concluded whether this interac­
tion is functionally significant. To test if the presence of this oncoprotein at the 
genes transcribed by pol III is required to induce its transcriptional activity, HeLa 
nuclear extracts were depleted with an anti-Myc antibody and then tested for in 
vitro transcription (IVT) using the adenovirus VAl gene as template. As positive 
control, the nuclear extracts were depleted of TBP, since this protein is essential for 
pol HI transcription, while for the negative control the pol H-specific factor TFIIB 
was chosen. If c-Myc is having an effect on the pol HI machinery, its depletion 
should affect pol HI activity. As expected, extracts depleted of TBP show a dra­
matic reduction in VAl transcription (Fig. 6.1, lane 4), while mock-depletion or 
immunodepletion of TFIIB have little effect (Fig. 6.1, lanes 2 and 3, respectively). 
When the extracts are depleted of c-Myc with an anti-Myc antibody, they display 
reduced VAl transcription (Fig. 6.1, lanes 5 and 6), although to a lesser extent 
than that observed for TBP. These results suggest the stable binding of endogenous 
c-Myc to a component of the pol HI transcriptional apparatus.
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6 . 2 . 2  c-Myc Binds to and Depletes a Factor Required for 
Pol III Transcription
Having established that the depletion of endogenous c-Myc affects pol HI transcrip­
tion, it was investigated whether a pol HI factor is codepleted. Since c-Myc cannot 
bind to a specific DNA sequence in class HI genes, its recruitment to these genes 
must be through a protein-protein interaction with one or more factors from the 
pol HI apparatus. So, when c-Myc is being depleted from the extract, its pol HI 
binding partner may also be removed and therefore pol HI transcription is reduced. 
Another possibility is tha t c-Myc depletion itself is affecting pol HI transcription. 
To assess if c-Myc depletion is actually removing a factor or factors from the ex­
tract, an experiment was designed to see whether recombinant c-Myc could catch 
this factor and remove it from the extract, without changing the endogenous c-Myc 
concentration. Whole cell extracts from CHO cells were preincubated with beads 
carrying GST, or GST fused to residues 1-262 of c-Myc encompassing the TAD 
(GST-Myc-N262), or GST fused to the C-terminal 92 residues of c-Myc containing 
the bHLH-LZ domain (GST-Myc-C92) (a recombinant c-Myc protein containing 
the full length c-Myc could not be used due to the fact tha t no one in the field 
has been able to produce it). After preincubation, the extracts were used in an IVT 
assay using different class III genes as templates, including tRNA^®^, tRNA^^S^ 5S 
rRNA, VAl and 7SL (Fig. 6.2). All the class HI genes tested exhibit reduced tran­
scription from whole cell extracts preincubated with GST-Myc-N262 (Fig. 6.2, lane 
3), compared to those preincubated with GST alone (Fig. 6.2, lane 1) or with the 
recombinant protein containing the C-terminal domain of c-Myc (GST-Myc-C92) 
(Fig. 6.2, lane 2). The slightly reduced activity observed for the extracts preincu­
bated with GST and GST-C92-Myc compared to the activity of the input material 
is probably due to the loss of activity usually obtained during the incubation period, 
which the input is not exposed to, and not to a specific reduction produced by GST 
or GST-C92-Myc. These results show that whole cell extracts preincubated with 
recombinant protein containing the N-terminal domain of c-Myc (G8T-Myc-N262) 
exhibit reduced pol HI activity. From this evidence it can be concluded tha t the 
extract preincubated with GST-Myc-N262 is depleted of a factor or factors required 
for pol HI transcription.
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Figure 6.2: Depletion with the N-terminal domain of c-Myc reduces pol III tran­
scription. Transcription of the tRNA^®^, tRNA^^S, 5S rRNA and 7SL 
RNA genes were assayed in whole cell extracts from CHO cells previously 
depleted for 2 hrs on ice of proteins binding to GST (lane 1), GST-Myc- 
C92 (lane 2) or GST-Myc-N262 (lane 3). Lane 4 is transcription assayed 
using the same whole cell extract which had not undergone the 2 hrs 
depletion period.
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6.2.3 T B P  Does  Not Reconstitute Pol III Transcription from 
c-Myc Immunodepleted Extracts
The experiments presented so far have shown that a factor or factors from the pol III 
machinery might be associating with c-Myc, specifically with its N-terminal region. 
However, it is still unclear which factor or factors might be involved in this protein- 
protein interaction. The most plausible candidate is TBP, which is known to bind 
the TAD of c-Myc [354,355]. As mentioned before, TBP is a subunit of TFHIB and 
is essential for transcription of all class HI genes [81,82]. Since transcription from 
class III genes containing both type I and type II promoters has been shown to be 
reduced by the preincubation of extracts with the N-terminal domain of c-Myc, it 
is quite probable tha t the protein being depleted is involved in the transcription of 
class HI genes with those types of promoters. Therefore, TBP is a good candidate for 
c-Myc’s interaction. To examine this possibility, increasing amounts of recombinant 
TBP were added to HeLa nuclear extracts previously depleted with an anti-c-Myc 
antibody and these reactions were used to transcribe the adenovirus VAl gene as 
template. Again, extracts depleted with an anti-TBP antibody served as positive 
control and an anti-TFHB antibody was used as negative control. Addition of 
recombinant TBP to TBP-immunodepleted extracts slightly reconstituted pol HI 
transcription (a complete reconstitution would require addition of Brf) from a VAl 
template (Fig. 6.3, lane 6) . However, recombinant TBP did not show any pol HI 
activity recovery from c-Myc-immunodepleted extracts. This was not due to the 
fact tha t a higher concentration of recombinant TBP was required, since addition of 
increased concentrations of it only produced a reduction in pol HI activity (Fig. 6.3, 
lane 10). This effect is known as squelching, where an excess of TBP competes for 
proteins involved in the transcriptional process, and depletes them from the reaction, 
leaving reduced pol HI activity. From these experiments it can be concluded that 
in the TBP-immunodepleted extract, TBP becomes the limiting factor, thus its 
addition gives some reconstitution. However, in the c-Myc-immunodepleted extract, 
addition of TBP did not recover pol HI transcription, thus something else (probably 
Brf) is limiting in this extract. In conclusion, the data presented so far suggest that 
other factor or factors are also being removed from the extract by depletion with 
anti-c-Myc antibody or with the preincubation of the N-terminal domain of c-Myc.
6.2 .4  c-Myc Does Not Associate with TFIIIC or Pol III
To study which factors, other than TBP, are actually interacting with c-Myc, pull­
down experiments were performed using whole cell extracts prepared from CHO
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Figure 6.3: Recombinant TBP does not reconstitute pol III transcription from c- 
Myc immunodepleted extracts. Transcription of the VAl gene was as­
sayed in HeLa nuclear extracts undepleted (lane 1), mock depleted (lanes 
2 and 3) or previously immunodepleted with antibodies raised against 
TFIIB (C18, lane 4), TBP (mTBP-6, lanes 5 and 6), or c-Myc (9E10, 
lanes 7 to 10). Immunodepleted extracts were complemented with re­
combinant TBP at a final concentration of 1 pg (lanes 6 and 8) or 1.5 
/ig (lane 9) or 2 pg (lane 10).
cells incubated with beads carrying equal amounts of recombinant GST, GST-Max 
or GST-Myc-N262. After incubation, bound proteins were eluted and analysed by 
western blotting using different antibodies. The first TF investigated was TFIIIC, 
which is required for transcription of class HI genes containing type I and 11 promot­
ers. Antisera raised against the subunits TFIHCo; and TFHIC/3 were used for these 
experiments. Immunoblotting of the eluted material with the antisera against these 
two subunits reveals that there is no interaction between either of these TFIIIC sub­
units and the recombinant proteins (Fig. 6.4 and data not shown). These results 
suggest that c-Myc does not associate with TFIIIC and therefore is not directly 
involved in c-Myc’s recruitment to class HI genes.
The next factor investigated was pol III itself. In this case, an antiserum against 
the pol HI subunit BN51 was utilized. As shown in Fig. 6.5, BN51 appears to 
be retained by the beads carrying CST-Myc-N262 (lane 4), while CST alone or 
CST-Max do not (lanes 2 and 3, respectively). This result is in accordance with the 
reduced pol HI activity observed for the extracts preincubated with CST-Myc-N262. 
Since the concentrations used in the pull-down assays of the CST fusion proteins 
do not correspond to the endogenous c-Myc protein levels, the result obtained with
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Figure 6.4: TFIIIC  does not inimunoprecipitate with the N-terminal domain of c- 
Myc. Proteins from CHO whole cell extracts (250 /ig) tha t remained 
bound to beads carrying 50 /ig of CST (lane 2), CST-Max (lane 3), 
or CST-Myc-N262 (lane 4) after extensive washing were resolved on 
an SDS-7.8% polyacrylamide gel and then analysed by Western im­
munoblotting with an antiserum Ab2 raised against TFIIICo;. Lane 
1 is 10% of input material.
this experiment might not represent an association between these two proteins at 
physiological ratios. To test whether endogenous c-Myc can associate with pol HI, 
coimmunoprecipitation experiments were performed using HeLa nuclear extracts. 
Although the pull-down experiments show that there is an interaction between pol 
HI and the N-terminal domain of c-Myc, this interaction could not be observed 
when material immunoprecipitated with monoclonal antibody against c-Myc was 
blotted against BN51. In the same manner, an antiserum against BN5I did not 
coprecipitate c-Myc (data not shown). These results suggest tha t endogenous c- 
Myc does not associate with pol HI at physiological ratios and that it is not the 
factor tha t is being depleted by c-Myc antibody.
6.2.5 c-Myc Associates with TFIIIB
Due to the lack of interaction between c-Myc and TFIIIC or pol III, c-Myc interac­
tion with TFHIB was investigated. As mentioned in the introduction, TFHIB is the 
most probable target for c-Myc binding since it contains TBP, which has been shown 
to bind c-Myc through its TAD [354,355]. Again, pull-down assays were performed 
and the eluted samples were analysed by western blotting. All three TFHIB sub­
units were tested for interaction with the CST fusion proteins. In the case of Bdpl, 
instead of using a CST-Myc-C92 fusion protein as negative control, a CST-Max fu­
sion protein was tested; equal amounts of CST or CST-fusion proteins were used for 
each reaction. As expected, immunoblotting revealed that TBP is retained by beads
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Figure 6.5: Pol III not immunoprecipitate with c-Myc. (A) Proteins from CHO 
whole cell extracts (150 pg) tha t remained bound to beads carrying 50 
pg  of CST (lane 2), CST-Max (lane 3), or CST-Myc-N262 (lane 4) after 
extensive washing were resolved on an SDS-7.8% polyacrylamide gel and 
then analysed by Western immunoblotting with an antiserum 113 raised 
against BN51. Lane 1 is 10% of input material. (B) HeLa nuclear extract 
(187.5 pg) was immunoprecipitated using an anti-c-Myc antibody (9E10, 
lane 2) or an anti-Cyclin A antibody (BF683, lane 3). Immunoprecipi­
tated material was resolved on an SDS-7.8% polyacrylamide gel and then 
analyzed by Western immunoblotting with antiserum 113 against BN51 
subunit of Pol HI. Lane 1 is 10% of input material.
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Figure 6.6: The N-terminal domain of c-Myc binds to the TFIIIB subunits TBP 
and Brf. Proteins from CHO whole cell extracts (150 pg) that remained 
bound to beads carrying 50 pg of CST (lane 2), CST-Myc-C92 (lane 
3), or CST-Myc-N262 (lane 4) after extensive washing were resolved 
on an SDS-7.8% polyacrylamide gel and then analysed by Western im­
munoblotting with antiserum 128-4 raised against Brf (top panel), with 
an anti-TBP antibody 58C9 from Santa Cruz (middle panel) or with an 
anti-Max antibody (lower panel). Lane 1 is 10% of input material.
carrying the CST-Myc-N262 fusion protein (Fig. 6.6, middle panel). In addition, 
both Brf and Bdpl also interact with the same N-terminal c-Myc fragment (Fig 6.6, 
upper panel and data not shown). The binding observed is specific, since neither 
of the subunits associate with CST alone or with the CST-Myc-C92 fragment. The 
lack of association between the TFHIB subunits and the C-terminal fragment of 
c-Myc is not due to a reduced concentration or inactivity of this recombinant pro­
tein, since a clear interaction between this fragment and the protein Max, which is 
well documented [315,316], can be observed at the same concentration used for the 
pull-down assays with TFIIIB. The association between TFHIB and the N-terminal 
domain of c-Myc is consistent with the fact that only this fusion protein was able 
to reduce pol HI activity in the IVT assays presented before.
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To test whether the association between TFIIIB and c-Myc observed in the 
pull-down assays still happens at physiological ratios with endogenous c-Myc, coim­
munoprecipitation assays were carried out. As positive control, an anti-RB antibody 
was used, as the R B/TFIIIB  interaction is well documented [4,179,182], whereas 
antibodies against E7 and cyclin D1 served as negative controls. Like that of the 
positive control RB, immunoprécipitations with monoclonal antibody against c-Myc 
were found to coprecipitate the Brf subunit of TFIIIB (Fig, 6.7A). This interaction 
is specific, since no coprecipitated Brf could be found in the immunoprecipitated 
material with antibodies against E7 and cyclin D1 (Fig. 6.7A). Furthermore, coim­
munoprecipitation assays also showed an interaction between the TFIIIB subunit 
TBP and c-Myc (Fig. 6.7B), which was expected as it has been previously de­
scribed [354]. Again, coimmunoprecipitation with RB served as a positive control 
for TBP, since the interaction between these two proteins is documented [179], while 
an anti-cyclin A antibody provided the negative control. From these experiments, 
it can be concluded tha t TFIIIB binds specifically to c-Myc, and this interaction 
appears to be through the TAD.
6.2.6 TFIIIB Reconstitutes Pol III Transcription from 
GST-M yc-N262 Depleted Extracts
As shown before, whole cell extracts preincubated with GST-Myc-N262 are depleted 
of a factor required for pol III transcription (Fig. 6.2). Although c-Myc binds to 
TBP and removes it from the extract, the addition of recombinant TBP alone does 
not reconstitute transcription of class III genes (Fig. 6.3); thus other factors are 
being removed by c-Myc’s depletion. From the results obtained so far, it can be 
concluded tha t c-Myc can associate with two TFIIIB subunits (Brf and TBP, Fig. 
6.6). Therefore, a similar experiment as the one using recombinant TBP was de­
signed, but this time it was assayed if addition of a fraction containing TFIIIB 
could restore pol III transcription of CHO whole cell extracts th a t had been pre­
viously preincubated with beads carrying GST or GST-Myc-N262. These extracts 
were used in transcription assays with tRNA^®^ as template. IVT reactions were 
supplemented either with a fraction containing pol HI, which served as a negative 
control, or a fraction containing TFIIIB (the fractions used were previously prepared 
by chromatography from HeLa nuclear extract). Figure 6.8 shows tha t addition of a 
fraction containing TFHIB can fully restore tRNA^®^ expression, whereas addition 
of a fraction containing pol III does not. From the results presented so far, it can be 
concluded tha t TFHIB binds specifically to the TAD of c-Myc and tha t this binding
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Figure 6.7: c-Myc interacts with the TFIIIB subunits Brf and TBP at physiological 
ratios. (A) HeLa nuclear extract (187.5 /ig) was immunoprecipitated us­
ing an anti-RB monoclonal antibody (G3-245, lane 2) as positive control 
or anti-E7 (TVG7 lOY, lane 3) and anti-Cyclin D1 (R124, lane 4) as 
negative control. Lane 5 was using an anti-c-Myc antibody (9E10). Im­
munoprecipitated material was resolved on an SDS-7.8% polyacrylamide 
gel and then analyzed by Western immunoblotting with antiserum 128-4 
against Brf and lane 1 is 10% of input material. (B) HeLa nuclear extract 
(187.5 /ig) was immunoprecipitated using an anti-RB monoclonal anti­
body (G3-245, lane 2) as positive control or an anti-Cyclin A antibody 
(BF683, lane 3) as negative control. Lane 4 was using an anti-c-Myc an­
tibody (9E10 ). Immunoprecipitated material was resolved on an SDS- 
7.8% polyacrylamide gel and then analyzed by Western immunoblotting 
with antibody 58C9 against TBP and lane 1 is 10% of input material.
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Figure 6.8: Reconstitution of pol III transcription using a PC-B fraction from GST- 
Myc-N262 depleted extract. Transcription of the tRNA^®^ gene was 
assayed in CHO whole cell extract previously incubated with beads car­
rying GST (lanes 1 to 3) or GST-Myc-N262 (lanes 4 to 9). Lanes 5 and 
6 were supplemented with 2 p\ and 4 /rl of a pol HI fraction, respec­
tively. Lanes 7 and 8 were supplemented with 2 p\ and 4 /il of a TFIIIB 
fraction. Lane 10 shows transcription from whole cell extract tha t had 
not undergone any manipulation.
is functionally significant. Furthermore, this interaction is consistent with the fact 
that induction of tRNA genes in vivo requires the TAD of c-Myc (Chapter 5).
6.2.7 Endogenous c-Myc Cofractionates with TFIIIB
The results shown above indicate tha t there is a physical and functional interac­
tion between c-Myc and TFHIB. A different way of demonstrating this association 
between endogenous c-Myc and TFHIB is by testing for the presence of c-Myc in bio­
chemically fractionated TFHIB. The different components of the pol III machinery 
(TFHIA, TFHIB and TFIIIC) can be separated from each other by chromatographic 
fractionation on phosphocellulose (PC) of nuclear extracts. Since the fractions from 
a PC column very crude, the fractionated material can be further purified using 
different types of chromatographic resins and gradients to achieve a cleaner sample. 
The presence of c-Myc was assayed by immunoblotting different TFHIB fractions 
purified through different types of resins, and probing them with an anti-c-Myc an­
tibody. Consistent copurification of TFIIIB and c-Myc would be suggestive of a 
stable interaction between these two factors.
Figure 6.9 demonstrates that c-Myc is readily detectable in TFIIIB fractions
117
6 c-M yc’s Association with the RN A Polymerase III Transcription Machinery
75 K-
1 2 3 4 5 6 7
Figure 6.9: A population of c-Myc molecules co-fractionates with TFIIIB. c-Myc is 
readily detectable in fractions containing TFIIIB and TFIID but not 
in fractions containing pol III or TFIIIC. Fractionated factors (10 /d) 
as indicated were analyzed by Western immunoblotting with anti-c-Myc 
antibody 9E10. The TFIID fraction in lane 2 was prepared by chro­
matography (Phosphocellulose followed by S-Sepharose). The TFIIIC 
fraction in lane 3 was oligo-purihed (Phosphocellulose followed by a B- 
block DNA-affinity column). The TFIIIB fraction in lane 4 was prepared 
by chromatography on Q-Sepharose followed by phosphocellulose. The 
TFIIIB fractions in lanes 5 and 6 were prepared by step fractionation 
on phosphocellulose followed by a MonoQ gradient. The pol III fraction 
in lane 7 was prepared by step fractionation on phosphocellulose and 
DEAE-Sephadex.
tha t have been purified through different resins like PC and Q-Sepharose (lane 4) or 
MonoQ (lanes 5 and 6). In contrast, no c-Myc was detected in fractions containing 
TFIIIC  (lane 3) or pol III (lane 7). As expected, a TFIID fraction also presented 
c-Myc (lane 2), although at lower levels than those observed for TFIIIB fractions 
because this TFIID fraction is very dilute.
Although the experiment presented above demonstrates tha t endogenous c-Myc 
copurihes with TFIIIB, it does not show whether c-Myc is interacting with ac­
tive TFIIIB. To study if this is happening, a PC fraction containing TFIIIB was 
chromatographed on Mono Q and gradient eluted fractions were obtained. These 
fractions were then immunoblotted for the presence of c-Myc using an antibody 
against it (Fig. 6.10, upper panel), as well as assayed for TFIIIB transcriptional ac­
tivity using VAl as template in the presence of TFIIIC and pol III (Fig. 6.10, lower 
panel). It can be observed from figure 6.10 that both c-Myc and TFIIIB activity 
are detected in the same fractions (41, 42, 43 or lanes 6 to 8), peaking at fraction 
42. Thus, c-Myc cofractionates closely with TFIIIB activity.
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Figure 6.10: c-Myc co-fractionates with TFIIIB activity during gradient chromatog­
raphy on MonoQ. The upper panel shows c-Myc content using 10 pi of 
the indicated fractions which were resolved on an SDS-7.8% polyacry­
lamide gel and analyzed by Western immunoblotting with anti-c-Myc 
antibody 9E10. The lower panel shows TFIIIB activity of individual 
fractions. In each case lane 1 contains input material (PC-B), lane 
2 contains flow-through, and lanes 3-11 contain fractions 38-46, re­
spectively. TFIIIB activity was assayed using 4 pi of the indicated 
fraction, 2pl of PC-C and 500 ng of pVAI; after 15 min incubation at 
30°C, nucleotides were added to assay transcription (this experiment 
was performed by Robert White).
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These data demonstrate tha t a population of c-Myc molecules copurihes with 
TFIIIB  on PC, Mono-Q and Q-Sepharose columns. Such copurification supports 
the data found by coimmunoprecipitation experiments indicating there is a specific 
stable interaction between endogenous c-Myc and TFIIIB.
6.2.8 Brf Interacts Directly with c-Myc in the Absence of  
T B P
Once it was established tha t c-Myc associates stably with TFIIIB, the interaction 
between the Brf subunit and c-Myc was analysed further. Although the pull-down 
and coimmunoprecipitation assays show tha t the TFIIIB subunit Brf associates with 
c-Myc, from these experiments it cannot be determined whether this association is 
through interaction of c-Myc with TBP, which is well documented, or whether it is 
a direct interaction between Brf and c-Myc. To test if this interaction is direct, pull­
down assays were performed using in vitro translated Brf instead of nuclear extract. 
Again, equal amounts of GST or GST-Myc-N262 were used. An interaction between 
recombinant Brf and the recombinant N-terminal domain of c-Myc was detected 
while beads carrying GST alone could not retain recombinant Brf (Fig. 6.11, lanes 
3 and 5, or 2 and 4, respectively). From this experiment, it can be concluded tha t 
Brf, like TBP, interacts with the TAD of c-Myc and this interaction does not require 
the participation of TBP.
6.2.9 T B P  Interacts with Max
As mentioned before, c-Myc forms heterodimers with the bHLH-LZ protein Max 
to induce activation of transcription from class II genes. c-Myc transcriptional 
activation from genes transcribed by pol II requires its heterodimerization with 
Max. In these genes, the Myc-Max heterodimer recognizes and binds specifically 
to a DNA sequence referred to as an E-box; however, c-Myc recruitment to class 
HI genes is not by DNA recognition, but through protein-protein interactions with 
the pol Hl-specific transcription factor TFIIIB. Therefore, it was investigated if the 
c-Myc binding partner Max can also associate with the subunits of this transcription 
factor. First, pull-down assays were performed with beads carrying equal amounts 
of recombinant GST, as a negative control, or with the recombinant fusion proteins 
GST-Max. The recombinant fusion protein GST-Myc-N262 was used as a positive 
control. As shown in figure 6.12, no interaction can be observed between Brf and 
the negative control (GST) or with GST-Max, although an interaction between Brf 
and GST-Myc-N262 is quite clear (Fig. 6.12A, upper panel, lane 4). On the other
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Figure 6.11: Brf binds to immobilized c-Myc. Reticulocyte lysate (5 pi) containing 
in vitro-translated Brf was added to beads carrying 50 pg of GST (lanes 
2 and 4) or GST-Myc-N262 (lanes 3 and 5) and incubated at 4 C with 
agitation. Proteins retained after extensive washing were resolved on a 
SDS-7.8% polyacrylamide gel and then visualized by autoradiography. 
Lane 1 show 10% of the input reticulocyte lysate containing in vitro- 
translated Brf.
hand, immunoblotting of the eluted material from beads carrying GST-Max appears 
to contain TBP (Fig. 6.12, lower panel, lane 3), suggesting an interaction between 
TBP and Max. Again, an interaction between the N-terminal domain of c-Myc and 
TBP was obtained, while no TBP is retained by beads carrying GST.
To analyse further the interaction between Max and TBP, it was investigated 
whether these proteins still associate at endogenous ratios. To achieve this, coim­
munoprecipitation analysis was performed with an anti-Max antibody. An anti-E7 
antibody was used as a negative control, although an interaction between TBP and 
E7 has been reported |356|. As positive control, an anti-RB antibody was used 
since its association with TBP through TFIIIB is well documented |179|. Western 
blot analysis of the immunoprecipitated material was performed using an antibody 
against TBP. A faint band which might correspond to TBP (albeit with slightly 
lower molecular weight) was be detected by immunoprécipitation with an anti-E7 
antibody (Fig. 6.12, lane 4). On the other hand, an interaction between TBP 
and Max, like tha t of the positive control RB, can be observed. These findings 
demonstrate that an association between TBP and Max is specific, and happens at 
physiological ratios.
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Figure 6.12: TBP binds to the c-Myc binding partner Max. (A) Proteins from CHO 
whole cell extracts (150 /ig) tha t remained bound to beads carrying 50 
/ig of GST (lane 2), GST-Max (lane 3), or GST-Myc-N262 (lane 4) 
after extensive washing were resolved on an SDS-7.8% polyacrylamide 
gel and then analysed by Western immunoblotting with anti-TBP an­
tibody. Lane 1 is 10% of input material. (B) HeLa nuclear extract 
(187.5 /ig) was immunoprecipitated using anti-RB antibody G3-245 as 
a positive control (lane 2), anti-Max antibody H-2 (lane 3) or anti-E7 
antibody TVG7 lOY (lane 4). Immunoprecipitated material was re­
solved on an SDS-7.8% polyacrylamide gel and then analyzed by West­
ern immunoblotting with anti-TBP antibody 58C9. Lane I is 10% of 
input material.
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6.3  Discussion
It has been previously demonstrated tha t c-Myc can activate directly pol III tran­
scription, without the induction of proteins involved in this process or the inhibition 
of the RB family (Chapter 5). Furthermore, c-Myc is localised at different class III 
genes in vivo. This chapter has addressed the molecular mechanisms of this locali­
sation, which might give an insight on how c-Myc is regulating pol III transcription. 
Although it has been shown th a t c-Myc is present at class III genes, in this chapter 
it was tested how this localisation is achieved. As demonstrated on figure 6.1, de­
pletion of this oncoprotein affects pol III activity; thus c-Myc is interacting stably 
with one or more components of the pol III machinery.
Once it was established tha t c-Myc localisation at class III genes is physiologically 
important, the mechanisms involved in this process were investigated. The first 
obvious possibility for c-Myc localisation is through the recognition of a specific DNA 
sequence present in class III genes. However, these genes do not contain the E-box 
sequence tha t c-Myc recognizes and binds to. Therefore, protein-protein interactions 
between the pol HI machinery and c-Myc were investigated. In the literature it has 
been shown tha t the TAD of c-Myc binds to TBP; thus, this protein seemed to 
be the most likely molecule to be involved in c-Myc recruitment. Although an 
interaction between c-Myc and TBP was detected, TBP addition to c-Myc depleted 
extracts did not restore pol HI transcription. These findings suggested tha t another 
protein or proteins are also involved in c-Myc’s binding to class HI genes. TFHIB 
contains TBP, therefore it is the most plausible factor to associate with c-Myc. 
Indeed, a stable association between TFHIB and c-Myc was demonstrated using 
several independent lines of evidence, (i) Pull-down experiments demonstrate an 
association between the Brf and TBP subunits of TFHIB and the recombinant N- 
terminal domain of c-Myc. (ii) Addition of TFHIB reconstitutes pol HI transcription 
from depleted extracts with recombinant c-Myc. (iii) The TFIIIB subunits TBP 
and Brf coimmunoprecipitate with endogenous c-Myc; this effect is specific, since 
these subunits are not seen with negative control antibodies, (iv) A population of 
endogenous c-Myc copurihes with TFHIB during a variety of distinct fractionation 
procedures; this is a specific association since no c-Myc could be detected in fractions 
containing TFIIIC or pol HI. From these chromatographic experiments, it cannot be 
excluded tha t c-Myc and TFHIB copurification is fortuitous; however, this seems to 
be unlikely given the coimmunoprecipitation data. Thus, these experiments suggest 
tha t a proportion of endogenous TFHIB exists in association with c-Myc.
In contrast, no interaction between c-Myc and TFIIIC  could be detected. In
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the case of pol III, the first experiments performed with recombinant c-Myc sug­
gested tha t there was an interaction between this oncoprotein and the pol III spe­
cific subunit BN51. However, the concentration of the recombinant c-Myc used in 
these experiments does not represent the physiological levels of the protein. When 
this interaction was investigated further, at the normal physiological ratios of both 
proteins, no association could be detected. Furthermore, addition of pol HI to a 
depleted extract with recombinant c-Myc (GST-Myc-N262) did not reconstitute pol 
HI transcription. In addition, no endogenous c-Myc could be found in fractions 
containing pol HI. From this evidence it can be concluded th a t there is probably 
no interaction between endogenous c-Myc and pol III. Another TF that is required 
for pol III transcription is TFHIA. As mentioned in the introduction of this thesis, 
TFHIA is only required for transcription of class III genes containing type I pro­
moters, like tha t of 5S rRNA. Since c-Myc immunodepletion or depletion with its 
N-terminal domain not only reduced the transcription of 58 rRNA genes, but also 
tha t of tRNA genes, which contain type II promoters and do not require TFHIA, 
the participation of this TF in the recruitment of c-Myc was not investigated.
The interaction observed between c-Myc and the TFHIB subunits, Brf and TBP, 
appears to be through the TAD of c-Myc, Although these subunits are detected in 
association with c-Myc, this interaction might be regulated by TBP-c-Myc bind­
ing. Further analysis should be performed to study whether c-Myc can bind to B”. 
For this to be achieved, interaction studies have to be performed with purified and 
separated subunits of TFHIB and recombinant c-Myc in the absence of other pro­
teins tha t could mediate their interaction. So far, the experiments presented here 
demonstrate tha t c-Myc associates stably and specifically with the TFHIB subunits 
TBP and Brf. The interaction of these two proteins with c-Myc appears to be with 
the TAD of c-Myc; however, further analysis should be performed to study in detail 
the association of Brf and c-Myc. It is also interesting to note tha t the region of 
c-Myc to which TFHIB binds, the TAD, is required for the induction of tRNA genes 
in vivo. Thus, this association is likely to be physiologically im portant for c-Myc 
induction of pol III transcription.
An interesting finding obtained in the experiments presented here is the inter­
action observed between c-Myc’s binding partner Max and the transcription factor 
TBP (Fig. 6.12). TBP is involved in transcription by all three pols. The fact tha t 
Max can associate with it might suggest tha t Max and its binding partners (the 
Myc and Mad families) are involved in the regulation of genes transcribed by all 
three pols. It is already known tha t c-Myc-Max regulate a wide number of genes
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transcribed by pol II; and from the results presented in this thesis, c-Myc can also 
regulate transcription by pol III. However, the relevance of Max association with 
TBP and the induction of pol HI transcription by c-Myc has still to be determined. 
In the case of pol I transcription, it will be interesting to study if c-Myc-Max het­
erodimers activate it through a protein-protein interaction of Max and TBP. Indirect 
experiments suggest th a t c-Myc might be involved in the regulation of pol I tran­
scription, since expression of ribosomal RNA genes appears to be reduced in c-Myc 
null cells [191]. Furthermore, N-Myc, another Max binding partner, has been shown 
to induce transcription of ribosomal genes in neuroblastomas [357]. Therefore, it 
will be interesting to study the interaction between Max and TBP, and its possible 
participation in the regulation of transcription by all three RNA polymerases.
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7.1  Introduction
The Id family (inhibitors of DNA binding/differentiation) of helix-loop-helix (HLH) 
proteins were discovered 10 years ago, as proteins tha t inhibit both DNA binding and 
differentiation [358]. They are members of a larger family of transcription factors, 
referred to as the HLH family which comprises >200 members. The HLH transcrip­
tion factors form heterodimers with each other through the HLH domain, composed 
of two amphipathic a  helices, each 15-20 residues long, separated by a shorter in­
tervening loop [19]. Adjacent to the HLH domain, a region of highly basic residues 
is present. The presence of both basic regions from the heterodimer is required 
for DNA binding to the canonical E Box recognition sequence CANNTG [19,359]. 
The bHLH proteins are involved in tissue specific cell differentiation, e.g. myo- 
genin in skeletal muscle differentiation, neurogenin in neurogenesis, and SCL/tal-1 
in hematopoiesis [360]. To exert their action, these tissue-specific bHLH proteins 
require to heterodimerize with ubiquitously expressed bHLH proteins, which include 
E2-2, and the E2A gene products, E12 and E47, among others. The heterodimers 
containing two basic regions of each bHLH protein can then bind to DNA and ac­
tivate expression of genes involved in differentiation. The Id proteins can also bind 
to the ubiquitously expressed bHLH proteins, however, because they lack the basic 
region, the heterodimers tha t are formed are unable to bind to DNA. The Id proteins 
quench the ubiquitously expressed bHLH proteins, so tha t they can no longer form 
dimers with tissue-specific bHLH proteins and differentiation is blocked. Thus, the 
Id proteins act as negative regulators of bHLH proteins and hence of differentiation 
(Fig. 7.1) [358,359,361].
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7.1.1 Cellular functions of Id Proteins
In mammals, the Id family is composed of four members, Id l to Id4, which apart 
from the HLH domain, are highly sequence divergent [358]. These proteins play an 
essential role during development in processes like neurogenesis and lymphopoiesis, 
as well as organogenesis; they present functional redundancy, so if one gene is miss­
ing, the other three can overcome this lost [359]. As mentioned before, the Id 
proteins inhibit cell differentiation by binding and sequestering bHLH TPs which 
drive the expression of genes involved in this process [358]. In agreement with this 
model, Id expression in terminally differentiated cells is low or absent (except for 
Id2 expression in myelopoiesis, which is upregulated in differentiated cells) [359]. 
Since differentiation and cell growth are mutually exclusive, these proteins actually 
act as positive regulators of cell growth and induce cells to continue proliferating, 
a property which confers on them a wider role in biological processes like cell cycle 
progression and tumour development. Thus, as it might be expected, expression of 
Id genes is high not only in undifferentiated cells but also in tumour cells [16].
7.1.2 Role of  the Id Family in Tumourigenesis
The overexpression of Id genes has been shown to present oncogenic properties in 
both primary and immortalized cells. When overexpressed in primary fibroblasts 
with another oncoprotein like Bel-2, they produce immortalization of the cells [359]. 
Deregulation of Id expression has been observed in different types of primary tu ­
mours, including overexpression of Id2 in pancreatic cancer [362]; overexpression of 
Id l, 2 and 3 in astrocytic tumours [363], and colorectal adenocarcinomas [364]; and 
overexpression of Id l in breast cancer [364]. In fact, breast mammary tumours tha t 
express high levels of Id l are frequently associated with infiltrating, more aggressive 
tumours, which suggest a relationship between Id expression and disease progres­
sion [359]. Moreover, Id function is required for vascularization and invasiveness 
of tumour growth in vivo [364]. Studies using transgenic mice overexpressing Id 
genes have also demonstrated their participation in oncogenesis. Transgenic mice 
tha t overexpress Id2 protein in thymocytes not only present a block in early thy- 
mopoiesis, but also an aggressive T  cell hyperproliferation tha t resembles lymphoma, 
suggesting tha t Id2 overexpression predisposes T cells to oncogenic transformation 
in vivo [365].
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Figure 7.1: Id proteins as dominant-negative antagonists of basic helix-loop-helix 
(bHLH) transcriptional regulators. (A) bHLH proteins typically bind 
consensus E-box regulatory sequences in a heterodimeric configuration 
and function to activate differentiation-linked gene expression. (B) In the 
presence of excess Id protein, the class A bHLH partner is sequestrated 
from the heterodimeric complex, resulting in an Id-bHLH heterodimer 
that is unable to bind DNA, resulting in inhibition of differentiation. 
This is typically found in proliferating cells. (Taken from (361)).
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7.1.3 Functions of  Id in Growth Control
A role for Id proteins in cell cycle reentry and induction of cell growth has been 
observed in mammalian cells using antisense oligonucleotides against the Id mR- 
NAs [366]. From these experiments, it was demonstrated tha t Id genes are early 
responsive genes whose expression is strongly dependent on the presence of growth 
factors. These proteins participate in growth induction following growth factor 
stimulation of quiescent cells, since if their expression is inhibited by specific Id an­
tisense oligonucleotides, there is a significant delay in DNA synthesis after addition 
of growth factors, with a specific reduction of the Id mRNA levels [366]. Serum 
withdrawal (from 20% to 0.5%) in mice fibroblasts reduces Id expression to 50% in 
<1 h and declines to undetectable levels in quiescent cells [361,366]. After serum 
addition, their expression recovers rapidly and peaks at 30 min, followed by a second 
peak as cells enter the S phase [361,366]. If these proteins are expressed ectopically, 
they promote cell growth and therefore inhibit differentiation. Furthermore, indi­
rect evidence of Id regulation of cell growth comes from the observation tha t these 
proteins are highly expressed in rapid proliferating cells, like those from early devel­
opment, while most mature differentiated tissues do not express them [367]. More 
evidence to show the contribution of Id expression to cell growth has come from 
experiments performed with smooth muscle cells. M atsumara et. al have demon­
strated tha t overexpression of Id2 promotes cell growth of vascular smooth muscle 
cells via increased 8-phase entry [368]. In this model, Id2 inhibits the expression 
of the cyclin kinase inhibitor p21, and this regulation depends on phosphorylation 
of H 2 by cyclin E/cdk2 [368]. All the evidence presented so far demonstrates that 
these proteins are im portant positive regulators of cell growth and proliferation.
7.1.4 The Id Proteins and the RB Family
The mechanisms by which the Id proteins regulate cell cycle reentry and cell growth 
appear to be not only by binding to and antagonising other bHLH protein’s function, 
but also by regulating proteins of the cell-cycle control machinery. In particular, the 
Id2 protein has been shown to bind the RB tumour suppressor protein and the 
related proteins pl07 and pl30 [7,8,16]. As mentioned in the introduction of this 
thesis, the tumour suppressor protein RB, regulates the cell cycle by binding and 
inhibiting TFs which drive expression of genes required for G l/S  phase progression, 
like E2F-DP1. This inhibition can only be achieved by unphosphorylated RB, since 
i t ’s phosphorylated form cannot bind to the TFs and therefore cannot inhibit their 
function anymore. It is interesting to note tha t Id2 binds to the pocket proteins
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in their unphosphorylated active form, through its HLH domain, inactivating their 
growth inhibitory function. Id2 has been shown to reverse the RB-mediated cell 
cycle arrest when coexpressed with RB in the human osteosarcoma cell line SAOS-2 
which lacks RB [7]. Furthermore, it can also relieve the cell cycle arrest induced by 
the cyclin kinase inhibitors p l6  and p21, in cells containing functional RB (U20S) by 
inactivating RB [8]. A role for Id l, which might also be used by the other members 
of the Id family, in cell cycle progression has also been described. Id l can inhibit 
the expression of the cyclin kinase inhibitor by binding and inhibiting
the bHLH TF E2A which drives its expression [369]. A decrease of p21 causes the 
activation of cyclin E/cdk2 which inactivates RB by phosphorylating it and allowing 
the expression of genes required for G l/S  progression.
The data summarized in this introduction illustrate tha t the Id proteins are 
positive regulators of both cell cycle progression and cell growth, while being negative 
regulators of differentiation. The genes transcribed by pol HI are known to be 
essential for cell growth [10]; moreover, their expression gets downregulated during 
differentiation [149]. Since Id expression and pol HI activity appear to happen in 
the same conditions, it would be interesting to investigate whether expression of 
Id proteins might have an effect on pol III activity. This chapter addresses this 
hypothesis; although only the effect of Id2 on pol HI activity was studied.
Transcription by pol HI is tightly regulated by RB and the pocket proteins (pl07 
and pl30) [3,182,184]. Similar to RB repression of E2F, the active unphosphorylated 
form of RB binds to the specific pol HI factor TFHIB, sequestering it from class 
HI genes, hence repressing pol HI transcription [182]. Since Id2 has been shown to 
bind and inhibit the RB family and block their repressive action exerted on TFs like 
E2F/D P1, it might also participate in the activation of pol HI by relieving TFHIB 
from RB repression. From this reasoning, it would be interesting to study whether 
Id2 can actually regulate pol HI activity. The following experiments presented in 
the results section were designed to assess if indeed this is the case. Due to the fact 
tha t the other members of the Id family have not been shown to interact directly 
with the RB family, their participation in the regulation of pol HI transcription was 
not investigated. In the future, it would also be interesting to investigate a role for 
Id l in the regulation of pol HI transcription, since it has been shown that it can also 
regulate RB activity through indirect mechanisms [369]. However, in this chapter 
only the relationship between pol HI transcription and M2 expression is going to be 
investigated.
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7.2  Results
7.2.1 Id2 Competes with Brf for RB Binding
As mentioned in the introduction, Id2 can form heterodimers with RB, sequestering 
this tumour suppressor from heterodimers formed with transcription factors and 
therefore, allowing them to activate expression of their target genes and thus cell 
proliferation [7,8]. One of the transcription factors which RB binds and represses is 
the specific pol III factor TFIIIB [3,179,182]. Since activation of pol III transcription 
is also required for appropiate cell growth (and hence cell proliferation), it might be 
upregulated by Id2 through sequestration of RB from TFIIIB /R B  complexes, allow­
ing TFIIIB recruitment to class III genes and hence their expression. To determine 
if Id2 can actually sequester RB from TFIIIB /R B  complexes, immunoprécipitation 
analysis was performed. Endogenous RB from HeLa nuclear extracts was immuno- 
precipitated using an anti-RB antibody (C-15) in the presence of in vitro translated 
Id2, or in vitro translated Brf, subunit of TFIIIB, or both. As a control for the 
disruption of the TFIIIB /R B  complex upon addition of protein, rabbit reticulocyte 
lysate was utilized. As previously shown by other authors, RB immunoprecipitates 
in vitro translated Id2, as well as in vitro translated Brf (Fig. 7.2, lanes 1 and 2, 
respectively). However, when both proteins are added at the same concentration 
to the immunoprécipitation assay, the interaction between RB and Brf diminishes, 
while the interaction between Id2 and RB remains equal to the one seen when no 
Brf is present (Fig. 7.2, lane 3). The reduction observed in the interaction between 
RB and Brf in the presence of Id2 is specific, since addition of rabbit reticulocyte 
lysate did not have any effect on the binding of these two proteins (Fig. 7.2, lane 
4). This result suggests tha t Id2 has more avidity for RB than the TFHIB subunit 
Brf, and thus is able to sequester RB from TFIIIB /R B  complexes. If indeed this is 
happening in vivo, Id2 might be able to activate pol HI transcription by sequester­
ing RB and thus releasing TFHIB from RB repression. To assess this, the following 
experiments were designed.
7.2.2 Pol III Transcription in Id2 Knockout Cells
Having established tha t Id2 can successfully compete with TFHIB for RB, it was 
investigated whether Id2 expression has any effect on pol HI transcription. To assess 
this, transcription of the pol HI transcribed gene B2 was assayed in wild type or 
Id2 null mouse embryo fibroblasts. Total RNA extracted from wild type and Id2 
knockout cells was analysed by Northern blot. When Jd2 null cells and matched
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Figure 7.2: In vitro translated Id2 binds more avidly to RB than the TFIIIB subunit 
Brf, HeLa nuclear extract (187.5 /ig) was immunoprecipitated using an 
anti-RB antibody (C-15) in the presence of in vitro translated Id2 (lane 
1), in vitro translated Brf (lane 2), both (lane 3), or in vitro translated 
Brf plus rabbit reticulocyte lysate (lane 4). Immunoprecipitated material 
was resolved on an SDS-7.8% polyacrylamide gel and then visualized by 
autoradiography.
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Figure 7.3: Id2 expression affects pol III activity in vivo. Total RNA (10 //g) ex­
tracted from wild-type (Id2+/+) or Id2-null fibroblasts (Id 2 -/-) was anal­
ysed by Northern blot using a DNA probe against the pol III transcript 
B2 (upper panel) and ARPP PO (lower panel).
wild-type fibroblasts are compared, the former show lower expression of pol III 
transcripts from the B2 repetitive gene family (Fig. 7.3, upper panel). Levels 
of B2 RNA provide a convenient and reliable indication of pol III transcription 
activity, since these transcripts are rapidly degraded after being transcribed [10|, 
thus reflecting pol III transcriptional activity at the time of extraction of RNA and 
not build up products. mRNA encoding acidic ribosomal phosphoprotein (ARPP) 
PO was used as loading control, and although there is a slight decrease of ARPP PO 
mRNA in the Id2 knockout cells compared to the wild type, the decrease observed 
for the B2 transcript is considerably more striking (Fig. 7.3). From the results 
obtained here, it can be concluded that pol III activity is indeed sensitive to the 
presence of endogenous Id2 in vivo.
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7.2.3 Id2 Is Required for Pol III Transcription i n  v i t r o
To analyse further if the presence of endogenous Id2 stimulates pol III transcription, 
in vitro transcription of the pol III template VAX from immunodepleted extracts 
was performed. HeLa nuclear extracts were incubated for 2 hours, prior to the 
in vitro transcription, with different antibodies, including an anti-Id2 antibody, to 
deplete them of the particular protein th a t the antibody would recognise. As positive 
control, the nuclear extract was depleted of TBP, since this protein is essential 
for pol HI transcription, while for the negative control the pol H-specific factor 
TFHB was chosen. Depletion of the bHLH protein E47 was also used as a negative 
control, since it shares the same HLH motif as Id2 and has not been shown to 
produce any effect on pol HI transcription so far. If Id2 is having an effect on 
pol HI transcription, as observed for the B2 transcript in the Id2 knockout mouse 
embryo fibroblasts compared to wild type, its depletion should affect its activity. As 
previously demonstrated (Chapter 6), extracts depleted of TBP show a dramatic 
reduction in VAl transcription (Fig. 7.4, lane 3). In contrast, mock-depletion 
or immunodepletion of TFHB have little effect on pol HI transcription (Fig. 7.4, 
lanes 2 and 4, respectively). When the extracts are depleted of Id2 with an anti- 
Id2 antibody, they display reduced VAl transcription (Fig. 7.4, lane 5), although 
to a lesser extent than tha t observed for TBP. However, depletion of the bHLH 
transcription factor E47 does not have any effect in VAl transcription, proving tha t 
the reduction in pol III activity obtained from the Id2-depleted extracts is specific 
(Fig. 7.4, lane 6). The evidence presented so far demonstrates tha t endogenous Id2 
has a positive effect on pol HI activity.
7.2.4 Overexpression of  Id2 Activates Pol III Transcription
Id2 has been shown to be overexpressed in different types of cancers, e. g. neurob­
lastomas, pancreatic carcinomas and astrocytic tumours [16,362,363]. Moreover, 
it has been shown to transform primary cells when overexpressed, acting as a co­
operating oncogene [359], and to predispose T cells to oncogenic transformation in 
vivo [365]. Pol HI transcription is upregulated in different types of cancer, as well 
as in transformed cell lines [10]. Transformed cells grow faster than normal cells. 
In rapid growing cells, pol HI transcripts, including tRNAs and 58 rRNA, must be 
produced in bulk to meet the need for protein synthesis. Since Id2 overexpression 
has been shown to induce cell growth, as well as being highly expressed in rapidly 
proliferating cells [367], it would be interesting to study if it can also upregulate 
pol HI activity. To achieve this, mouse fibroblasts (Balb/c 3T3) were transiently
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Figure 7.4: Immunodepletion of Id2 reduces pol III activity. Transcription of the 
VAl gene was assayed using HeLa nuclear extracts undepleted (lane 1), 
or previously immunodepleted for 2 hours on ice with antibodies raised 
against TBP (MTBP-6, lane 3), TFHB (C-18, lane 4), Id2 (C-20, lane 
5), or E47 (N-649, lane 6) or mock depleted (lane 2).
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Figure 7.5: Activation of pol III transcription by Id2 overexpression. Balb/c 3T3 
cells were transiently transfected with pVAl (0.5 /xg), pCAT (0.5 //g) 
and pld2 (2 pg), encoding wild-type Id2 (lanes 2) or empty vector (lane 
I). RNA was extracted after 48 hrs of transfection. VAl (upper panel) 
and CAT (lower panel) RNA levels were assayed by primer extension 
analysis.
transfected with empty vector or an Id2 expression vector, together with the class 
III gene, adenovirus VAl, and the SV40-CAT vector as control. Total RNA was 
extracted and analysed by primer extension. As seen in figure 7.5, transfection of 
Id2 expression vector stimulated pol III transcription of the adenovirus VAl gene in 
fibroblasts, compared to empty vector. This effect is specific, since the transcription 
of the cotransfected SV40-CAT reporter remained the same in both conditions (Fig. 
7.5, lower panel). This result demonstrates that overexpression of Id2 induces pol 
III transcription.
7.2.5 Id2 Overexpression and Pol III Transcription in RB 
Knockout Cells
RB represses pol III transcription in a phosphorylation-dependent manner. Id2 can 
bind to the hypophosphorylated form of RB. In figure 7.2, it was clearly shown that 
Id2 has greater avidity for RB than the TFIIIB subunit Brf in an in vitro system. 
However, from this evidence it cannot be concluded whether the sequestration of 
RB is the mechanism that Id2 is using to activate pol HI transcription. To assess
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if this is the case, immortalized fibroblasts from wild-type or RB knockout mice 
were subjected to the same transient transfection as the one performed above. As 
expected, transient transfection with an Id2 expression vector stimulated pol III 
transcription of the adenovirus VAl gene in the wild-type fibroblasts, compared to 
empty vector (Fig. 7.6, upper panel, lanes 2 and 1, respectively). If sequestration of 
unphosphorylated RB is the sole mechanim by which Id2 is inducing pol III activity, 
then no upregulation of VAl would be expected from transfection of this protein 
into RB knockout cells. However, when Id2 was transfected in RB null fibroblasts, a 
robust and specific induction was still obtained (Fig. 7.6, upper panel, lane 4). This 
is a specific effect on VAl expression, since the cotransfected SV40-CAT reporter 
was unaffected (Fig. 7.6, lower panel). The induction of VAl transcription observed 
in the RB+/+fibroblasts is stronger than th a t observed in the R B "/" fibroblasts. 
This implies a participation of RB in the Id2 activation of pol HI transcription, 
since when RB is not present, the induction observed is smaller than tha t obtained 
when it is. However, if the sequestration of RB from TFIIIB /R B  complexes were 
the sole mechanism by which Id2 activates pol HI transcription, there would not 
have been any stimulation of the VAl transcript in the R B "/" cells. Therefore, 
from these results it can be concluded tha t the sequestration of RB does not appear 
to be the sole mechanism by which Id2 triggers pol HI activity.
7.2.6 Pol III Activity in Id2/RB Knockout Cells
From the results obtained from transfection into RB knockout cells, it appears tha t 
Id2 is stimulating pol HI activity not only through the sequestration of hypophospho­
rylated RB, but also through a different unknown mechanism. In this experiment, 
Id2 is overexpressed under artificial conditions and might not reflect an accurate 
physiological role. To analyse further whether Id2 is using a secondary mechanism 
to upregulate pol HI activity in addition to relieving TFHIB from RB inhibition, 
pol HI transcription of the B2 repetitive gene family was studied in mouse em­
bryo fibroblasts carrying variable Id2/RB genotypic backgrounds (Id 2 "/" /R B "/" , 
Id2+/+/RB+/+, Id2'*‘/" /R B " /“ , Id2 '^/+/R B "/"). Northern blot analysis of total 
RNA extracted from the four types of mouse embryo fibroblasts was performed. 
If Id2 is activating pol HI transcription only through RB inhibition, then the 
Id 2 " /" /R B "/" , Id2+/"^/RB~/"should present the same levels of the B2 transcript. 
As shown n Fig. 7.7, this does not appear to be the case. The Id 2 " /" /R B "/"  
presents lower B2 RNA levels than the Id2’*'/‘^ /R B "/"  (Fig. 7.7, lanes 1 and 2, 
respectively). Furthermore, when there is only one Id2 gene present in an RB null
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Figure 7.6: Activation of pol III transcription by Id2 does not require neutralisation 
of RB. Immortalized fibroblasts from RB null (R B "/", lanes 3 and 4) 
or wild-type (RB+/^, lanes 1 and 2) were transiently transfected with 
pVAl (0.5 / i g ) ,  pCAT (0.5 pg) and pld2 (2 / i g ) ,  encoding wild-type Id2 
(lanes 2 and 4) or empty vector (lanes 1 and 3). RNA was extracted 
after 48 hrs of transfection. VAl (upper panel) and CAT (lower panel) 
RNA levels were assayed by primer extension analysis.
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context, the B2 RNA levels are higher than those of the Id2/RB knockout cells. 
When both Id2 genes are present in an RB knockout background, the highest ex­
pression of the B2 transcripts is observed (Fig. 7.7, lane 4), which confirms th a t Id2 
upregulation of pol III activity is RB-independent. The mRNA encoding ARPP PO 
was used as a loading control, since it is known not to be modulated by mitogens 
or serum growth factors, cell cycle or the RB pathway [287]. These findings are in 
agreement with the data obtained from the transfections, as well as for the M 2/RB 
wild type compared to M 2/RB knockout mice. Taken together, they indicate th a t 
the positive effect of Id2 on pol III transcription is through both RB-dependent and 
RB-independent mechanisms.
7.2.7 Id2 Overexpression and Pol III Transcription in 
R B / p l 0 7 / p l 3 0  Knockout Cells
In the literature, it is well documented that Id2 not only binds to RB but also to 
the two RB-related proteins, pl07 and pl30 [8,16]. As with RB, Id2 binds only 
to the hypophosphorylated active forms of pl07 and pl30 [16]. As mentioned in 
the introduction of this thesis, pol III transcription is also tightly regulated by 
the hypophosphorylated forms of these proteins and, like RB, they bind to TFIIIB 
and repress its function, hence downregulating pol III activity [184]. Since Id2 
induction of pol III activity appears to be partially RB-independent, and this HLH 
protein can bind and sequester the pocket proteins which are able to repress pol 
HI transcription, it was tested whether Id2 overexpression continues to activate the 
pol HI transcript VAl in the absence of the entire RB family. To achieve this, the 
same transient transfection experiment as the one described before was performed 
in primary fibroblasts from wild-type or RB-pl07-pl30 triple knockout mice (TKO). 
After the transfection, total RNA was extracted and analysed by primer extension. 
As expected, transfection of Id2 expression vector stimulated pol HI transcription 
of the adenovirus VAl gene in the primary fibroblasts, whereas the cotransfected 
SV40-CAT reporter remained unaffected. In the TKO cells, overexpression of Id2 
still produced a specific induction of the VAl transcript compared to empty vector. 
This effect is specific since the SV40-CAT reporter stayed constant. Although the 
TKO cells present higher pol HI activity, the overexpression of Id2 produced a 
similar increase in both the wild-type and the TKO cells (^1.5 fold increase in the 
wild-type compared to ~1.25 increase in the TKO cells). From these findings it can 
be concluded tha t Id2 can stimulate pol HI transcription in the absence of the entire 
RB family.
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Figure 7.7: Pol III activity in different Id2/RB genotypic backgrounds. Total RNA 
(10 //,g) extracted from Id2/RB null fibroblasts (Id2"/“ /R B “/" , lane 1), 
wild-type fibroblasts (Id2+/+/RB+/+, lane 2), heterozygous Id2/RB null 
fibroblasts (Id2+ /-/R B -/~ , lane 3), or wild-type Id2/RB null fibroblasts 
(Id2+/+/RB“ /“ , lane 4) was analysed by Northern blot using a DNA 
probe against the pol III transcript B2 {upper panel) and ARPP PO 
{lower panel).
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Figure 7.8: Activation of pol III transcription by Ici2 does not require neutralisation 
of pocket proteins. Primary fibroblasts from pl07-pl30-RB triple knock­
out cells (TKO, lanes 3 and 4) or wild-type (WT, lanes 1 and 2) were 
transiently transfected with pVAl (0.5 /ig), pCAT (0.5 /ig) and pld2 (8 
/ig), encoding wild-type Id2 (lanes 2 and 4) or empty vector (lanes 1 and 
3). RNA was extracted after 48 hrs of transfection. VAl (upper panel) 
and CAT (lower panel) RNA levels were assayed by primer extension 
analysis.
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7.2.8 Id2 Localizes at Pol III Genes i n  v i v o
The experiments presented so far have shown that Id2 induces pol III transcription. 
Although this upregulation seems to be in part by relieving TFIIIB from RB re­
pression (Fig. 6.7 and 7.6), another novel mechanism must be also involved, since 
Id2 overexpression can still induce pol III function when the entire RB family is 
absent. A possible scenario might be tha t Id2 is actually interacting with the pol 
III apparatus associated with class III genes, and its presence on pol III templates 
might contribute to their transactivation. To test if endogenous Id2 is actually able 
to associate with genes transcribed by pol III in vivo, chromatin immunoprécipita­
tion was performed in mouse fibroblasts (Balb/c 3T3), since overexpression of Id2 
in these cells stimulated pol III activity (Fig. 7.5). Antibodies against Id2, the T FI­
IIB subunit TBP, the pol III subunit BN51 and the negative control TAFj48 were 
used to precipitate their respective proteins that had been previously cross-linked 
to chromatin. As expected, TBP and the pol III subunit BN51 are detected at 
tRNA^^y’-, tRNA^®^, and 5S rRNA genes, whereas the pol I-specific transcription 
factor TAFj48 is not (Fig. 7.9). It is interesting tha t endogenous Id2 was found to 
localise at the three pol III templates tested (Fig. 7.9, lane 6). This interaction is 
specific and not due to over cross-linking of proteins to DNA, since no signal was 
observed from either beads alone or TAFj48. These results demonstrate tha t Id2 
can associate with class III genes in vivo.
7.2.9 Endogenous Id2 Co-fractionates with TFIIIB Activity
From the chromatin immunoprécipitation assay, it can be concluded tha t Id2 is lo­
cated at pol III templates in vivo. The finding tha t Id2 can be found associated 
with class III DNA is quite novel, since it does not contain a DNA binding domain; 
in fact, the Id proteins are not considered to be associated with DNA, but rather act 
as negative regulators of DNA binding by sequestering other transcription factors 
from it [358]. Thus, the association observed of M2 with class III genes must be 
regulated through protein-protein interactions with one or more factors from the pol 
III apparatus. Since TFIIIB  has been shown to be a transcription factor tha t can 
associate with a broad range of regulatory proteins, including the RB family, c-Myc, 
p53, among others, it was investigated whether endogenous M2 could co-fractionate 
with it. A way of investigating if there is an association between endogenous M2 
and TFIIIB is by testing for the presence of M2 in biochemical fractions contain­
ing TFIIIB activity. The fractions containing TFIIIB activity were prepared by 
chromatography. First, the constituents of the pol III apparatus are separated by
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Figure 7.9: Id2 interacts with pol III templates in vivo. Chromatin immunoprécipi­
tation of Balb/c 3T3 cells (2x10^ per immunoprécipitation) with 20 p\ of 
the respective antibodies (M-19 against TAFj48, mTBP-6 against TBP, 
serum against the pol III subunit BN51 and C-20 against Id2). The 
immunoprecipitated DNA was quantified by PCR performed on the in­
put (diluted 1:200) and bound fractions, using primers against tRNA^^^ 
{dipper panel), tRNA^®^^ [middle panel) and 5S rRNA [lower panel).
143
7 Activation o f R N A  Polymerase III Transcription by M2
chromatographic fractionation of HeLa nuclear extracts (on phosphocellulose (PC)). 
Having a PC fraction containing TFIIIB, a second chromatogrophy on Mono Q is 
performed and gradient eluted fractions are obtained. These fractions were analysed 
by western blot for the presence of Id2 (Fig. 7.10, upper panel), as well as assayed 
for TFIIIB transcriptional activity using VAl as template in the presence of TFIIIC  
and pol III (Fig. 7.10, lower panel). As shown in figure 7.10, endogenous Id2 is 
detected in the fractions tha t present the highest TFIIIB activity (fractions 41 and 
42).
Further confirmation of the association between endogenous Id2 and TFHIB 
came from the detection of Id2 in TFIIIB fractions tha t had been purified through 
different chromatographic conditions (like chromatography on Q-Sepharose followed 
by PC, data not shown). Taken together, these data indicate tha t a population 
of Id2 molecules copurifies with TFIIIB. However, more experiments to study the 
interaction between Id2 and TFIIIB should be performed to confirm that a specific 
physical and functional interaction between these proteins is occurring. In addition, 
it would be interesting to test whether TFIIIC or pol III can also associate with M2.
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Figure 7.10: Id2 cofractionates with TFIIIB activity during gradient chromatogra­
phy on Mono-Q. The upper panel shows Id2 content using 10 /i\ of the 
indicated fractions which were resolved on an SDS-7.8% polyacrylamide 
gel and analyzed by Western immunoblotting with anti-Id2 antibody 
C-20. The lower panel shows TFIIIB activity of individual fractions. In 
each case lane 1 contains input material (PC-B), lane 2 contains flow­
through, and lanes 3-11 contain fractions 38-46, respectively. TFIIIB 
activity was assayed using 4 p\ of the indicated fraction, 2 p\ of PC-C 
and 500 ng of pVAl; after 15 min incubation at 30°C, nucleotides were 
added to assay transcription (the in vitro transcription was performed 
by Robert White).
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7.3  Discussion
The genes transcribed by pol III are essential for protein synthesis, which is usually 
upregulated when cells are cycling and growing at fast rates. Furthermore, it has 
been reported tha t down-regulation of pol III transcripts, like tha t of B2 gene, can 
cause a direct reduction in growth rate of up to 80% [224]. Therefore, the rate of pol 
III transcription is an im portant determinant of cell growth. Cells overexpressing 
Id2 have a faster growth rate than normal controls, with a larger proportion of 
the population in the S phase of the cell cycle [7,365]. This suggests tha t Id2 
overexpression confers an enhanced growth potential to the cells and hence has a 
positive function in growth regulation. Since pol III transcripts are essential to 
achieve a steady rate of cell growth, it is quite plausible tha t positive regulators of 
this process would be activating pol III transcription. The data presented in this 
chapter indicate tha t transcription by pol III is upregulated by the expression of the 
HLH protein Id2, thus providing another mechanism by which Id2 enchances cell 
growth.
One of the mechanisms by which Id2 has been shown to promote cell growth and 
cell cycle progression is by neutralizing the inhibitory effects of the tumour suppres­
sor protein RB and its related proteins pl07 and pl30 [7,8,16]. The RB family (or 
pocket proteins) regulate the cell cycle by fluctuating from an active hypophospho­
rylated form at the beginning of G l phase, which represses transcription of genes 
required for G l/S  transition by all three RNA pols [3,179,370], to an inactive hy~ 
perphosphorylated form at late G l and the rest of the cycle [262]. In particular, 
the pocket proteins down-regulate pol III transcription by binding to TFIIIB and 
sequestering it from pol III templates [182,184]. Since Id2 binds to the active under- 
phosphorylated forms of the pocket proteins, one possible mechanism of activation 
of pol III transcription would be by releasing TFIIIB from the inhibitory actions of 
the RB family. Coimmunoprecipitations with in vitro translated proteins showed 
tha t Id2 can compete effectively avidity for RB with TFIIIB, and can actually dis­
rupt the interaction between RB and the TFIIIB subunit Brf (Fig. 7.2). When Id2 
was overexpressed in vivo in wild-type cells, pol III transcription was clearly upreg­
ulated. It is interesting tha t when Id2 was overexpressed in vivo in RB knockout or 
in triple knockout cells (RB-pl07-pl30), it could still induce pol III transcription, 
suggesting tha t a different mechanism is also involved. In the RB knockout cells, 
the activation of pol III transcription is lower than tha t in the wild-type cells, im­
plying that RB neutralization does play a role in Id2 induction of pol III activity. 
However, the results demonstrate tha t the activation of pol HI by Id2 is through a
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pocket proteins-independent mechanism as well.
Due to the fact tha t Id2 can stimulate pol III transcription even in the absence 
of the RB family, it was investigated whether this protein could be interacting 
directly with pol III templates and the pol III apparatus to induce class III genes. 
The results presented here demonstrate tha t Id2 is localized at different pol III 
templates in vivo and tha t there might be a physical interaction between Id2 and 
the pol Ill-specific factor TFIIIB. The finding tha t Id2 is bound to DNA presents 
an exiting new function for this protein, since there is substantial evidence showing 
tha t the Id proteins function by forming complexes with other transcription factors 
and sequestrating them, with the consequent inhibition of their ability to bind DNA. 
Thus, to find tha t Id2 is present at pol III templates strikes as surprising. There is 
one report showing tha t an Id protein, Id l, can actually stimulate the DNA binding 
of another transcription factor and is present at the DNA-MIDAl complex. In 
this study, Inoue et. al. demonstrated tha t the association of Id l with MIDAl 
(mouse Id associated 1) potentiates the sequence-specific DNA binding activity of 
this transcription factor to a 7-bp sequence, GTCAAGC, present in the 5’ flanking 
region of several growth-factor/cytokine genes [371,372]. MIDAl has been shown 
to be required for growth of erythroleukaemia cells andtherefore is considered to act 
as a positive regulator of cell growth [371].
The fact tha t an Id protein can stimulate the DNA binding properties of another 
transcription factor presents a new insight into how Id might be regulating cell 
growth. Since the products made by pol III are im portant determinants of this 
process, Id2 localisation at pol III templates might be acting by potentiating the 
DNA binding properties of one or more pol Ill-specific factors. Preliminary studies 
presented in this chapter expose a possible interaction between Id2 and the pol 
Ill-specific factor TFIIIB, although this association has to be investigated further. 
TFIIIB has been shown to be regulated by a number of different tumour suppressor 
proteins (like RB and p53, [3,187,188]) as well as oncoproteins (like c-Myc and ERK 
[269,373]). It therefore appears to be a crucial factor involved in the determination 
of the rate of pol III transcription. Thus, it is im portant to confirm tha t there 
is an interaction between Id2 and TFIIIB, and if this association is responsible 
for the upregulation of pol III activity. Furthermore, it would be interesting to 
study whether Id2 can increase TFIIIB DNA binding or if there are other novel 
mechanisms participating. In addition, the interaction between Id2 and other pol 
Ill-specific factors or pol III itself has to be examined.
In conclusion, the results presented here expose a new function for Id2, the
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upregulation of pol III transcription, and might provide a more complete picture 
of how Id proteins regulate cell growth. W hether the other Id proteins can also 
regulate pol III activity remains to be determined, although this might be quite 
plausible since they have been shown to have growth-promoting functions.
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8.1 Discussion
8.1.1 Pol III Transcription and Cell Growth
Growing cells require to duplicate both their genetic material as well as their cell 
mass before they divide. While duplication of the genetic material occurs at one 
point during the cell cycle, duplication of the mass is a gradual and continous process 
tha t requires activation of diverse proteins, each responsible of specific processes tha t 
overall ensure constant growth. Because a cell’s dry mass is mainly constituted of 
proteins (70%), one of the main processses that must be activated for sustainable 
cell growth is protein synthesis; in fact, growth rate is directly proportional to the 
rate of accumulation of protein (see [11] for review). High rates of protein synthesis 
require an increase of the constituents of the translational machinery, i.e. ribosomes 
and tRNAs. Ribosomes are composed of proteins, encoded by genes transcribed by 
pol II; and rRNA, encoded by genes transcribed by pol I and pol III; whereas tRNAs 
are encoded in genes transcribed by pol III. rRNA availability mainly depends on 
the rate of rRNA synthesis, which has been shown to decrease in response to amino 
acid starvation and in stationary phase cells, demonstrating regulation coupled to 
growth (for review see [15]). rDNA from the 45S gene is transcribed by pol I, 
and the transcription factor regulated by growth has been identified to be TIF-IA. 
Moreover, the tumour suppressor protein RB appears also to be involved in pol I 
transcriptional regulation .
On the other hand, 5S rRNA, as well as tRNAs genes, which are also compo­
nents of the protein synthetic apparatus and therefore essential for protein synthesis, 
are synthesized by pol III. The rate of pol III transcription has been shown to be 
regulated by a diverse range of oncogenes and tumour suppressors, including Ras on­
coprotein as well as several viral oncoproteins, and the tumour suppressors RB and 
p53 [10,11,166,170]. In addition, some of the constituents of the pol HI machinery
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have been observed to be upregulated, which will ultimately induce class III gene 
transcription [12,168,170|. Evidence suggesting a possible regulation of pol III tran ­
scription by cell growth has come from experiments performed on rapidly growing 
cells like tumour and transformed cell lines. These cells present higher rates of pol 
III transcription than their normal counterparts and thus overexpress pol III prod­
ucts [11]. Further evidence of the requirement for a high level of pol III transcription 
in cell growth comes from the observation tha t mitogenic stimulation induces tRNA 
and rRNA, as well as ribosomal proteins and translation factors [10,11]. From these 
observations, a possible requirement for the activation of pol III transcription in the 
process of tumourigenesis is suggested.
8.1.2 The receptor ErbB2/neu and Pol III Transcription
Mitogens usually bind to and activate receptors at the plasma membrane th a t will 
ultimately transfer the signal to the nucleus via the activation of signalling cascades. 
Activation of pol III transcription by mitogens suggest the participation of a recep­
tor or receptors at the plasma membrane in this induction. One receptor tha t has 
received a lot of interest due to its oncogenic properties is the ErbB2/neu receptor. 
Notably gene amplification and overexpression of ErbB2/neu occurs in 25-30% of 
breast and ovarian carcinomas and is associated with poor prognosis [206,207]. Over­
expression of pol III products have been detected in ovarian cancers when compared 
with noncancerous tissue isolated in parallel from the same individuals [12]. In these 
samples, the levels of both mRNA and protein of the TFIIIC2 subunits were higher 
in the tumour tissue than the healthy tissue. Furthermore, microextracts prepared 
from tumour samples presented an increased TFIIIC2 activity when compared to 
the normal ovarian tissue [12]. In addition, pol III activity can be stimulated by 
raising the amounts of TFIIIC2 in extracts prepared from ovarian epithelial cell 
extracts, confirming tha t an increase in TFIIIC2 concentration does indeed affect 
expression of class III genes in ovarian tissue [12]. It would be interesting to analyse 
the expression of the ErbB2/neu receptor in these ovarian epithelial tumours, and 
test if there might be a correlation between ErbB2 overexpression and the stimula­
tion of pol III transcription observed; however, this research was not performed in 
W inter et. al.’s study. Chapters three and four of this thesis address this hypothesis. 
Instead of using ovarian tumour samples, an immortalized ra t epithelial ovarian cell 
line stably transfected with a constitutive active form of the ErbB2/neu receptor 
(ROSE-neu) or the /3-galactosidase protein (R0SE-/3gal) as control was used. As 
shown in chapter three, ErbB2/neu constitutive activation does indeed stimulate
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pol III transcription, with overexpression of all the pol III products tested; however, 
no overexpression of the TFIIIC2 subunits could be observed. Although no overex­
pression of TFIIIG2 was found in the ROSE-neu cells, previous studies have shown 
that its activity is slightly elevated when compared to tha t of ROSE-/?gal [226]. The 
fact tha t TFIIIC2 activity is increased with no apparent increment in its expression 
levels suggests tha t an increase in the expression levels of TFIIIC2 is not required 
as long as its activity is elevated.
Because no overexpression of the TFIIIC2 subunits could be found in the neu- 
overexpressing cells, and the induction in pol III transcription in these cells was so 
striking, other routes of transcriptional regulation were investigated. Due to the fact 
tha t the ErbB2/neu receptor is known to activate several signalling cascades which 
have been shown previously to stimulate pol III transcription, their activation in 
the ROSE cells was analysed. The ROSE-neu cells presented higher activation of 
the Ras signalling pathway, as well as of the kinase pYO^ GK TPgj-e are three main 
mechanisms by which ErbB2/neu could be targeting pol III transcription through 
the activation of these pathways. The first one is through the induction of the 
cyclin E  and D genes, which will ultimately affect RB function [5,170, 278, 282, 
283]. An increase in these two cyclins was observed in the neu-overexpressing cells. 
Furthermore, the RB tum our suppressor protein is highly phosphorylated in ROSE- 
neu cells compared to control; and as the co-immunoprecipitations showed, the 
interaction between RB and TFIIIB is reduced (Fig. 8.1). These findings present 
one mechanism by which ErbB2/neu constitutive expression might induce pol III 
activity.
The second mechanism involves an induction of the TFIIIB subunit TBP. Results 
in Chapter 3 demonstrate th a t in the ROSE-neu cells, the expression of TBP is 
increased compared to control cells. In addition, both TBP and Brf appear to be 
phosphorylated in the neu-overexpressing cells (Fig. 8.1). In a recent report, Scott’s 
group have shown that the Ras pathway, particularly through Erk, is responsible 
for phosphorylating the Brf subunit of TFIIIB, and this phosphorylation appears 
to upregulate pol III activity [269]. These findings present a possible explanation 
for the doublets present on the TBP and Brf proteins of the ROSE-neu extracts, 
and might account for the activation of pol III transcription in these cells. However, 
it still remains to be analysed whether the doublets observed in these proteins do 
correspond to phosphorylation or to a different modification. Also, it still needs to 
be determined what role this modification plays in the ErbB2/neu activation of pol 
III transcription.
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Figure 8.1: Pathways involved in ErbB2/neu upregulation of pol III transcription.
Activation of the ErbB2/neu receptor stimulates signalling pathways in­
cluding Ras and PI3K which will ultimately affect expression of different 
genes including TBP, c-Myc, cyclins E and D, and the pol III subunit 
BN51, as well as phosphorylation of Brf and RB which will act as positive 
effectors of pol III output. However, if c-Myc expression is compromised 
(by antisense oligonucleotides), the induction of class III genes observed 
by constitutive activation of ErbB2/neu does no longer occur, suggesting 
c-Myc as a main effector of ErbB2/neu.
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The third mechanism by which the activation of the Ras and signalling
pathways by ErbB2/neu could affect pol III activity is through the induction of the 
transcription factor c-Myc. Both these pathways are involved in the upregulation of 
c-Myc activity by increasing its half life (through phosphorylation by Erk, [282,283]) 
as well as by increasing its translation (through p70^®^ ,^ [285]). This transcription 
factor was investigated due to the fact tha t in a recent report it has been shown to 
mediate ErbB2/neu oncogenicity. In this report, when c-Myc activity was blocked, 
the cells were not longer malignant eventhough ErbB2/neu was still overexpressed. 
From these findings, it could be concluded tha t ErbB2/neu requires the induction 
of this transcription factor to exert its oncogenic effects. Although no previous data 
have shown a link between pol III transcription and c-Myc, the work described 
in this thesis presents a clear demonstration tha t this transcription factor actually 
upregulates pol III transcription. As shown in Chapter 4 and as previously docu­
mented in breast cells [5], ErbB2/neu overexpression in the rat ovarian epithelial 
cells induces c-Myc expression. To analyse whether c-Myc played any role in the 
induction of pol III transcription, c-Myc antisense oligos were tested to reduce c- 
Myc’s expression. When the neu-overexpressing cells were grown with the c-Myc 
antisense oligos, an unexpected decrease of pol III activity was obtained, which was 
now comparable to the normal levels usually observed in control cells (Fig. 8.1). A 
similar result was also obtained from in vitro transcription assays with whole cell 
extracts th a t were immunodepleted of c-Myc (Chapter 4). The fact tha t a reduction 
of this transcription factor could bring down pol III activity to normal levels is quite 
surprising, since neu-overexpression in the rat ovarian epithelium not only presented 
increased levels of this transcription factor, but also changed other conditions (e.g. 
RB-phosphorylation and increased TBP levels) which are known to affect pol III 
activity. From these results, it could be concluded th a t downregulation of c-Myc 
can override the other conditions, and is a crucial determinant in the activation of 
pol III transcription caused by neu-overexpression.
To better understand the mechanism used by ErbB2/neu to upregulate pol III, 
each of the different processes involved should be studied further. To address this, 
it would be interesting to perform experiments in which the Ras pathway on one 
hand, and the p70^®^  ^ kinase on the other are downregulated by specific inhibitors 
and study what effects are obtained concerning RB activity, TFIIIB and c-Myc 
induction. Furthermore, c-Myc’s role in RB activity, TFIIIB protein modifications 
and induction of the pol III subunit BN51 should also be addressed.
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8.1.3 Activation o f  Pol III Transcription by c-Myc
The finding tha t c-Myc induction by neu-overexpression produces an increase in pol 
i n  transcription, presents a novel mechanism by which pol III activity can be upreg- 
ulated. The exact mechanism by which c-Myc is exerting its positive effect on pol 
III was investigated in Chapters 5 and 6, using systems where only c-Myc expression 
was affected, avoiding other conditions th a t could interfere with this study (however, 
it would be interesting in the future to investigate whether downregulation of c-Myc 
in the ROSE-neu cells has any effect on RB-phosphorylation and TFIIIB and BN51 
induction). To achieve this, the experiments to analyse c-Myc regulation of pol III 
were performed on c-Myc-knockout cells and arrested primary cells transfected with 
the fusion protein c-Myc-ER. These systems confer the advantage of studying the 
regulation of c-Myc in an environment where there is only one variable changed, tha t 
is, c-Myc expression; thus, the changes observed in pol III activity are going to re­
sult only from the change in c-Myc. The results presented in Chapter 5 demonstrate 
tha t c-Myc positively regulates expression of different pol III transcripts.
Because c-Myc is responsible for increasing the expression of cyclins D and E, 
which will ultimately induce phosphorylation of RB, this mechanim seemed to be 
the most plausible involved in c-Myc regulation of pol III transcription. However, 
contrary to what was expected, RB expression did not play any role in c-Myc upreg- 
ulation of pol III, since its over express ion in RB null fibroblasts, as well as RB-pl07- 
pl30 null fibroblasts, still managed to produce activation of pol III transcription to 
a similar extent to tha t observed in wild-type cells. The next possibility considered 
was tha t c-Myc could be upregulating constituents of the pol III apparatus. How­
ever, no increase in the expression of mRNAs encoding several proteins belonging to 
the pol III apparatus was observed. Furthermore, pol III activity still responded to 
c-Myc expression even in the absence of pol II transcription. From these findings, 
it was concluded tha t c-Myc did not require any intermediary to acheive regulation 
of pol III activity; instead it must be working directly on it.
Although in the primary fibroblasts no induction was observed for the pol III 
subunit BN51, in immortalised and transformed cells c-Myc can increase BN51 ex­
pression (Chapter 4 and [287]). Preliminary data by Felton-Edkins using c-Myc 
RNA interference in transformed cervical cells show that the mRNA encoding of 
this pol III subunit decreases in response to a reduction in c-Myc expression. This 
evidence implies tha t in transformed cells c-Myc might also be targeting other routes 
to achieve high levels of pol III products, and suggest tha t in rapid growing cells 
like cancer cells further mechanisms are involved in the upregulation of pol III tran-
154
8 Discussion and Conclusions
scription by c-Myc to ensure pol III output (see Fig. 8.2).
As observed in Chapter 5, c-Myc is capable of activating pol III transcription 
through a direct mechanism, and as the chromatin immunoprécipitation experiments 
showed, it is localised at class III genes in both primary as well as immortalised and 
transformed cells [373]. Having established that c-Myc utilises a direct mechanism 
to target pol III, the recruitment agent was investigated. Chapter 6 addressed 
this question, and the results show tha t c-Myc interacts with the pol IH-specific 
transcription factor TFIIIB. In addition, an interaction between Max and TBP was 
detected, which might increase the efficiency of the binding between c-Myc and 
TFIIIB. These experiments demonstrate tha t c-Myc is being recruited to class III 
genes through protein-protein interactions with TFIIIB.
8.1 .4  Possible Mechanism of  Induction of Class III Genes by 
c-Myc
The mechanism by which c-Myc is capable of transactivating of its target genes had 
remained unclear until recent years. In the literature, there is now evidence showing 
tha t c-Myc may activate transcription through chromatin remodelling [322]. In eu­
karyotes, the DNA is packaged into nudeosomes composed of histones. The histones 
have been shown to be modified through acétylation by histone acetyltransferases 
(HATs) and deacetylation by histone deacetylases (HDACs), having a positive or 
negative effect, respectively, on transcription. Acétylation levels are controlled by 
sequence-specific activators or repressors which will recruit HATs or HDACs, respec­
tively, and will ultimately mediate transcriptional activity. c-Myc has been shown to 
recruit HATs and induce histone acétylation of several target genes [318,319]. The 
recruitment of HATs is through the N-terminal transactivation domain of c-Myc, in 
particular MBII, tha t binds to TRRAP (TRansactivation/ tRansformation-domain 
Associated Protein), a large ATM-related protein tha t is a component of several 
different multisubunit HAT complexes [322,353].
As presented in this thesis, transactivation of class HI genes by c-Myc is through 
recruitment of this protein to promoters by TFIIIB (Chapters 5 and 6). However, it 
did not address the mechanism involved in the transactivation. Due to the fact tha t 
regulation of gene expression of other c-Myc target genes appears to be modulated 
via histone acétylation, it seems fairly likely tha t the same mechanism might be in­
volved in the regulation of pol III transcription. Previously, it has been documented 
tha t chromatin remodelling does exert an effect upon pol III activity [374]; thus 
c-Myc function might be the recruitment of HATs to class HI genes . Evidence tha t
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A. Normal Cells
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B. Transformed Cells
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Figure 8.2: Possible mechanisms of pol III activation by c-Myc in normal cells com­
pared to transformed cells. (A) As demonstrated in Chapter 6, acti­
vation of pol III transcription in primary fibroblasts is through direct 
interaction with proteins of the pol III appparatus (TFIIIB) and thus 
localization of it at class III genes. (B) Possible induction of pol III 
activity in transformed cells by c-Myc through interaction with TFIIIB 
as well as induction of constituents of pol III (BN51), and other positive 
regulators of its activity (Id2).
156
8 Discussion and Conclusions 
>  Pol I ----------------------► rRNA -
c-Myc— ► Pol II -------^  Ribosomal proteins
(/) 3
2
< O
Translation initiation factors g 0
CO (/)
ro Ü
 Q)
>  Pol i l l ---------------------
Figure 8.3: c-Myc as a key regulator of cell growth. The transcription factor c-Myc 
has been recognised to transactivate expression of genes whose products 
are part of the translational apparatus, and thus affect the biosynthetic 
capacity of cells.
suggests this to be the possible mechanism used by c-Myc comes from the results 
obtained with the m utant AMyc-ER, which lacks a region within the TAD, from aa 
106 to 143, tha t includes MBII, and therefore is incapable of binding to TRRAP. As 
shown in Chapter 5, AMyc-ER failed to activate both tRNA and cyclin D2 tran­
scription upon addition of OHT. In addition to these findings, data tha t supports 
this mechanism comes from the experiments using c-myc null cells, where the nat­
ural occurring m utant c-MycS did not manage to rescue the c-myc null phenotype 
for class III genes. Although c-MycS contains the MBII domain, McMahon et al. 
demonstrated that c-MycS does not bind to TRRAP; for this binding to occur, the 
N-terminal domain must be almost complete |352]. These data support the hypoth­
esis tha t recruitment of TRRAP and complexes with HAT activity and modification 
of histone acétylation may contribute to the regulation of class III gene expression 
by c-Myc in vivo.
In the recent years, the product of the proto-oncogene c-myc has been shown 
to participate in the regulation of both cellular proliferation and growth, and is 
known to be involved in tumourigenesis. It can regulate RB phosphorylation state 
by inducing the expression of proteins involved in this process (i.e. cyclins and 
cdc25A), allowing progression of the cell cycle from G1 phase to S phase, as well as 
increasing the expression of molecules (both ribosomal proteins and rRNA) involved
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in translation (see Chapter 5, Table 5.1, see Fig. 8.3) allowing an increase in cell 
mass. Since some of the products synthesized by pol III are constituents of the 
translational apparatus, it would be economical for the cell to utilise the same protein 
to regulate the expression of all the molecules involved in this process, and ultimately 
in cell growth. The results in this thesis demonstrate tha t c-Myc is able to induce 
the products synthesized by pol III, thus presenting this transcription factor as a 
key regulator of cell growth. In the future it would be interesting to investigate 
what role does the increase of pol III output by c-Myc play in tumourigenesis. The 
pol III product 7SK RNA has been suggested to participate in the transformation 
process by regulating transcriptional initiation of the c-myc gene [375]. In fact, the 
induction of c-myc gene expression by 7SK RNA appears to be in direct proportion to 
transformation and tumourigenicity [375]. These results suggest tha t the regulation 
by c-Myc of class III genes may act as a positive feedback towards its own expression, 
as well as having an effect on cell growth and tumourigenesis.
8.1.5 Induction o f  Pol III Transcription by Id2
A third protein tha t was shown to regulate transcription by pol III was the product 
of the proto-oncogene Id2. The HLH Id2 protein was considered because it is a target 
gene of N-Myc as well as c-Myc [7,16], as well as being an inhibitory binding partner 
of the hypophosphorylated form of RB, which is a known repressor of pol III activity. 
Although Id2 had been found previously to be a target gene of N-Myc, no induction 
of its transcription could be observed in the quiesced primary fibroblasts transfected 
with c-Myc-ER upon addition of OHT. One possible reason for the discrepancy in the 
results obtained here with those previously documented could be the cells chosen for 
the assay. In the work presented here, primary fibroblasts previously quiesced were 
used, while Id2 induction by N-Myc has been documented in neuroblastomas and 
immortal fibroblasts [16]. It seems that Myc transactivation of the Id2 gene might 
depend on other factors tha t are present in transformed and immortal cells, thus 
no upregulation is aparent in normal cells. Further investigation into this subject 
is required to understand the exact mechanism involved in Myc transactivation of 
Id2.
As demonstrated in Chapter 7, Id2 can upregulate expression of class III genes. 
Although the obvious mechanism used by Id2 to regulate pol III activity seemed to 
be through inactivation of RB, the fact tha t transfection of Id2 in RB null and RB- 
pl07-pl30 null cells still managed to induce pol III activity indicated that this was 
not the only mechanism involved. The experiments presented in this thesis suggest
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tha t M2 can actually exert its positive effects through interaction with proteins of 
the pol III transcriptional apparatus, specifically with TFIIIB, and can be found 
localised at class III genes. This is the first time tha t the HLH M2 protein has 
been documented to localise at DNA, which came as a great surprise since M2 lacks 
DNA-binding domains and none of the known pol III factors has an HLH domain. 
Although the data presented here seems quite encouraging, further research into this 
m atter should be performed to confirm these results.
8.1.6 TFIIIB as a Possible Determinant of  Pol III Activity
From the findings presented in this thesis an obvious conclusion tha t can be drawn 
is the fact tha t all three oncoproteins, i.e. ErbB2/neu, c-Myc and probably M2, 
appear to control pol III output through regulation of TFIIIB. ErbB2/neu stim­
ulated TFIIIB  activity through several mechanisms, including the increase in the 
expression of the TFIIIB subunit TBP, protein modifications in TBP and Brf, by 
inducing phosphorylation of RB and thereby reducing RB binding to TFIIIB, and 
finally, through induction of c-Myc. The fact that TFIIIB is being upregulated at 
so many different levels confirms its significance as a regulatory hub controlling the 
expression of class III genes. TFIIIB has received a lot of interest in the past since 
its function has been shown to be the target of tight control by tumour suppressors, 
like RB and p53, as well as being frequently activated by viral and cellular oncopro­
teins, like Ras (reviewed in [11]). This evidence suggests tha t TFIIIB is a crucial 
determinant of the rate of pol III transcription, which is not surprising since it is re­
sponsible for recruiting pol III to the start site and positioning it for initiation [121]. 
Furthermore, it provides an indication tha t its activation may be a significant step 
towards tumour development.
8.2 Conclusions
RNA Polymerase III synthesizes a variety of essential cellular products, including 
5S rRNA, tRNA and U6 snRNA, which play an essential role in the biosynthetic 
capacity of cells and, ultimately, of growth. The work described in this thesis demon­
strates tha t three different oncoproteins, ErbB2, c-Myc and M2, which have been 
clearly implicated in tumour development and induction of cell proliferation and 
growth, participate in the positive regulation of class III gene expression.
Although ErbB2/neu appears to deregulate multiple factors to achieve activa­
tion of pol III, including phosphorylation of RB and induction of the pol III subunit 
BN51, all three oncoproteins target TFIIIB  to achieve upregulation of class III genes.
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TFIIIB is Highly Regulated
pl6
pl6TAg 
(SV40 & Py)
E7 (HPV)
ElA
E6 (HPV) 
Mdm2/Arf
► C d k s2 ,4 & 6
I
Ras ErbB2/neu
RB, pl07 
pI30
TFIIIB
TAX (HTLV-1)
Drl
REPRESSORS 
OF TFIIIB
ACTIVATORS 
OF TFIIIB
Figure 8.4: TFIIIB is highly regulated by several different proteins. The growth re­
pressors RB, pl07, pl30, D rl and p53 can all repress TFIIIB by direct 
interactions. The function of these repressors can be blocked by sev­
eral viral proteins including the large T antigen (TAg) from SV40 and 
poliomavirus (Py), the Adenovirus ElA, the HPV E7, as well as the 
cellular proteins Cdk 2, 4 and 6, which relieve TFIIIB from repression 
by RB; adenovirus E lA  also relieves repression of D rl; and HPV E6 and 
the cellular protein Mdm2 which block p53. In contrast, a variety of 
oncoproteins have been shown to stimulate TFIIIB including Ras, Erk, 
ErbB2/neu, c-Myc, CK2, Id2 and the viral protein TAX from human 
T-cell leukaemia virus type 1 (HTLV-1) (for review see |11|).
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implying tha t TFIIIB is a major determinant for dictating the rate of pol III tran ­
scription. Both c-Myc and Id2 can interact directly with TFIIIB, as well as being 
localised at class III DNA. This interaction might allow recruitment of coactivators 
and chromatin-modifying activities, or it might block effects of negative regulators 
of the pol III machinery. Because all three proteins are positive regulators of cell 
growth, it seems th a t in order to control this process, they target transactivation of 
pol III products which are major determinants of the rate of translation, and there­
fore essential for growth. Given the frequency with which these three oncoproteins 
get deregulated in human cancers, it seems highly likely th a t pol III transcription 
will become deregulated in a large proportion of malignancies. This also suggests 
tha t deregulation of TFIIIB may be an im portant requirement in the process of 
tumourigenesis.
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